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Abstract 
For many ion channels there are few, if any, pharmacological agents, and even fewer 
showing specificity. In this study, a set of pharmacological tools were developed to 
investigate TRPM3, a widely expressed transient receptor potential (TRP) channel for 
which no functional role has yet been identified. 
Human TRPM3 was first expressed in HEK 293 cells and shown to be activated by 
hypo-osmotic challenge or sphingosine, consistent with previous reports. In addition, 
TRPM3 was activated by pregnenolone sulphate. Hydrophobicity analysis of the 
TRPM3 amino acid sequence revealed a short and reasonably unique peptide in the 3`d 
extracellular loop (E3) region, to which polyclonal antiserum (TM3E3) was produced. 
Extracellular application of TM3E3 inhibited TRPM3 function with a high degree of 
specificity, having no effect on TRPM2 or example members of other sub-types of 
mammalian TRP, TRPC5 or TRPV4. The data validate E3-targeting as an approach for 
production of isoform-specific channel blockers and reveal a specific agent for blocking 
TRPM3. 
The cellular and tissue functions of TRPM3 were also investigated. RT-PCR and 
immunocytochemistry demonstrated TRPM3 expression in human saphenous vein 
smooth muscle cells, where sphingosine- and pregnenolone sulphate-induced calcium 
responses were also apparent. These calcium responses could be selectively blocked by 
TM3E3. Furthermore, TRPM3 activators inhibited matrix metalloproteinase and 
interleukin-6 secretion, indicating a protective function for TRPM3 in vascular smooth 
muscle cells. Medium throughput screening systems were employed to screen a library 
of compounds for further TRPM3 modulators with vascular relevance. Cholesterol, 
antidepressants, antipsychotics, calmodulin inhibitors, and PIP2 all inhibited TRPM3, 
whereas nifedipine and elevated temperature activated the channel. TRPM3 appears to 
be regulated by a large number of different chemicals and mechanisms. 
In summary, TRPM3 has constitutive, protective, activity which can be suppressed by a 
multitude of compounds, including known vascular disease factors such as cholesterol. 
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Chapter 1 
Introduction 
Vascular system 
The cardiovascular system comprises the heart and blood vessels, and is essential for 
maintaining organ function and blood pressure. Blood pressure refers to the force 
exerted on the blood by contraction of the heart, and is regulated by factors such as the 
resistance of blood vessels. The heart circulates blood around the body's vascular 
network via the systemic or pulmonary circulation. The systemic circulation carries 
oxygenated blood away from the heart and around the body, and returns deoxygenated 
blood to the right side of the heart. The role of the pulmonary circulation is to oxygenate 
the blood. Deoxygenated blood is carried to the lungs, oxygenated, and returned to the 
left side of the heart. 
Vascular physiology 
Blood vessels are divided into 3 main groups; arteries, veins and capillaries. Arteries 
carry blood away from heart, and are subjected to the greatest hydrostatic pressure. As a 
result their vessel walls are thicker and more complex than veins, although they both 
share common physiological features. With the exception of capillaries, blood vessels 
are comprised of 3 major layers; tunica intima, tunica media, and tunica adventitia 
(Figure 1.1). The tunica intima, a single layer of endothelial cells, lines the vessel lumen 
and protects the tunica media from the shear stress of the blood flow. Vascular smooth 
muscle cells (VSMC) are the predominant cell type in the tunica media, and are 
arranged circumferentially to the vessel lumen to allow for contraction necessary to 
regulate the diameter of the vessel. The tunica adventitia forms the outer layer, and is 
primarily comprised of connective tissues which provide support for the tunica media, 
plus a network of much smaller vessels termed the vasa vasorum. The vasa vasorum 
supply blood to the outer tissues of large blood vessels, and in larger vessels will also 
extend to the tunica media. Also present are small nerve fibres which innervate the 
smooth muscle of the tunica media. Conversely, capillaries have very thin vessel walls 
that are only one endothelial cell layer thick, ideal to allow gas exchange between the 
blood and surrounding tissues. 
2 
Tunica 
adventitia 
Tunica media 
smooth muscle cells 
Figure I. I. General structure of an artery or vein The schematic depicts the 3 major 
layers; the tunica intima, tunica media and tunica adventitia plus separating layers of 
elastic connective tissue (reproduced from www. lab. anhb. uwa. edu. au). 
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Vascular disease 
Knowledge of the structure and function of the blood vessels that make up the 
cardiovascular system is essential for understanding vascular diseases. Cardiovascular 
disease (CVD) refers to conditions that affect the heart and blood vessels, and is 
responsible for 1 in 3 deaths in the Western world, more than half of which are solely 
due to coronary heart disease (CHD) (British Heart Foundation statistics database 
www. heartstats. org). CHD results from atherosclerosis, a build up of cholesterol and 
fatty deposits in vessel walls that can eventually obstruct blood flow to the heart. 
Atherosclerosis usually results from damage to the endothelial layer as a result of risk 
factors including accumulation of low-density lipoprotein cholesterol, diabetes, 
hypertension, and components in cigarette smoke (Wilson et al., 1998). This damage 
results in the recruitment of inflammatory cells which secrete cytokines and growth 
factors. These penetrate the tunica media and induce the proliferation and migration of 
VSMC to remodel the outer vessel wall. However, the VSMC can also invade the 
lumen. This results in the formation of a lesion comprised of a lipid core which is 
protected from the circulating blood by a layer of VSMC, referred to as an 
atherosclerotic plaque. The plaque obstructs the blood vessel, causing a general 
narrowing that may restrict blood flow. If coronary vessels are obstructed, the reduced 
oxygen supply to the heart muscle can cause angina. As atherosclerosis progresses, 
factors secreted by the VSMC themselves can have a dual effect on the atherosclerotic 
plaque; In particular matrix-degrading metalloproteinases (MMPs) can interact with the 
extracellular matrix and stabilise plaque structures, forming a fibrous cap. Alternatively 
prolonged exposure to these secreted factors can weaken the fibrous cap tissue and 
cause it to rupture (Newby, 2007). The rupture of a plaque structure exposes the lipid 
core to the circulating blood and can induce the formation of a blood clot. If the blood 
clot creates a sudden complete block of the vessel, the result is myocardial infarction. 
Depending on the progression of cardiovascular disease, treatments may be as simple as 
a lifestyle change, lipid-lowering drugs such as statins, or antihypertensive and 
antiplatelet drugs. Severe cases where blood flow is restricted will require physical 
intervention, usually balloon angioplasty. A balloon attached to a catheter is inserted 
into the partially blocked vessel and inflated to push the plaque against the wall of the 
artery, thus widening the vessel and restoring normal blood flow. Often a small stent is 
inserted in the narrowed area to support the damaged vessel wall and keep the artery 
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open. In more severe cases where there are several regions of occlusion, or even 
complete block, coronary artery bypass surgery is performed. This involves bypassing 
the damaged coronary artery with a graft, commonly the great saphenous vein or the left 
internal mammary artery, to provide an alternative route for blood flow. Each of these 
surgical techniques will inadvertently cause damage to the vessel, and the artery will 
reseal around an inserted stent, or in the case of bypass surgery the graft has a 50% 
likelihood of failure within 10 years (British Heart Foundation statistics database 
www. heartstats. org). The primary mechanism for this is once again proliferation and 
migration of the VSMC, triggered by the vascular injury, leading to invasion of lumen 
in a process known as neointimal hyperplasia. Neointimal hyperplasia can be replicated 
in cultured human saphenous vein (Figure 1.2). 
Vascular smooth muscle cells 
VSMC phenotypic switching 
One state of the VSMC is a differentiated and contractile phenotype. In this state, the 
cells proliferate at a slow rate, and their primary function is the regulation of blood 
vessel diameter, thus regulating vascular tone and blood pressure. During blood vessel 
growth or in response to vascular injury, VSMC can revert to an undifferentiated or 
synthetic phenotype and display a dramatic increase in proliferation and migration to 
form new tunica media and repair vascular injury. This phenotypic switching can result 
from exposure to growth factors, and also atherogenic factors such as lipids, 
inflammatory mediators, mechanical trauma and reactive oxygen species. The result is 
upregulation of genes that encode proteins required for cell-cycle progression, and 
downregulation of genes necessary for the contractile machinery of the cell (Owens et 
al., 2004). 
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Freshly harvested vein Organ-cultured vein 
Figure 1.2. Model for neointimal hyperplasia in cultured saphenous vein 
Immunocytochemistry of saphenous vein section before (left hand panel) and 2 weeks 
after organ culture. Sections were stained orange for smooth muscle a-actin. Vein was 
obtained with consent from a patient undergoing coronary artery bypass surgery. Scale 
bar 1 mm. Reproduced with permission from (Cheong et al., 2005). 
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VSMC contraction 
Contraction of VSMC is slow, sustained and involuntary, and results from the 
interaction of myosin and actin filaments. These interactions are closely regulated by 
changes in intracellular Ca2+ concentration. An increase in intracellular Ca2+ causes 
activation of the protein calmodulin (CaM), which in turn increases the activity of 
Ca2+/CaM-regulated myosin light chain kinase (MLCK). When active, MLCK can 
phosphorylate the myosin regulatory light chain, altering its conformation and allowing 
it to interact with actin, thus promoting contraction. Alternatively, VSMC contraction is 
caused by a Ca2+ independent mechanism which involves sensitisation of the contractile 
apparatus to Ca2+ (Somlyo et al., 2000). Activation of cell-surface receptors activates 
the monomeric G protein RhoA, which binds GTP and translocates to the cell 
membrane where it activates Rho kinase. Rho kinase then phosphorylates myosin light 
chain phosphatase rendering it inactive, and unable to dephosphorylate myosin. This 
increases the Ca2+ sensitivity of smooth muscle myofilaments, allowing MLCK 
contraction to dominate. 
Calcium signaling 
The concentration of free Ca2+ in the cytosol is responsible for a multitude of cellular 
processes, including the regulation of transmitter release, muscle contraction, gene 
transcription, cell proliferation and cell death (Berridge et al., 2000). Intracellular Ca2+ 
is closely regulated by Ca2+ permeable ion channels, exchangers and receptors located in 
both the plasma and intracellular membranes (Figure 1.3). Cytosolic Ca2+ is removed 
from the intracellular environment either by extrusion from the cell by the 
Na /Ca2+exchanger and the plasma membrane Ca2+-ATPase, or by uptake into 
intracellular stores by the endoplasmic (or muscle-specific sarcoplasmic) reticulum 
Ca2+-ATPase. Intracellular Ca2+ is increased by release from stores through ryanodine 
and inositol-1,4,5-triphosphate (IP3) receptors. Alternatively, Ca2+ can enter the cell by 
crossing the plasma membrane via a multitude of differentially-activated Ca2+- 
permeable cation channels. 
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Extrusion of Ca 2+ 
Differences in electrical charge and ionic concentration between the intra and 
extracellular environments result in an electrochemical gradient across the plasma 
membrane which determines the direction an ion will move. The gradient for Ca2+ ions 
is maintained by the extrusion of Ca2+ from the cell by two main systems; the plasma 
membrane Ca2+-ATPase (PMCA) and the Na+/Ca2+ exchanger (NCX). Together these 
proteins keep intracellular levels in the nM range, creating a driving potential for Ca2+ 
influx into cells. 
PMCA has 10 putative transmembrane domains which form 4 main units, including 
both N and C-terminal units, a phospholipid-interacting site, and a catalytic site. CaM 
binding to the intracellular C terminus regulates the activity of the protein, and increases 
its affinity for Ca2+ (Guerini, 1998). The extrusion of Ca2+ by PMCA is powered by the 
hydrolysis of ATP, which binds to the catalytic site and transfers a phosphate group to 
the protein, producing a phosphorylated intermediate. The exact mechanism of Ca2+ 
transport is unclear, but 2 Ca2+ ions are transferred for every ATP molecule hydrolysed. 
Although PMCA has a low transport rate, it has a high affinity for Ca2+. This allows the 
pump to respond to very small changes in Ca2+, thus maintaining a low basal level of 
Ca2+. The existence of 4 PMCA genes and their alternative splicing produces 
functionally distinct isoforms which are differentially expressed in various cell types 
(Strehler et al., 2001). 
The NCX is driven by the movement of Na' down its electrochemical gradient into the 
cell. Excess Na' must then removed by the Na+/K+-ATPase in order to maintain the 
gradient. Despite having a lower affinity for Cat+, the NCX has a much faster transport 
rate, and is more efficient than PMCA for removing a large number of Ca2+ ions 
quickly. The protein comprises 9 transmembrane domains with an external N terminus 
and internal C terminus, but the exact structure-function relationships required for 
binding and transport of Ca2+ ions is not understood (Shigekawa et al., 2001). For 3 Na+ 
entering the cell, one Ca2+ is extruded against its electrochemical gradient. 
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Figure 1.3. Summary of proteins involved in membrane transport of Ca 2+ Proteins 
shown include: NCX, Na`/Ca2+ exchanger; Na' pump, Na+/K+-ATPase; VGCC, 
voltage-gated Ca 2+ channel; ROC, receptor-operated Ca 2+ channel; SOC, store-operated 
Ca 2+ channel; SMOC, second messenger-operated Ca2+ channel; SAC, stretch-activated 
channel; PMCA, plasma membrane Cat+-ATPase; SERCA, sarco(endo)plasmic 
reticulum Cat+-ATPase; RyR, ryanodine receptor; IP3R, inositol 1,4,5-phosphate 
receptor; NAADP-R, NAADP-sensitive Ca 2+ release channel. SR represents 
sarcoplasmic reticulum, the muscle equivalent of the endoplasmic reticulum (ER). 
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Ca2+ uptake by intracellular stores 
The majority of cellular Ca2+ is sequestered within intracellular organelles, the largest of 
which is the endoplasmic reticulum (or the sarcoplasmic equivalent in muscle). The 
sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA), of the same Ca2+-ATPase family 
as PMCA, is responsible for the transfer of Ca2+ from the cytoplasm against its 
concentration gradient into the lumen of the ER/SR. SERCA transports 2 Ca2+ for every 
ATP hydrolysed, is sensitive to phospholambam, and is selectively and irreversibly 
inhibited by thapsigargin. Alternative splicing of 3 SERCA genes results in an array of 
SERCA proteins with different properties, allowing for the intricate regulation of Ca2+ 
sequestration (Periasamy et al., 2007). 
Mitochondria can also take up Ca2+ from the cytosol via a Ca2' uniporter which spans 
the inner mitochondria) membrane (Parekh, 2003). The uniporter is activated by a rise 
in cytosolic Ca2+. Ca 2+ uptake is driven by the negative potential across the inner 
membrane which results from proton extrusion by the electron transport chain. 
Accumulated Ca2+ can subsequently be released via Ca2+/Na+ and Ca2+/H+ exchangers. 
Ca2+ release from intracellular stores 
IP3 and ryanodine receptors (IP3R and RyR) are the principal intracellular Ca2+ channels 
responsible for the release of Ca2+ from intracellular stores. Located in the ER 
membrane, both receptors exist as tetramers, with large N termini projected into the 
cytoplasm. In addition, both receptors are sensitive to Ca2+, thus are termed Ca2+- 
induced Ca2+-release channels (CICR), and will release a large amount of Ca2+ from 
stores in response to a small Ca2+ influx across the plasma membrane. However both 
receptors are inhibited by high concentrations of Ca2+. Furthermore, the receptors are 
regulated by CaM binding and phosphorylation by PKC and PKA (Nadif Kasri et al., 
2002). 
Ca2+ is released form stores when IP3, an important second messenger produced by the 
phosphoinositide signalling system, binds to the IP3R and increases its affinity for Cat+. 
Receptor activation and the subsequent Ca2+ transport requires the binding of both IP3 
and Ca2+. The IP3R protein consists of 6 transmembrane domains that form the Ca2+ 
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pore, plus a cytoplasmic N terminal IP3 binding domain, and also a regulatory domain 
containing PKA-dependant phosphorylation sites and nucleotide binding sites. Several 
antagonists have been characterised, including heparin which competitively inhibits 
IP3R by interacting directly with the IP3 binding site, caffeine which interacts with 
nucleotide binding sites, and polyamines and tetraalkyl ammonium cations which 
interact with the transmembrane Ca2+ channel domain and block Ca2+ flow 
(Michelangeli et al., 1995). IP3Rs are also expressed in the nucleus, in an organelle 
continuous with the nuclear envelope termed the nucleoplasmic reticulum (Echevarria et 
al., 2003). These nuclear IP3Rs are responsible for nuclear IP3-induced Ca2+ release. 
The RyR displays high affinity for the plant alkaloid ryanodine, and the physiologically 
relevant cyclic ADP ribose (Sharma et al., 2000). Although similar in structure to the 
IP3R, the RyR is much bigger, and can be distinguished by its different pharmacology; 
it activated by caffeine, and inhibited by ruthenium red and high concentrations of 
ryanodine. 
Nicotinic acid adenine dinucleotide phosphate (NAADP) is a signalling nucleotide that 
regulates intracellular Ca2+ via release from NAADP-sensitive Ca2+ stores that are 
separate from IP3- and cADPR-sensitive ER/SR stores. NAADP-induced Ca2+ release is 
dependent on a proton gradient, which is maintained by a lysosomal, ATP-dependent 
proton pump. This suggests the channel responsible for this Ca2+ release is located in 
the lysosome. A likely candidate is TRPMLI, a member of the TRP superfamily that is 
predominantly expressed in lysosomes (Zhang et al., 2007). 
Voltage-gated Ca2+ channels 
Voltage-gated ion channels open in response to membrane depolarisation to allow the 
passage of ions. There are 6 types of voltage-dependent Ca2+ channels (VGCC); those 
that are high voltage-activated and require large depolarisations to activate, including 
long lasting L-, neuronal N-, P-, Q- and R-type, and transient T-type channels that are 
low voltage-activated channels, activated by small depolarisations. Individual channel 
types can be distinguished by their sensitivity to various toxins. L-type channels are 
selectively inhibited by dihydropyridines such as nifedipine, N-type channels are 
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blocked by c, -conotoxin GVIA, and P/Q-type channels are blocked by co-agatoxins. The 
R-type channels are resistant to all of these toxins. 
The dihydropyridine-sensitive L-type VGCC has been well characterised, and in 
addition to inhibition by dihydropyridines, is also sensitive to block by classical Ca2+ 
antagonists such as phenyalkamines and bexothiazapines. The protein exists as a 
complex of 5 subunits, the pore-forming al-subunit, plus regulatory auxiliary ß-, , y- and 
a28-subunits. The a1-subunit resembles other voltage-gated ion channels, with a 
tetrameric association of 4 domains, each with 6 transmembrane domains designated 
S1-S6. Positively charged lysine and arginine residues in the S4 in each of the 4 
domains collectively form the voltage sensor, whereas negatively charged residues in 
the pore loops between S5 and S6 are responsible for the Ca2+ selectivity of the 
channels (Dolphin, 2006). The ai-subunit also contains the binding site for 
dihydropyridines in a hydrophobic region on its extracellular surface. 
The auxiliary ß-subunit contains mainly hydrophilic residues and is not glycosylated, 
thus is presumed to be intracellular. Interactions between the a1- and (3-subunits 
modulate channel gating and trafficking of the channel complex to the plasma 
membrane. The a2-subunit is extracellular, and is linked via disulfide bonds to the 
transmembrane S-subunit. These 2 subunits are believed to increase current amplitude 
and activation rate. The role of the -y-subunit is not known, but it is believed to form 4 
transmembrane segments. 
Ligand-gated ion channels 
Ligand-gated ion channels (LGIC) are transmembrane ion channels that are opened or 
closed in response to the binding of an extracellular ligand mediator. LGIC that are 
permeable to Ca2+ include the ionotropic glutamate receptor N-methyl-D-aspartate 
(NMDA), and ATP-gated P2X receptors. 
NMDA receptors are expressed in the CNS at glutamatergic synapses where they 
mediate synaptic transmission. The channels are unusual in that they are both ligand- 
gated and voltage-dependent. Functional receptors are comprised of a heterodimer of 2 
subunits, NR1 and NR2, and alternative splicing and differential expression of these 
12 
subunits allows for multiple receptor isoforms with varying properties. NMDA receptor 
ligand-activation requires the binding of both an agonist (glutamate or other 
structurally-related amino acids), and a coagonist (glycine or D-serine). NMDA 
receptors are not voltage-gated channels; instead, depolarisation regulates the inhibitory 
effect of external Mg+ (MacDonald et al., 1990). 
P2X receptors are cation-permeable LGIC activated by extracellular ATP. There are 7 
genes that encode P2X subunits, P2X1-P2X7, and these can exist in multiple spliced 
forms (North, 2002). Each subunit comprises 2 transmembrane domains, intracellular 
N- and C-termini, and a large extracellular loop containing conserved lysine residues to 
which ATP binds. The transmembrane domains of a single subunit are insufficient to 
form an ion conducting pore, therefore functional channels exist as homo- or 
heterotrimeric structures (Roberts et al., 2006). 
Stretch-activated channels 
Mechanosensitive, or stretch-activated channels (SAC), are non-selective cation 
channels that are activated by stretch of the plasma membrane. Originally discovered in 
chick skeletal muscle, SAC have subsequently been identified in a range of different 
cell types (Kalapesi et al., 2005). Examples of SAC include the two-pore domain K' 
channels TREK and TRAAK (Maingret et al., 2000), and members of the TRP cation 
channel superfamily (Pedersen et al., 2007). The exact mechanism for SAC activation is 
not yet understood; mechanosensitivity may be directly modulated via SAC associations 
with the actin cytoskeleton, or alternatively membrane stretch may activate PLC or 
PLA2 to stimulate cellular signalling cascades, intermediates of which could activate 
SAC. Ultimately SAC activation can result in depolarisation of the membrane, causing 
activation of VGCC. 
Second-messenger-operated channels 
Second-messenger-operated channels (SMOC) are activated by various second 
messengers produced as a result of signalling cascades. An example of SMOC are the 
cyclic nucleotide gated (CNG) channels. CNG channels were first identified in 
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photoreceptors and olfactory sensory neurons, where they are gated by second 
messengers produced by visual and olfactory signalling cascades, such as cGMP and 
cAMP respectively (Bradley et al., 2005). 
Receptor-operated channels 
Receptor-operated channels (ROC), such as homologues of the Drosophila TRP family, 
are activated as a result of the stimulation of G-protein coupled receptors (GPCR) such 
as M2 and M3 muscarinic receptors and the at-adrenergic receptor. Ligand activation of 
a GPCR induces a conformational change which allows the exchange of GDP for GTP 
on the associated Ga subunit. This allows Ga to dissociate from the Gpy subunit in order 
to activate signalling cascades. A common GPCR signalling cascade involves the 
activation of PLC, which then hydrolyses PIP2 into DAG and IP3, and subsequently 
activates ROC. In addition, IP3 production activates the IP3R and thus causes an 
increase in Ca2+ release form stores, thereby activating store-operated channels (SOC). 
Store-operated Ca2' channels 
Stimulation of plasma membrane receptors to generate IP3 not only depletes 
intracellular Ca2+ stores, but also causes a sustained Ca2+ influx across the plasma 
membrane. This sustained Ca2+ influx is referred to as capacitative Ca2+ entry or store- 
operated Ca2+ entry (SOCE), and results from the opening of plasma membrane Ca2+ 
channels in response to the emptying of ER stores (Berridge, 1995). Extracellular Ca2+ 
entry in response to Ca2+ release from stores occurs through store operated Ca2+ 
channels (SOC). Inhibition of SERCA by thapsigargin, which blocks the reuptake of 
Ca2+ into the ER, can induce SOCE, suggesting SOC are activated by the process of 
store depletion, not by the Ca2+ that is released from the stores (Thastrup et al., 1989). 
Homologues of the drosophila trp gene family are believed to encode SOC 
(Birnbaumer et al., 1996). 
There are several theories for how SOCE occurs. The conformational coupling theory 
suggests that IP3Rs can translocate from the ER membrane to associate with SOC in the 
plasma membrane, resulting in direct refilling of Ca2+ stores. Alternatively, there may 
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be a separate Ca2+ sensing protein that can detect luminal store depletion, translocate to 
the plasma membrane, and interact with SOC. A likely candidate is suggested to be 
stromal interaction molecule (STIMI), which senses ER luminal Ca2+ and transduces 
information directly to the plasma membrane (Hewavitharana et al., 2007). A third 
hypothesis is that a diffusible Ca2+ influx factor is produced by the stores in response to 
Ca2+ depletion, which diffuses to the plasma membrane to activate SOC. Finally, SOCE 
may result from the fusion of vesicles containing SOC with the plasma membrane 
(Rosado et al., 2005). 
Ca2+ homeostasis in VSMC 
Smooth muscle contraction is initiated by an increase in intracellular Ca2+ 
concentration, thus VSMC express a plethora of Ca2' channels to closely regulate Ca2+ 
homeostasis. In general, contraction requires the activation of GPCR, resulting in the 
stimulation of PLC by the Ga subunit, the production of IP3, and the release of Ca2+ 
from IP3-dependent Ca2+ stores. This store release will also activate SOC in the plasma 
membrane. In addition, Ca2+-permeable ROC are activated, and in combination with 
ATP-activated P2X receptors, the cation movement into the cell depolarizes the plasma 
membrane and activates VGCC. All of these combined events allow for the large 
increase in intracellular Ca2+ that is necessary to cause smooth muscle contraction. 
Of the 6 VGCC, only L-type and T-type channels are expressed in VSMC. L-type 
channels are well characterised as regulators of the Ca2+ entry necessary for VSM 
contraction and vasoconstirction, and the vasodilatory and anti-hypertensive properties 
of dihydropyridines result from inhibition of L-type VGCC expressed in smooth 
muscle. T-type channels contribute less to vasoconstriction, and instead are suggested to 
regulate the cell cycle, thus controlling gene expression necessary for cell growth and 
division (Cribbs, 2006). Furthermore, T-type channels are upregulated, and L-type Ca 2+ 
channels are downregulated in proliferating VSM, suggesting that proliferating SMC 
require transient voltage-dependent Ca2+ influx. 
Non-voltage gated channels are also expressed in VSM. ATP can regulate smooth 
muscle activity via P2X1 and P2X4, which are widely expressed in vascular smooth 
muscle (Lewis et al., 2001). P2Xi causes smooth muscle contraction (Banks et al., 
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2006), and P2X4 regulates vascular tone (Yamamoto et al., 2006). Although little is 
known about the function of CNG channels in VSM, they are reportedly expressed in 
freshly isolated smooth muscle, and may play a regulatory role in VSMC (Cheng et al., 
2003). SOCE has been implicated in contraction, proliferation and gene transcription in 
smooth muscle, suggesting SOC play an important role in regulating intracellular Ca2+ 
in VSM. Finally, Ca2+-permeable SAC are reportedly expressed in mesenteric, 
coronary, bladder and cerebral arteries (Welsh et al., 2002; Wu et al., 2001). Ca2+ influx 
through Ca2+ channels can also occur in cells in the absence of any stimulus. This Ca2+ 
leak is believed to occur through distinct channels referred to as leak channels. 
Reports dating back to the late 1970s suggested ROC and SOC in VSM were formed by 
a novel and distinct Ca2+ channel (Bolton, 1979; Van Breemen et al., 1978). It is now 
apparent that a likely candidate for this novel Ca2+ channel are members of the TRP 
channel superfamily, many of which have now been identified as ROC, SOC, SMOC 
and SAC (Beech et al., 2004). TRP channels are suggested to be responsible for 
nonselective cation current in VSM (Walker et al., 2001), and specifically have been 
demonstrated to have a functional relevance; TRPC6 and TRPV2 are suggested to form 
SAC (Muraki et al., 2003; Welsh et al., 2002), TRPC1 is a candidate for a native SOC 
in smooth muscle (Xu et al., 2001), and furthermore Ca2+ leak channels are suggested to 
be TRP channels in smooth muscle (Beech et al., 2004). 
Transient receptor potential (TRP) channels 
The Transient Receptor Potential (TRP) channels form a diverse superfamily of cation 
channels, and were originally identified in Drosophila melanogaster as the genes 
responsible for visual transduction (Montell et al., 1989). Photoreceptors in the trp 
mutant displayed a transient, rather than sustained, response to light stimulation, thus 
termed the transient receptor potential. This response was characterized by a reduction 
in Ca2+ entry, indicative of a defect in the activation of a cation channel. TRP channels 
are now recognised as the largest known family of ion channels, with 28 mammalian 
TRP channels identified thus far. Despite sharing a common putative 6 transmembrane 
domain structure and permeability to cations, TRP channels are activated by a huge 
diversity of signals, including both external stimuli and changes in local intracellular 
environment. 
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Based on sequence homology, TRP channels are divided into seven subfamilies; 
canonical or classical (TRPC), vanilloid receptor-related (TRPV), and melastatin-related 
(TRPM), as well as the more distantly related polycystins (TRPP), mucolipidins 
(TRPML), ankyrin (TRPA) and NOMPC (TRPN) (Figure 1.4). 
TRP structure 
TRP protein conformation is believed to resemble that of classical voltage-gated ion 
channels, in particular KK channels for which the structure is well characterised. 
Intracellular N and C termini are connected to 6 transmembrane domains designated S 1- 
S6, and the S5-S6 linker forms the pore. TRP channels are also presumed to function as 
tetramers. In contrast to voltage-gated channels, TRP channels are not believed to be 
voltage activated, as the majority of family members lack the necessary positive 
residues on S4. However, voltage-modulation of TRP channels has been demonstrated 
(Nilius et al., 2005b). Negatively charged residues that form selectivity filters in the 
pore loop of ion channels are often absent in TRP channels, therefore they tend to be 
non-selective cation channels. However, some family members, such as TRPV6, 
display high selectivity for Cat+. 
There are also common structural features conserved between the different subfamilies 
(figure 1.5). These include coiled coil domains in the N- and C-termini of TRPC, TRPM 
and TRPA, plus a number of N-terminal ankyrin repeats that range from zero in TRPM, 
TRPP and TRPML, to as many as 14 in TRPA 1 (Clapham, 2003). There is also a highly 
conserved C-terminal sequence that immediately follows S6, termed the TRP domain. 
In TRPC, the TRP domain contains the sequence EWKFAR which is referred to as the 
TRP box, but this is less conserved in TRPV and TRPM (Clapham, 2003). C-terminal 
CaM binding domains are present in TRPV, TRPM and TRPC, but have not yet been 
identified in other family members. 
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Figure 1.4. Mammalian TRP family tree The evolutionary distance is shown by the 
total branch lengths in point accepted mutations (PAM) units, which is the mean 
number of substitutions per 100 residues. Figure and legend reproduced from (Clapham, 
2003). 
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Figure 1.5. Mammalian TRP superfamily TRP channels contain 6 TM domains plus 
a pore loop. A. The six mammalian subfamilies. Domains indicated include: A, Ankyrin 
repeats; CC, coiled-coil domain; TRP, TRP domain; enzyme, protein kinase domain 
(TRPM6/7) or ADP-ribose pyrophosphatase domain (TRPM2). B. Putative TRP 
channel tetramer forming homo- or heteromeric channels. S5-S6 linkers (blue) line the 
pore. 
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TRPC 
Members of the mammalian TRPC subfamily are the closest relatives of their 
Drosophila counterparts, with a common function as receptor operated channels. There 
are 7 mammalian TRPC proteins, subdivided into 4 subfamilies. Although mRNA has 
been detected in mouse tissue, TRPC2 is a pseudogene in human (Vannier et al., 1999). 
The TRPC family can be divided into subgroups based on sequence homology and 
functional similarities; TRPC1,4 and 5; TRPC3,6 and 7; and TRPC2 (Clapham et al., 
2001). All TRPC members contain the TRP box, 3-4 N-terminal ankyrin repeats, a C- 
terminal coiled coil and a C-terminal CaM/IP3R binding site, plus they are all inhibited 
by lanthanides. 
TRPC3,6 and 7 form non-selective, diacylglycerol (DAG)-activated cation channels 
that can interact with each other to form heteromultimers (Hofmann et al., 2002). 
TRPC4 and 5 are unusual in that they are activated by micromolar concentrations of 
lanthanides, and inhibited by DAG. Both channels contain a PDZ-binding motif at their 
C terminus, and form heteromultimers with TRPC1, to which they are closely related 
(Strubing et al., 2001). TRPC1, TRPC3, TRPC4 and TRPC7 are reported to form SOC, 
but the store-operation of TRPC5 is controversial. TRPC5 is predominantly expressed 
in brain tissue, and is activated by many different signals within a single cell including 
receptor stimulation, lanthanides and lysophospholipids (Flemming et al., 2006; Zeng et 
al., 2004) 
TRPV 
The TRPV family has 6 members, and is named after founding member TRPV 1, which 
is activated by the inflammatory vanilloid, capsaicin. All TRPV family members 
contain N-terminal ankyrin repeats and the TRP domain; however the TRP box is less 
conserved than in TRPC and TRPM families. 
TRPVI-4 are non-selective cation channels capable of activation by multiple stimuli, 
commonly heat. Referred to as `thermoTRPs', heat-activated TRPV channels play a role 
in thermosensation. TRPV 1 is well characterised, and known to be activated by many 
different stimuli including noxious chemicals (capsaicin, endocannabinoids, 
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anandamide, camphor, piperine and allicin), PIP2 and heat (? 43°C) (Venkatachalam et 
al., 2007). Activation is enhanced by exposure to low pH. TRPV2 and TRPV4 are both 
sensitive to hypotonic shock, presumably as a result of cell swelling. Specifically the 
stretch activation of TRPV4 is believed to occur through PLA2-mediated arachadonic 
acid and subsequent metabolites (Watanabe et al., 2003). TRPV3 is also activated by 
arachadonic acid and menthol (Hu et al., 2006; Macpherson et al., 2006). 
TRPV5 and TRPV6 are not activated by heat, and unlike other TRPV members, show 
high selectivity for Cat+. Their activity is regulated following insertion into the plasma 
membrane, and form heteromers with each other (Hoenderop et al., 2003). 
TRPP 
There are 2 TRPP channels characterised thus far; TRPP 1 and TRPP2. Although they 
form non-selective cation channels, they share little homology with other TRP 
members, and TRPP1 contains a much larger 1St extracellular loop. TRPP2 is mainly 
localised in intracellular membranes and complexes to TRPP1 in order to translocate to 
the plasma membrane to form cation channels (Qian et al., 2003). TRPP1 putatively 
contains 11 TM domains, however the structural similarity of the first 6 domains means 
it is classed as TRPP channel. Two additional TRPP homologues, TRPP3 and TRPP5, 
have been identified in mammals. TRPP3 is localized to a taste receptor cells in the 
tongue, and mice lacking TRPP3 do not display taste responses to sour stimuli 
(Ishimaru et al., 2006). The function of TRPP5 is unknown. 
TRPML 
Named after the founding member mucolipin-1, there are 3 mammalian TRPML 
proteins. TRPMLI and TRPML2 reside in the lysosomal membrane as a result of 
lysosomal targeting signals, and TRPML3 localises to the ER membrane. Only 
TRPML1 has been shown to form a non-selective cation channel, and is reported to 
regulate lysosomal Ca2+ release. TRPMLI is also reported to be permeable to 
monovalent cations, and may allow proton flux to regulate acidity of the lysosome. 
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Furthermore, TRPML is a likely candidate for the lysosomal NAADP-activated Ca2+ 
channel (Zhang et al., 2007). 
TRPA 
The single mammalian TRPA channel, TRPA1, was previously referred to as ANKTMI 
due to the presence of multiple N terminal ankyrin repeats. TRPA 1 is a further example 
of the ability of TRP to be stimulated by a multiplicity of signals. It is activated by 
pungent compounds including isothiocyanates, allicin, cinnemaldehyde, acrolein, 
tetrahydrocannabinol, plus components of wasabi and horseradish, products of PLC 
stimulation, and noxious cold. TRPA1 is suggested to act as the mechanosensitive 
transduction channel of vertebrate hair cells, which functions as a `gating spring' 
formed by the multiple ankyrin repeats (Corey et al., 2004). 
TRPN 
Studies in Drosophila demonstrated that loss-of-function mutations in the no 
mechanoreceptor potential C (nompC) gene abolished mechanosensory signalling 
(Walker et al., 2000). This suggests that the nompC gene encodes an ion channels 
necessary for mechanosensory transduction, and now referred to as TRPN channel. 
TRPN channels are not present in mammals. They contain several conserved TRP 
features, including the TRP box, plus N terminal ankyrin repeats. Similar to TRPA1, the 
presence of ankyrin repeats suggests they are likely to be mechanically gated. 
TRP1i 
The TRPM subfamily contains 8 members that are further divided into 4 subgroups of 
pairs which display significant sequence homology; TRPM 1 and TRPM3, TRPM2 and 
TRPM8, TRPM4 and TRPM5, and TRPM6 and TRPM7. All members are relatively 
long proteins that contain conserved features such as the TRP box. However, a `TRPM 
homology region' of approximately 700 amino acids replaces the N-terminal ankyrin 
repeats. TRPM members have multiple protein forms as a result of alternative splicing 
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events. The founding member melastatin (TRPM1), for which the family is named, has 
been shown to be downregulated in melanoma cell lines (Duncan et al., 2001). There 
are no known activators for the TRPM 1 channel, and it is believed to be constitutively 
active. 
TRPM2 is a widely expressed, non-selective cation channel that can be activated by 
hydrogen peroxide (H202), ADP-ribose (ADPR), arachadonic acid and tumour necrosis 
factor a (TNFa). It contains a C-terminal Nudix enzymatic domain, homologous to 
human NUDT9 ADPR hydrolase, which functions as an ADPR pyrophosphatase 
(Nagamine et al., 1998). This domain is unique to TRPM2, and binds intracellular 
ADPR (Perraud et al., 2001). Intracellular Ca2+ sensitises the channel to ADPR 
(McHugh et al., 2003). Ca2+ influx resulting from activation by TNFa or H202 leads to 
cell death, thus TRPM2 is believed to be a cell fate modulator (Hara et al., 2002). 
Recently, TRPM2 has been reported to be activated by warm temperatures via direct 
heat-evoked channel gating, and ADPR-induced activity is potentiated at increased 
temperatures (Togashi et al., 2006). The closely related TRPM8 also exhibits 
temperature-dependant gating, and can be regulated by both cold stimuli and the cooling 
agents menthol and icilin (Peier et al., 2002). TRPM8 activity is regulated by PIP2 
binding to regions in the TRP box, suggesting regulation of many TRP channels by PIP2 
may depend on this highly conserved region (Rohacs et al., 2005). 
Unlike other members of the TRP family, TRPM4 and TRPM5 are impermeable to 
Cat, and instead are selective for monovalent cations (Nilius et al., 2005a). They are 
also directly gated by intracellular Ca2+ and regulated by PIP2. TRPM4 is expressed as 
two splice variants, a smaller, constitutively active TRPM4a variant, plus a longer and 
Ca2+-activated TRPM4b variant. TRPM5 is also sensitive to temperature change, and is 
activated by heat in the range of 15-35°C (Talavera et al., 2005). 
TRPM6 and TRPM7 have C terminal enzymatic activity in the form of an a-kinase 
domain, and are thought to be involved in magnesium homeostasis (Runnels et al., 
2002). Both are selective for divalent cations, and are inhibited by intracellular Mgt+. 
Furthermore the 2 related channels can coassemble to form multimeric structures 
(Chubanov et al., 2004). TRPM7 activity is regulated by pH, ATP, lipids, and 
translocation, and the channel is upregulated following a decrease in extracellular pH 
(Venkatachalam et al., 2007). 
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TRPM3 
TRPM3 forms non-selective cation channels, and shares significant sequence homology 
with TRPM I. While endogenous protein is primarily expressed in the brain, mRNA has 
also been detected in human kidney, brain, spinal cord, liver, testis, ovaria and pancreas 
(Grimm et al., 2003; Lee et al., 2003a). Although present in human and bovine kidney, 
TRPM3 is not expressed in the same tissue in mouse, suggesting species and tissue- 
specific expression of the protein (Grimm et al., 2003). Overexpression of the protein in 
HEK 293 cells shows it is primarily located at the plasma membrane, indicating a 
functional membrane-spanning channel (Grimm et al., 2003). 
The TRPM3 gene is alternatively spliced to encode functionally distinct splice variants, 
all of which are constitutively active cation channels. The human variant hTRPM31325, 
which encodes a protein of 1325 amino acids, was originally reported to be activated by 
a reduction in extracellular osmolarity, presumably as a result of cell swelling (Grimm 
et al., 2003). Subsequently lipid activators of hTRPM31325 were described; specifically 
intermediates in sphingolipid metabolism including D-erythro-sphingosine (SPH) and 
the related analogues N, N-dimethyl-D-erythro-sphingosine (DMS) and dihydro-D- 
erythro-sphingosine (DHS) (Grimm et al., 2005). The effect appears specific, as 
additional lipid activators were ineffective, and SPH did not activate other TRP family 
members. In addition, activation occurred independently of PKC, IP3R and Ca2+ store 
depletion. It is not clear from this study whether SPH activates the TRPM3 channel 
directly, and it is possible that activation is the result of SPH-induced cell swelling. A 
further 6 human variants have been identified, designated hTRPM3a-f (Lee et al., 
2003a). These variants possess much shorter N termini, and as a result lack the TRPM 
homology region present in other TRPM proteins. The variant hTRPM3a is comprised 
of 1555 amino acids, and is reported to form a store-operated channel, showing 
enhanced Ca2+entry when stores are first depleted by thapsigargin or carbachol (Lee et 
al., 2003a). The increased Ca2+ in hTRPM3a-expressing cells is small, and furthermore 
SPH-activation of hTRPM31325 is not influenced by thapsigargin, suggesting store 
depletion may not be a predominant regulatory mechanism of TRPM31325 (Grimm et 
al., 2005). 
A further 5 variants have been identified in mouse, mTRPM3aI-5 (Oberwinkler et al., 
2005). A single splicing event creates a longer pore region in TRPM3a1, and 
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comparison with TRPM3a2 demonstrated a change in the cation selectivities 
(Oberwinkler et al., 2005). Both variants are inhibited by Mgt+. Splice variants with a 
shorter pore (hTRPM31325 and mTRPM3a2) are permeable to divalent cations, however 
TRPM3a1 exhibited no inward current in the presence of high extracellular divalent 
cations (Grimm et al., 2005; Oberwinkler et al., 2005). Alternative splicing is likely to 
be a method to regulate activation and functional properties of expressed TRPM3 
channels. 
The physiological function of TRPM3 is unknown, but the ability of TRPM31325 to 
respond to changes in extracellular osmolarity, together with its localisation to the 
kidney, suggests a role for the channel in renal Ca2+ homeostasis. Interestingly TRPM3 
mRNA is downregulated in renal tumours, so perhaps reduced TRPM3 expression plays 
a role in tumorigenesis (Lee et al., 2003a). Northern blot analysis shows a high 
expression of TRPM3 in epithelial cells of the choroid plexus, the area of the brain 
responsible for the production of cerebrospinal fluid (Oberwinkler et al., 2005). 
TRP channels in disease 
Mutations in TRP channels are linked to several human diseases. Autosomal dominant 
polycystic kidney disease (ADPKD) results from mutations in the PKD2 gene, which 
encodes polycystin-2 (TRPP2) (Kottgen, 2007). ADPKD is characterised by the 
replacement of healthy renal tissue with fluid filled cysts. The gene encoding TRPMLI 
is mutated in mucolipidosis type IV (MLIV), a lysosomal storage disorder characterised 
by large intracellular lysosomes (Qian et al., 2005). The exact roles of TRPP and 
TRPML channels in the progression of ADPKD and MLIV have yet to be elucidated. 
TRPC6 and TRPM6 are also associated with kidney disease. Mutations in the TRPC6 
gene are linked to focal segmental glomerulosclerosis (Huber et al., 2006), while 
mutation of the gene encoding TRPM6 results in hypomagnesemia with secondary 
hypocalcemia, presumably as a result of defective Mg2+ homeostasis (Walder et al., 
2002). Ca2+ and Mg2+ deficiency is also linked to guamanian amyotrophic lateral 
sclerosis and parkinsonism dementia, and a TRPM7 variant produces a protein with a 
missense mutation associated with these disease states (Hermosura et al., 2005). 
In addition to abnormalities that result from gene mutation, the expression of certain 
TRP genes can also be correlated to human disease, specifically cancer. Both TRPV6 
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and TRPM8 are upregulated in prostate cancers (Tsavaler et al., 2001; Wissenbach et 
al., 2004). Northern blot analysis indicated TRPM8 was also upregulated in breast 
colon, lung and skin cancers (Tsavaler et al., 2001). Conversely TRPM1 is 
downregulated in malignant melanomas, suggesting it in fact functions as a tumour 
suppressor protein (Duncan et al., 2001). 
Evidence for TRP expression in VSM 
Members of TRPC, TRPV, TRPM and TRPP are all expressed in vascular smooth 
muscle, but for many the physiological function of the channel in the vasculature has 
yet to be elucidated (Dietrich et al., 2006). 
All TRPM channels, except TRPMI, are expressed in the vasculature (Yang et al., 
2006). The PKC-dependent regulation of TRPM4 activity regulates myogenic tone 
(Earley et al., 2004), and TRPM6 and TRPM7 are required for Mg2+ homeostasis in 
A7R5 smooth muscle cell line (He et al., 2005). Furthermore TRPM7 is highly 
expressed in VSM, and when the blood vessel endothelium is damaged, the shear stress 
of blood flow results in the translocation and accumulation of TRPM7 at the plasma 
membrane, suggesting a role in the pathological response to vessel injury (Oancea et al., 
2006). 
TRPCI forms a SOC in vascular smooth muscle (Xu et al., 2001), and is present in both 
contractile and proliferative VSMC (Beech, 2005). Specifically, TRPC1 is linked to the 
excessive proliferation of VSMC that results in neointimal hyperplasia (Kumar et al., 
2006). TRPC4 is also implicated in store-mediated regulation of VSMC proliferation 
(Zhang et al., 2004), while TRPC5 is implicated in SIP-induced VSMC migration (Xu 
et al., 2006b). TRPC3 and TRPC6 are involved in both receptor-mediated and pressure- 
induced vasoconstriction, suggesting they play a role in regulating myogenic tone and 
blood pressure (Inoue et al., 2006). TRPC7 is also a ROC in the vasculature, and is 
predicted to have similar functions to TRPC6 (Maruyama et al., 2006). 
TRPPI and TRPP2 are also expressed in the vasculature, where they are suggested to 
form homo- and heteromultimeric complexes with TRPC 1 (Tsiokas et al., 1999). 
Patients with polycystic kidney disease, which results from mutations in TRPP genes, 
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display thinning of arterial walls which can lead to internal bleeding. Furthermore SOC 
Ca2+ entry is reduced in TRPP2 knockout mice, and as these mice develop 
haemorrhaging the suggestion is that TRPP2 is necessary for maintaining the structural 
integrity of vessels (Kim et al., 2000). 
The function of TRPV channels in VSM is less well characterised. TRPV mRNA is 
expressed in rat aorta and pulmonary artery, and the established TRPV4 activator 
4aPDD evoked Ca2+ responses in blood vessels, suggesting TRPV4 protein is expressed 
and functional (Yang et al., 2006). Furthermore TRPV4 is suggested to form a Ca2' 
signalling complex with RyR and Ca2+-activated K+ channels in VSM, which is 
responsible for arterial contraction (Earley et al., 2005). TRPV2 expression has been 
confirmed in mouse aortic myocytes where it is activated by hypotonic stimulation, 
suggesting it forms a stretch-activated channel in VSM (Muraki et al., 2003). 
In summary, several TRP family members are demonstrated to be expressed, and to 
have functional roles, in VSM. In order to improve understanding of the role of these 
multifunctional channels in vascular biology and disease, further investigation is needed 
to characterise their activation mechanisms, endogenous modulators, and putative 
interactions with other proteins and signalling complexes. The development of selective 
pharmacological agents as tools will allow for the investigation and characterisation of 
existing and novel TRP channels in the vasculature. 
Pharmacological agents as channel blockers 
Channel blockers are molecules that bind to an ion channel and inhibit the flow of ions 
through its pore. They may do this directly, or through changing the conformation of the 
protein to its closed state. Specific inhibitors are essential to characterise ion channels, 
determine their physiological roles and produce new drugs. Traditionally, ion channel 
blockers were naturally occurring substances such as toxins. Synthetic ion channel 
blockers have also proved useful, for example the use of nifedipine was central to 
distinguishing between VGCC types. Novel channel blockers can be identified through 
screening vast chemical libraries using high throughput systems. 
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As well as inhibiting channel function by directly blocking the pore, recent methods can 
inhibit function by reducing channel expression. One example is small interfering RNA 
(siRNA), in which small, double stranded sections of RNA interfere with the expression 
of a gene's complementary DNA through involvement in the RNA interference (RNAi) 
pathway. siRNA can be transiently transfected or recombinantly expressed in the 
desired cell type. A drawback is that siRNA has varying effects in different cell types, 
and can induce non-specific effects such as triggering an immune response. A solution 
may be to convert siRNA into naturally occurring microRNAs. 
TRP channel blockers 
There are many existing TRP antagonists that have been used to investigate TRP 
channel function. A summary of TRP channel agonists and antagonists is presented in 
Tables 1.1 & 1.2. 
Lanthanide ions (Gd3+, Lai+) block Ca2+ permeable cation channels, and have been used 
to characterise channels of the TRP family (Halaszovich et al., 2000). Although known 
to inhibit many TRP family members, micromolar concentrations of lanthanides 
activate TRPC4 and TRPC5 (Zeng et al., 2004). Although the exact mechanism of 
inhibition is not understood, Gd3+ has been postulated to interact with the lipid 
membrane to antagonize mechanosensitive channels (Hamill et al., 1996). The 
imidazole SKF96365 is a known inhibitor of both receptor-mediated and store-operated 
Ca2+ entry, and blocks all TRPC family members except TRPC4, and also TRPV2 
(Halaszovich et al., 2000; Inoue et al., 2001). 
2-Aminoethoxydiphenylborate (2-APB) inhibits store-operated calcium channels and 
several TRP isoforms (Xu et al., 2005a). The mechanism by which 2-APB regulates 
TRP channels is complicated by the fact that inhibition is not a common feature as 
several TRP channels are unaffected by 2-APB, and interestingly, 2-APB stimulates 
TRPV 1, TRPV2 and TRPV3 (Chung et al., 2004). Inhibition is concentration- 
dependent, occurs from the extracellular side of plasma membrane only, and exhibits 
slight voltage-dependence, suggesting that 2-APB disrupts cation flow through the 
channels either by entering the electric field, or by modulating channel gating (Xu et al., 
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2005a). It is not known whether stimulation by 2-APB occurs at the same 2-APB 
binding site, or via a distinct site. 
Ruthenium red is a non-selective ryanodine receptor antagonist which blocks all TRPV 
family members, plus TRPA1 and TRPM6 (Dray et al., 1990; Nagata et al., 2005; 
Voets et al., 2004b), and also Cat+-activated K+ channels (Wu et al., 1999). Ruthenium 
red is a highly charged inorganic cation and is suggested to block L-type Ca2+ channels 
in guinea-pig isolated ventricular heart cells by interacting with negatively charged pore 
residues that are involved in Ca2+ permeation (Malecot et al., 1998). In TRPV 1, 
inhibition by ruthenium red is dependent upon 4 acidic residues in the pore region of the 
channel that form a ring of negative charge (Garcia-Martinez et al., 2000). Specifically, 
mutation of an aspartate residue reduced sensitivity of the channel to ruthenium red 
blockade, and reduced its permeability to divalent cations. This suggests a direct 
interaction of the aspartate residue with both divalent cations and ruthenium red, 
presumably because the spatial arrangement of acidic carboxyl groups creates a high 
affinity binding site for cationic molecules in the pore. However, the mutation of the 
aspartate residue did not completely prevent the inhibitory effect of ruthenium red, 
indicating a contribution of other amino acid residues from the pore region of the 
channel. 
Extracellular application of the non-steroidal anti-inflammatory agent flufenamic acid 
(FA) inhibits ADPR-induced current in TRPM2-expressing cells (Hill et al., 2004a). 
This action is not selective, as FA also inhibits TRPM4 and TRPM5, plus TRPC3 
TRPC7 and TRPC5, while increasing TRPC6 currents (Inoue et al., 2001; Lee et al., 
2003b; Tesfai et al., 2001; Ullrich et al., 2005). Commonly used to treat rheumatoid 
arthritis, FA also targets chloride channels, voltage activated Na+ channels, voltage 
activated K+ channels, and GABAA receptors (Naziroglu et al., 2007). Prolonged 
application of FA produced irreversible inhibition of TRPM2, suggesting a 
conformational change in the TRPM2 protein occurs, rather than direct binding and 
blockade of the pore. The imidazole antifungal agents clotrimazole (1-[(2-chlorophenyl) 
diphenylmethyl]-1H-imidazole) and econazole (1-[2-[4-chlorophenyl) methoxy]-2-(2,4- 
dichlorophenyl) ethyl]-1H-imidazole) have also been described as TRPM2 blockers 
(Hill et al., 2004b). Again these agents are irreversible and non specific, as econazole 
has also been shown to inhibit TRPV5 (Nilius et al., 2001). 
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In addition, both ADPR-induced currents and H202-induced Ca2+-entry can be inhibited 
by the PLA2 inhibitor N-(p-amylcinnamoyl)anthranilic acid (ACA) (Kraft et al., 2006). 
Other PLA2 inhibitors and intracellularly applied ACA were ineffective, suggesting that 
the block is independent of PLA2 inhibition. ACA also inhibited both menthol-induced 
TRPM8 current and A1F4 -induced TRPC6 current, proving it is not selective. Inhibition 
by ACA was accelerated by decreasing pH therefore it would appear that ACA, a weak 
acid at higher pH7.4, is more effective in its uncharged state. Inhibition is likely to be 
due to modulation of channel gating as channel open probability was reduced and the 
block was not voltage dependent (Kraft et al., 2006). 
TRPC6 is also inhibited by the myosin light chain kinase (MLCK) inhibitor, 1-(5- 
chloronaphthalene-l-sulphonyl)homopiperazine (ML-9). Inhibition occurs regardless of 
which side of membrane it is applied, and is independent of MLCK as other MLCK 
inhibitors had no effect. ML-9 also inhibits TRPC5 but activates TRPC7 (Shimizu et 
al., 2006). 
Polyamines including putrescine, spermidine, spermine, and the synthetic polyamine 
philanthotoxin-343 (PhTX-343) cause irreversible, dose-dependent block of TRPM7 
The voltage-dependence of the inhibition indicates a blocking site within the electric 
field of the ion channel, accessible from the extracellular side only, thus causing 
disruption of cation flow through the pore (Kerschbaum et al., 2003). Spermine also 
blocks TRPM5 and the long splice variant TRPM4b (Nilius et al., 2004a; Ullrich et al., 
2005). 
The TRPV 1 antagonists capsazepine, BCTC, and iodo-resiniferatoxin (I-RTX) are 
suggested to share the same binding pocket with the potent agonists capsaicin and 
resiniferatoxin (RTX) at transmembrane domains 2-3 of TRPV 1 (Jordt et al., 2002; 
Valenzano et al., 2003). These compounds are similar in that they share a relatively 
polar aromatic head group linked to a hydrophobic tail group. However, capsazepine 
can also inhibit proton activation of the channel, suggesting a more general disruption 
of channel gating (Tominaga et al., 1998). N-(4-tertiarybutylphenyl)-4-(3- 
cholorphyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC) and iodo- 
resiniferatoxin (I-RTX), an analogue of the potent TRPV 1 activator resiniferatoxin 
(RTX), also inhibit TRPV 1 (Bevan et al., 1990). Many of these agents are non-specific, 
and BCTC, thio-BCTC and capsazepine have been shown to block the TRPMB menthol 
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response, while I-RTX and capsazepine had no effect (Behrendt et al., 2004). Residues 
necessary for binding these antagonists may be conserved between these two channels, 
as the predicted capsaicin binding region of TRPV 1 shares 36% sequence homology 
with the equivalent region in TRPM2. 
The epithelial Na' channel blocker amiloride also inhibits TRPC6, TRPC7, TRPA 1, 
TRPMLI and TRPP2 (Nagata et al., 2005). Amiloride and its analogues block by 
interacting with an extracellular part of the channel that is outside of the electric field of 
the pore (Busch et al., 1994). TRPC members TRPC3, TRPC5 and TRPC6 can be 
inhibited by the Na+/Ca2' exchange inhibitor KB-R7943, although the mechanism for 
this block is not established (Kraft, 2007). 
It is clear that existing TRP antagonists lack specificity, and cannot distinguish between 
members of the same TRP subfamily, or even between different ion channels. However, 
the differential modulation of different TRP members by compounds such as 
lanthanides, 2-APB and FA can be exploited, and it is possible to use a combination of 
non-specific blockers in order to identify some TRP isoforms in native cells. For 
further, specific characterisation of these channels, selective tools must be developed. 
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Name Agonists Antagonists 
TRPC1 Store depletion, membrane stretch Gd +, La +, SKF96365,2-APB 
TRPC2 DAG 
TRPC3 Store depletion, DAG Gd +, La-", SKF96365,2-APB, KB- 
R7943 
TRPC4 Store depletion, CaM antagonists La +(mM), 2-APB 
TRPC5 Gd +& La +(µM), SIP, LPC, La + (mM), SKF96365,2-APB, 
protons, store depletion CaM antagonists, KB-R7943, ML-9 
TRPC6 A1F4 , DAG, flufenamic acid, 
PIP3 Gd +, La +, SKF96365,2-APB, 
amiloride, ACA, KB-R7943, ML-9 
TRPC7 Store depletion, DAG, ML-9 La +, SKF96365, amiloride 
TRPV1 Heat (43°C), PIP2, vanilloids, BCTC, capsazepine, ruthenium red 
anandamide, camphor, piperine, 
allicin, ethanol, eicosanoids, 
nicotine, protons, 2-APB 
TRPV2 Heat (52°C), cell swelling, 2-APB La +, SKF96365, ruthenium red 
TRPV3 Heat (>33°C), PUFAs, menthol, Ruthenium red 
camphor, 2-APB 
TRPV4 Constitutively active; heat (>27°C), Gd +, La +, ruthenium red 
cell swelling, 4aPDD, PMA, 
epoxyeicosatrienoic acids 
TRPV5 Constitutively active Gd +, La +, ruthenium red, econazole 
TRPV6 Constitutively active; store La +, ruthenium red 
depletion, 2-APB potentiates 
TRPA1 Cold (17°C), icilin, isothiocyanates, Gd +, ruthenium red, menthol, 
allicin, cinnemaldehyde, acrolein, gentamicin, amiloride 
cannaboids, membrane stretch, 
DAG, PUFAs 
TRPML Constitutively active; activity Amiloride 
enhanced by Ca2+, pH, NAADP 
TRPP2 Constitutively active; activity Gd 3+ La +, amiloride, 2-APB, 
enhanced by Ca2+, PIP2 activity suppressed by TRPP 1 
TRPP3 Constitutively active; activity Gd +, La +, flufenamic acid 
enhanced by Ca2+ 
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Name Agonists Antagonists 
TRPMI Constitutively active Gd +, La + 
TRPM2 Intracellular ADPR, NAD, Ca +, Flufenamic acid, econazole, 
arachadonic acid, H2O2 clotrimazole, ACA 
TRPM3 Constitutively active; activity Gd +, La +, Mg +, 2-APB 
enhanced by store depletion, cell 
swelling, sphingolipids 
TRPM4 Ca +, voltage modulated, PIP2 Intracellular nucleotides, flufenamic 
acid, spermine 
TRPM5 Heat (15-30°C), Ca +, voltage Flufenamic acid, spermine, H+ 
modulated, PIP2 
TRPM6 Constitutively active Mg +, ruthenium red 
TRPM7 ATP, protons, activation of PKA, Mg +, La +, spermine, H+, 2-APB 
PIP2 
TRPM8 Cold (<26°C), menthol, icilin, PIP2 La +, BCTC, capsazepine, ACA, 2- 
APB 
Table I. I. Pharmacology and regulation of TRP channels Mechanisms of action 
discussed further in main text. 
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Antibodies as channel blockers 
Antibodies are immunoglobin proteins of the immune system that recognise and 
neutralise foreign objects, known as antigens. They are synthesised and secreted by 
plasma cells derived from immune system B cells as part of the humoral immune 
response. B cells can recognise and engulf an antigen, and present MHC molecules on 
their surface to attract a matching T cell. T cells then secrete cytokines to activate the B 
cells, causing them to proliferate and differentiate into antibody secreting plasma cells. 
When the secreted antibodies bind the target antigen, they mark it for destruction by 
killer T cells. 
Antibody structure 
Antibodies are Y-shaped, and consist of 4 polypeptide chains connected by disulphide 
bonds. There are 2 identical heavy chains (-50 kDa) and 2 identical light chains (-25 
kDa), divided into constant and variable regions (Figure 1.6). The variable regions form 
the antigen-binding site, and are responsible for the antibody's specificity. The antigen- 
binding sites are identical, and are each complementary to a small area on the surface of 
the antigen molecule. They are formed from several loops of polypeptide chain that can 
be mutated to change the amino acid sequence, without changing the basic antibody 
structure, allowing for huge diversity. The constant regions determine immune function, 
and are used to divide antibodies into 5 major classes, IgA, IgD, IgE, IgG and IgM. 
Following exposure to antigen, IgM are produced, and after -10 days, IgG are 
produced. This is referred to as the primary immune response. If the immune system is 
exposed to the antigen for a second time, B cells will remember the antigen, and launch 
a secondary immune response. 
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Figure 1.6. Structure of immunoglobulin type G (IgG) The `Y' shaped IgG molecule 
consists of 2 'heavy' chains composed of 4 domains, and 2 `light' chains composed of 2 
domains. The N-terminal variable regions of both the heavy and light chains form the 
antigen binding sites. 
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Polyclonal and monoclonal antibodies 
Polyclonal antibodies are a mixture of structurally different IgG immunoglobins 
secreted by different B-lymphocyte lines. Each will recognise a different epitope on the 
sequence of a specific antigen. They are commonly produced by immunising an animal 
with an antigenic peptide over a number of weeks before harvesting the antibodies in 
the serum, called the antiserum. As polyclonal antiserum contains a mixture of 
antibodies that bind the epitope with varying affinities, it can produce non-specific 
effects, but also has a greater chance of binding the target epitope with a higher affinity. 
Monoclonal antibody technology allows for the production of large amounts of identical 
antibodies by fusing the parent B-cell with an infinite myeloma cell to create a 
hybridoma (Kohler et al., 1975). 
Monoclonal antibodies are usually produced in mice, therefore although highly selective 
and useful for functional studies in vitro, they face problems for in vivo use due to the 
host's immunological response. These antibodies will be recognised as of foreign 
origin, and provoke a human anti-murine Antibody (HAMA) immune response in 
human subjects. This would result in rapid destruction and removal of the antibodies, 
probably long before they exerted their intended effect. The host response can be 
reduced through the use of chimeric antibodies, produced by transgenic fusion of 
immunoglobin genes to produce an IgG molecule with variable regions from the host 
animal, and human constant domains. Antibodies that are completely human in origin 
are much more difficult to obtain. However, recent developments have allowed for the 
production of humanised antibodies, which are produced by combining only the mouse 
complementarity-determining region with a human IgG molecule, to further reduce 
HAMA. Such antibodies are produced by selection from phage-display libraries of 
human antibody fragments, or from the immunisation of transgenic mice (Brekke et at., 
2003). Another approach is the use of `intrabodies', where DNA encoding an antibody 
is delivered into the cell, however this method faces problems of cellular delivery 
common with techniques such as siRNA (Lobato et at., 2003). 
Antibodies are large, poorly soluble, and unstable unless stored correctly. The solubility 
of antibodies can be improved by cleaving the protein into Fab and Fv fragments. 
However, these antibody fragments are less immunogenic, less stable, and are prone to 
proteolysis and aggregation. The solution to this problem may be the use of nanobodies, 
36 
fragments of antibodies discovered in camels that contain only the heavy chain, yet have 
evolved to be fully functional, stable, and display a strong affinity for their target 
antigen (Hamers-Casterman et al., 1993). Nanobodies show potential as novel agents 
for the treatment of certain cancers. Nanobodies can be fused with specific enzymes and 
targeted to cancer cell receptors in mice, where they function to convert a pro-drug to a 
toxic chemical that kills any cells in the immediate vicinity (Revets et al., 2005). 
Antibodies in disease 
Autoimmune disease results from the failure of the host to recognise 'self' olecules, 
thus inducing an immune response against its own cells and tissues. Examples include 
rheumatoid arthritis, myasthenia gravis, coeliac disease, diabetes mellitus type 1, 
psoriasis, systemic lupus erythematosus, multiple sclerosis and Graves' disease. 
Myasthenia gravis is a neuromuscular disease characterised by muscle weakness. 
Weakness is typically caused by antibodies directed against nicotinic acetylcholine 
receptors at the post-synaptic neuromuscular junction. These antibodies cause inhibition 
of acetylcholine-induced muscle contraction, either by preventing ACh binding, or by 
marking the receptor for internalisation. While myasthenia gravis is an autoimmune 
disease and features antibodies directed against `self proteins, there is no known 
causative pathogen. A second category of myasthenia gravis results from autoantibodies 
targeted against muscle specific kinase (MuSK) a tyrosine kinase receptor involved in 
the formation of the neuromuscular junction. Antibodies inhibit MuSK binding its 
ligand, agrin. 
Antibodies as tools 
Antibodies can be engineered to recognise any number of surface-expressed proteins, 
allowing for their use in a multitude of experimental procedures. Commonly, purified 
antibodies are used to detect proteins present in a particular lysate using ELISA or 
Western blotting methods, or to examine protein localisation and expression in different 
cell and tissue types using immunohistochemistry. In addition, the high specificity an 
antibody displays for its target antigen, plus the ability to eliminate the antigen from the 
body, makes antibodies attractive as biological tools and therapeutic agents. Such 
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therapeutic antibodies can selectively block the action of a molecule, target specific 
cells, and even deliver other agents to target cells so they can exert their effect (Brekke 
et al., 2003). More recently, antibodies have been recognised as specific ion channel 
blockers, and have demonstrated functions for these particular channel proteins (Dallas 
et al., 2005). 
Antibodies targeted to particular ionotropic neurotransmitter receptor subunits have 
been shown to modulate the function of the receptor. In particular, antibodies targeted to 
extracellular regions of neuronal nicotinic acetylcholine receptors, and P2X2 or P2X4 in 
rat neurones, inhibit ACh- and ATP-evoked currents respectively. Conversely, 
extracellularly targeted antibodies to P2X7 and GABAA receptors increased the 
maximum current amplitude evoked by agonist application (Ekema et al., 2001; Kim et 
al., 2001). Antibodies targeted to the extracellular N-terminus of STIM1 in the plasma 
membrane inhibited Ca2+ entry via arachidonic acid-regulated Cat+-selective channels, 
suggesting a role for STIM1 in the plasma membrane that is independent of store- 
operated Ca2+ entry (Mignen et al., 2007). A polyclonal antibody targeted to the C- 
terminal functional domain of TRPMLI inhibited channel activity, and was used to 
demonstrate TRPML1 forms a lysosomal NAADP-sensitive Ca2+ release channel 
(Zhang et al., 2007). 
E3 targeted antibodies 
Antibodies targeted to the 3`d extracellular loop (E3) of ion channels function as highly 
selective blockers of Ca2+ flux and current through the channel, and can be used to 
elucidate physiological function of the protein. Currently there are 8 E3-targeted 
antibodies. The first study to develop a specific antibody-blocker demonstrated that 
polyclonal antibodies targeted to the voltage-gated K+ channels K,, 1.2 and K,, 3.1 
inhibited whole cell currents, and established that K1.2 in particular is functional in 
neuronal cells (Zhou et al., 1998). Polyclonal antibodies have also proven successful as 
inhibitors of the voltage gated Na+ channel, Na 1.5, plus the TRP channel TRPV 1 
(Klionsky et al., 2006; Xu et al., 2005b). There are fewer studies where monoclonal 
antibodies have been successful as channel blockers. Monoclonal antibodies 
demonstrated specific inhibition of the voltage-gated K+ channel hEagl, implicating a 
function for the channel in modulating tumour cell growth (Gomez-Varela et al., 2007). 
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Furthermore, E3-targeted antibodies have been used to elucidate physiological roles for 
TRP channels expressed in the vasculature. T1E3, directed against the E3 of TRPC1, 
initially revealed a role for TRPC1 as a store-operated Ca2+ channel of vascular smooth 
muscle (Xu et al., 2001). Further studies shown TRPC1 upregulation as a feature in the 
SMC proliferation that underlies neointimal hyperplasia, a key player in occlusive 
vascular disease (Kumar et al., 2006). Importantly, T1E3 significantly reduced 
neointimal growth in cultured human vein sections, suggesting that such selective 
TRPC1 blockers have potential in the prevention of vascular failure. A second anti- 
TRPCI antibody targeted to a different sequence in E3 is commercially available 
(Alomone Laboratories, Israel). This antibody is also an effective blocker of the TRPC 1 
channel, and has been shown to inhibit Ca2+ entry in platelets, suggesting TRPC 1 is 
necessary for the normal response of platelets to agonists that induce SOCE (Rosado et 
al., 2002). The blockade of TRPC5 current using the E3-targeted T5E3 antibody proved 
a functional role for the channel in SOCE in rabbit pial arterioles, and in a separate 
study by the same authors suggested a role for TRPC5 in VSMC motility (Xu et al., 
2006a; Xu et al., 2006b). 
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Aims of the thesis: 
1. To develop an isoform-specific blocker of TRPM3 to use in functional 
experiments. 
2. To determine the expression and function of TRPM3 in vascular smooth muscle. 
3. To identify novel modulators of the TRPM3 channel. 
40 
Chapter 2 
Materials and Methods 
General Solutions 
Solutions were prepared in MilliQ water and adjusted to pH 7.4 using 4M NaOH unless 
otherwise stated. Solutions used in cell culture or microbiology were sterilised by 
autoclaving prior to use. 
Standard bath solution: 130 mM NaCl, 5 mM KCI, 10 mM HEPES, 8 mM D- 
glucose, 1.2 mM MgC12 and 1.5 mM CaC12. Osmolarity is 
kept between 290 and 310 mOsm with mannitol. 
Balanced salt solution: 125 mM NaCI, 5.4 mM KCI, 16 mM NaHCO3,0.8 mM 
MgCl2,5.5 mM D-glucose, 20 mM HEPES, 0.75 mM 
NaH2PO4,1.8 mM CaC12,0.1% BSA. 
Phosphate Buffered Saline: 2.5 mM Na2HPO4,9 mM NaH2PO4 and 154mM NaC1. 
PBS/Tween-20: 0.05 % Tween-20 in PBS. 
Chemicals 
General salts were purchased from Sigma, UK. 
Compound stocks were stored at -20°C unless otherwise stated. Thapsigargin 
(Calbiochem) was stored at a stock concentration of 1 mM in DMSO. Adenosine 5'- 
triphosphate disodium salt (Sigma, UK) was stored at a stock concentration of 100 mM 
in H2O. Verapamil hydrochloride (Sigma, UK) was stored at a stock concentration of 10 
mM in H2O. D-erythro-sphingosine C18 (Sigma, UK or Matreya, US), D-erythro- 
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dihydro-sphingosine (Sigma, UK) and D-erythro-N, N-dimethyl-sphingosine 
(Calbiochem) were stored at stock concentrations of 20 mM and 100 mM in ethanol. 
Glucosylsphingosine (psychosine) from bovine brain (Sigma, UK) was stored at a stock 
concentration of 50 mM in methanol. Pregnenolone sulphate (Sigma, UK) was stored as 
a stock concentration of 100 mM in DMSO. Progesterone, 50-pregnan-3a-OL-20-one 
(pregnanolone), 5a-pregnan-3a-OL-20-one and 5-pregnan-3ß-OL-20-one (all Sigma, 
UK) were stored as stock concentrations of 25 mM and 50 mM in DMSO. 3ß-hydroxy- 
5a-pregnan-20-one (isoallopregnanolone, Sigma, UK) was stored as a stock 
concentration of 25 mM in MeOH. (±)-S-nitroso-N-acetylpenicillamine (Calbiochem) 
and NG-Nitro-L-arginine methyl ester hydrochloride (Sigma, UK) were stored at stock 
concentrations of 100 mM in DMSO. 5-cholesten-3ß-ol-7-one (7-ketocholesterol, 
Sigma, UK) and 7-ß-hydroxycholesterol (Sigma, UK) were stored at stock 
concentrations of 50 mM in ethanol. Water soluble cholesterol (Sigma, UK) and methyl 
ß-cyclodextrin (Sigma, UK) were added to recording solutions directly just before use. 
Hydrogen peroxide (Sigma, UK) was supplied as a 30% (w/w) solution and stored at 
4°C. Gadolinium and carbachol were stored at stock concentrations of 100 mm in water 
at room temperature. 4a-phorbal-12,13-didecanoate (Calbiochem) was stored at a stock 
concentration of 50 mM in DMSO. L-a-lysophosphatidylcholine C16: 0 (Sigma, UK) 
and L-a-lysophosphatidylinositol C16: 0 soybean extract (Avanti Lipids, US) were 
stored at stock concentrations of 50 mM in methanol. Tumour necrosis factor-a (TNFa, 
human) (Sigma, UK) and 12-O-tetradecanoylphorbol 13-acetate (TPA), (Sigma, UK) 
were stored at stock concentrations of 10 gg ml-1 and 1 mM respectively, in H2O. 
The final concentration of vehicle in solutions was never more than 0.1%. For dose 
response curves, stock concentrations were further diluted in vehicle before addition to 
the bath solution at 1: 1000 to keep the final vehicle concentration constant. 
High-throughput compound screen 
The following chemicals were stored at stock concentrations of 10-100 mm at -20°C. 
All were purchased by AstraZeneca from Sigma, UK, unless otherwise described: 
Lipid screen (10 mM stocks in ethanol) - D-erythro-sphingosine, dihydro-D-erythro- 
sphingosine, sphingomyelin (bovine brain), L-threo-Dihydrosphingosine, 
42 
sphingosylphosphorylcholine#, sphingosine-l-phosphatet, N, N-dimethyl-D-erythro- 
sphingosine #, C2 ceramidet, C8 ceramidet, C8 ceramide-l-phosphatet, carbacyclin, 
palmitic acid, a-lipoic acid, stearic acid, 1-O-Octadecyl-2-O-methyl-sn-glycero-3- 
phosphorylcholine, methanandamide, arachadoinc acidt, L-a-Lysophosphatidylcholine 
(egg yolk), platelet-activating factor 16#, lyso-platelet activating factor 16#, platelet- 
activating factor 16 antagonist#, platelet-activating factor 18#, lyso-platelet activating 
factor 18#, ginkolide A#, hepoxillin A3#, Rev 59011, Rev 5901 paraisomert, misoprostol, 
leukotriene Bat, leukotriene C4t, leukotriene D4t, leukotriene E4t, prostaglandin A2 t 
prostaglandin B2t, prostaglandin D2 t' prostaglandin Elt, prostaglandin E2t, 
prostaglandin F2at, prostaglandin I2t, prostaglandin Kit, 15-deoxy-112.14-Prostaglandin 
J2 (15d-PGJ2)t, 9,11-dideoxy-9a, ll a-methanoepoxy Prostaglandin Fla (U46619)t, 
carbocyclic thromboxane A2t, thromboxane B2t, carbaprostacyclint, sulprostonet, 
AH6809t, BW245Ct, trans-BTP Dioxolanet, L-a-lysophosphatidic acidt, 8(S), 15(S)- 
Dihydroxy-Eicosa-5,8,11,17-Tetraenoic Acid (DiHETE)t, 5(S),! 5(S)-DiHETEt, 5(S), 
6(R)-DiHETEt, 15(S)-DiHETEt, 12(R)-DiHETEt. 
purchased from Calbiochem, UK. 
purchased from the Cayman Chemical Company. 
Lipid screen (10 mM stocks in DMSO) - Cholesterol, cholesterol esterase, lipase, ß- 
cyclodextrin, oleic acid, linoleic acid, dihydrolipoic acid, lipase, phosphatidylinositol 
4,5-bisphosphate disodium salt. 
Peptide screen (10 mM stocks in DMSO) - Angiotensin II acetate (human), 
endomorphin I, luteinizing hormone releasing hormone acetate salt (human), melanin 
concentrating hormone (rat), bradykinin acetate, Substance P acetate salt hydrate, 
[Args]-vasotocin acetate salt, [Arg8]-vasopressin, bombesin acetate hydrate , oxytocin 
acetate salt hydrate, thyrotropin releasing factor (Calbiochem). 
Small molecule screen (100 mM stocks in DMSO) - 1-(4- 
methanesulphonamidophenoxy)-3-(N-methyl-3-4-dichlorophenethylamino)-2-propanol 
benzoic acid salt (AM 92016), amiloride hydrochloride, 4-aminopyridine, amiodarone 
hydrochloride, 2-aminoethyl diphenylborinate, amitriptyline hydrochloride, 
anandamide, antozoline hydrochloride, benzocaine, benzyl isothiocyanate, bepridil 
hydrochloride, bisindolylmaleimide I, bupivacaine, calmidazolium chloride, canrenoic 
acid potassium salt, capsaicin, carbamazepine, chloroquine diphosphate, (+)- 
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chlorpheniramine maleate, chlorpromazine hydrochloride, chromanol, cinnamaldehyde, 
citalopram hydrobromide, clotrimazole, 1-benzyl-4-pentylimino-1,4-dihydroquinoline 
hydrochloride (CP 339818), dexamethasone, 4,4'-Diisothiocyanatostilbene-2,2'- 
disulfonic acid disodium salt hydrate (DIDS), 5,5-diphenylhydantoin, diphenhydramine, 
doxepin hydrochloride, epigallocatechin-3-gallate, erythromycin, ethosuximide, 
felodipine, flecainide acetate, fluoxetine hydrochloride, fluspirilene, fluvoxamine 
maleate, gabapentin, haloperidol, imipramine hydrochloride, indapamide, ketoconazole, 
lamotrigine, lidocaine, linopirdine, loperamide hydrochloride, menthol, mepivacaine, 
(±)-methoxyverapamil hydrochloride, mexiletene hydrochloride, mibefradil 
dihydrochloride, N-(6-aminohexyl)-5-chloro-l-naphthalenesulfonamide hydrochloride, 
N-acetylprocainamide hydrochloride, nicardipine hydrochloride, nicotine, nifedipine, 
niflumic acid, nimodipine, nisoldipine, nitrendipine, nortriptyline, papaverine 
hydrochloride, perhexiline maleate salt, 3-phenyl-l-pyrolidin-1-yl-propenone, 
procainamide, propafenone hydrochloride, quinidine sulphate, QX222, QX314, R(+)- 
SCH-23390 hydrochloride, RCL R41,038-1, riluzole, ruthenium red, 1 ß-[3-(p- 
methoxyphenyl)-propyloxy] p-methoxyphenetyl-lH-imidazole-hydrochloride (SK&F 
96365), (±)-solatol hydrochloride, spironolactone, SR 33805, (±)-sulpiride, 
tetraethylammonium chloride, thioridazine hydrochloride, tocainide, triamterene, 
venlafaxine, verapamil, vinpocetine. 
ß-cyclodextrin and methyl ß-cyclodextrin were stored at stock concentrations of 10 mm 
in 1M NaOH at room temperature. When added to bath solution, the pH was adjusted 
back to 7.4 with 1M HCI. 
The final concentration of vehicle in solutions was never more than 0.5%. For dose 
response curves, stock concentrations were further diluted in vehicle before addition to 
bath solution at 1: 1000 to keep the final vehicle concentration constant. 
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TRPM3 cDNA and transformation of competent cells 
Luri-Bertani (LB) medium: 1% tryptone, 0.5% yeast extract, 170 mm NaCl, pH 7.0. 
LB-amp Agar plates: 1% agar in LB medium supplemented with 50 µg ml-1 
ampicillin. 
Transformation of competent cells 
When bacterial cells are treated with calcium chloride they take up water, swell and 
become competent. Competent cells are capable of absorbing foreign DNA, which they 
then replicate along with their own, in a process called transformation. TRPM3 cDNA 
(GenBank accession number AJ505026) was kindly provided by the Harteneck 
laboratory (Berlin, Germany) as a TRPM3-YFP fusion construct subcloned in the 
TOPOpcDNA3.11V5 expression vector (Invitrogen). The coding sequence of YFP was 
subcloned in-frame by using Notl and AvrII restriction sites (Grimm et al., 2003). For 
transformation, approximately 20 ng of plasmid DNA was added to 100 µl of ice- 
thawed XL-GOLD Supercompetent cells (Stratagene), gently mixed, and incubated on 
ice for 30 minutes. The cell mixture was heat shocked at 42°C for 45 seconds to induce 
DNA uptake, followed by further incubation on ice for 1 minute. The mixture was then 
streaked onto LB-amp plates and incubated overnight at 37°C to allow the growth of 
bacterial colonies. The pcDNA3.1 vector contains the ampicillin resistance (amp') gene 
which encodes ß-lactamase, an enzyme that detoxifies ampicillin by catalysing the 
hydrolysis of an integral ß-lactam ring. This allowed for selection of successfully 
transformed bacteria containing pcDNA3.1 that were able to grow on the LB-amp 
plates. A single colony was selected in order to isolate DNA from transformed bacterial 
cells. 
DNA preparation 
5 ml aliquots of LB media supplemented with 50 µg ml-1 ampicillin were inoculated 
with a single colony transformed with TRPM3 plasmid DNA as described, and 
incubated overnight at 37°C, 200 rpm. The resulting cultures were used immediately for 
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small-scale DNA preparation using a Plasmid Mini Kit (Qiagen) or diluted 1: 100 in LB- 
medium for large-scale DNA preparations according to manufacturer's instructions. The 
mini-prep construct was analysed by restriction mapping and sequenced in forward and 
reverse directions to confirm the DNA in the preparation was TRPM3 before large-scale 
preparation using the Endofree Plasmid Maxi Kit (Qiagen). The EndoFree Plasmid 
Maxi Kit has an extra endotoxin removal step to remove lipopolysaccharides. Such 
endotoxins are present in bacterial lysates and can affect transfection of the plasmid 
DNA by competing for transfection reagent. The maxi-prep DNA was sequenced fully 
before storage at -20°C. 
Restriction mapping of DNA 
Restriction enzymes can be used to specifically cleave phosphodiester bonds within 
DNA at a particular sequence of bases. Restriction enzymes ScaI and NdeI (New 
England Biolabs) were used in conjunction with the manufacturers recommended 
buffers (NE buffers 3 and 4 respectively) to cleave DNA. An individual 10 pl reaction 
comprised TRPM3 DNA (1.5 µg), buffer (1 µl), and restriction enzyme (1 µl) and were 
incubated for 1 hour at 37°C. Scal was predicted to cleave DNA twice (both the vector 
and TRPM3) to produce 2 DNA fragments approximately 6.6 kb and 4.3 kb. NdeI was 
predicted to cleave once to produce a single DNA fragment approximately 10.0 kb. 
Restriction enzyme DNA digests were analysed by agarose gel electrophoresis and were 
as predicted, confirming the mini-prep DNA was TRPM3. 
Agarose gel electrophoresis 
TAE buffer: 40 mM TRIS base, 1.14% v/v glacial acetic acid, 0.1mM 
ethylenediaminetetraacetic acid (EDTA). 
2% Agarose-EtBr gel: 0.5 g electrophoresis grade agarose in 25 ml 1x TAE; the 
mixture was heated in a microwave until dissolved, and 2 
µl ethidium bromide (EtBr) was added before pouring. 
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DNA samples were analysed by separation alongside a marker lane on a 2% agarose gel 
containing ethidium bromide. Ethidium bromide intercalates base pairs of DNA and 
fluoresces when exposed to UV light, allowing visualisation of the DNA. Samples were 
mixed with 6x blue/orange loading dye and gels were run at 100 V in an 
electrophoresis tank (BioRad) containing 1x TAE buffer. A Benchtop 100bp DNA 
ladder (Promega), consisting of 11 fragments ranging in size from 100-1000bp in 100bp 
increments, was included for comparison. The DNA fragments were viewed using a 
Bio-Rad gel documentation system and Quantity One software (Bio-Rad). The quantity 
and size of the DNA was estimated by comparison with the intensity and distance 
travelled by the marker bands. 
Automated DNA sequencing 
DNA sequencing was performed in forward and reverse directions using universal 
primers on the mini- and maxi-prep products by Lark Technologies using a high 
throughput PE Biosystems Sequencer (Applied Biosystems). 
Cell culture 
Cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM)-F12 + 
Glutamax-1 (Gibco) supplemented with 10% foetal calf serum (FCS) and 100 units ml"' 
penicillin-streptomycin (PenStrep), at 37°C in a 5% CO2 incubator. PenStrep is a broad 
spectrum bacteriostatic and bacteriocidal with activity against both gram negative and 
gram positive organisms, and was used in cell culture to prevent infection of the cell 
media. Cells were grown to confluence (never more than 80%) before passage. Cells 
were detached from the surface of cell culture flasks (Sarstedt, US) using Trypsin- 
EDTA solution (Sigma, UK), resuspended in prewarmed media at the appropriate cell 
density, and transferred to fresh culture flask(s). 
Human saphenous vein (HSV) was obtained with local research ethical committee 
approval. HSV smooth muscle cells were kindly prepared by Dr K. Porter. These 
primary cells were maintained in DMEM-F12 with 10% FCS and 1% PenStrep and 
discarded after passage 4. 
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For long term storage cells were stored under liquid N2. Cells detached by Trypsin- 
EDTA were resuspended in an equal volume of cell freezing medium (Sigma) and 
aliquoted in 1 ml volumes into CryoTube freezing Vials (Nunc, Denmark). Vials were 
stored at -80°C for 24 hours before transfer into a liquid nitrogen storage container. 
When required, cells were thawed quickly at 37°C and resuspended in prewarmed 
media. 
Stable cell lines 
CHO K1 cells stably expressing human TRPV4 (a kind gift from AstraZeneca) were 
maintained in Ham's F12 (Gibco) in the presence of 1 mg ml-1 G418 (Sigma). G418 is 
an aminoglycoside antibiotic, similar in structure to neomycin, that blocks polypeptide 
synthesis in both prokaryotic and eukaryotic cells. It was used for the selection of 
TRPV4 expressing cells as the CHO-TRPV4 cell line contained the neomycin gene that 
conferred resistance. 
For the stable expression of human TRPM3, human TRPC5 and human TRPM2, the T- 
REx expression system (Invitrogen, UK) was employed. T-REx is a HEK 293 cell line 
that stably expresses the tetracycline repressor protein from the blasticidin resistant 
plasmid pcDNA6/TR, under the control of the human cytomegalovirus (CMV) 
promoter. These cells can additionally be transfected with a second, zeocin resistant 
plasmid containing the gene that expresses the protein of interest. This second gene is 
repressed by the binding of the tetracycline repressor protein. When tetracycline (tet) is 
present in the cell culture media, it binds the tetracycline repressor protein and stops 
repression of transcription, allowing rapid expression of the gene of interest. TRPM3 
(Genbank accession number AJ505026) minus the YFP tag, or TRPC5 (accesssion 
number AF0544568) channel DNA was subcloned into the pcDNA4 vector and 
transfected into T-REx 293 cells (Invitrogen) by F. Zeng (Zeng et al., 2004). The 
tetracycline-inducible TRPM2 cell line was kindly provided by A. Scharenberg 
(McHugh et al., 2003). Tetracycline-inducible cell lines (TRPM3, TRPM2 and TRPC5) 
were maintained in the presence of 250 tg ml-1 ZeocinTM (InvivoGen) and 10 tg ml" 
Blasticidin S (InvivoGen). To induce TRP channel expression, cells were incubated 
with 1 gg ml-1 tetracycline (Sigma, UK) for 24-72 hours prior to experiments. 
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For FLIPR experiments, a tetracycline-inducible stable TRPM2 cell line was kindly 
provided by AstraZeneca. TRPM2 expression was induced by 1 µg ml'' doxycycline 
(dox), a synthetic derivative of tetracycline, for 24 hours prior to experiments. 
Transfection 
Preparation of poly-L-lysine coverslips 
Sterile glass coverslips were transferred into a 24 well plate and overlaid with 200 tl of 
100 µg ml'' poly-L-lysine (Sigma) for 1 hour at 37°C. Coverslips were washed 3 times 
with PBS and allowed to air dry before use. 
Quantification of TRPM3 DNA 
The concentration of the EndoFree maxi-preparation of TRPM3 DNA was determined 
as 1 µg µl'ß using a UV 1101 Biotech photometer (WPA, Cambridge, UK). 
Transient transfection 
Wild-type HEK 293 cells were plated onto poly-L-lysine coated coverslips in a 24-well 
plate with a final volume of 0.5 ml DMEM and grown to -80% confluency. TRPM3 
cDNA (1 µg) or empty vector was mixed with 36 µl of FuGENE® 6 Transfection 
Reagent (Roche, UK) and 564 µl OPTIMEM® serum free medium, and incubated for 
half an hour at room temperature to allow DNA-liposomes to form. The DNA: FuGENE 
complex (20 µl) was then added directly to cell media within each well. Functional 
studies were carried out 48 hours after transfection on successfully transfected cells 
identified by their YFP-fluorescence at an excitation wavelength of 480nm. 
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Peptide-specific antibody design 
Hydropathy Analysis 
Hydrophilicity analysis was performed using Lasergene software (DNAStar) to identify 
transmembrane and surface regions of the TRPM3 protein. The Kyte-Doolittle 
hydropathy plot uses a `hydropathy scale', in which each amino acid is given a score 
between -4.5 and 4.5 (where 4.5 is the most hydrophilic), in order to compare the 
hydrophilic and hydrophobic properties of the amino acid side chains within a protein 
(see table). In addition, the computer program assigns a `window size'; this corresponds 
to the number of amino acids whose hydrophobicity scores will be averaged in order to 
produce a smoothed plot, the default window size being 9 amino acids. The computer 
program calculates an average hydrophobicity score for each assigned window, and 
these averages are plotted in a Kyte-Doolittle plot in which the y axis represents the 
hydrophobicity score, and the x axis represents the amino acid position within the 
protein sequence (Kyte et al., 1982). Although this method only gives a prediction of a 
protein structure, this was sufficient to identify the amino acid sequence of the putative 
3`d extracellular loop of TRPM3. 
Antibody generation 
TM3E3 polyclonal antiserum was prepared in rabbit to peptide [C]LFPNEEPSWKLA, 
a region corresponding to the 3rd extracellular loop (E3) of TRPM3 (Figure 2.1). E3 
targeting is emerging as a widely reliable method for the design of subtype-specific 
blocking antibodies for an array of ion channels. The N-terminal cysteine residue of the 
peptide is not present in the native protein sequence, but was included in order to 
conjugate the peptide to a carrier protein, keyhole limpet hemocyanin (KLH). KLH is 
used to increase the antigenicity of a synthesised peptide in order to stimulate an 
immune response. E3 is considered a good target for antibody production as it is not 
thought to be glycosylated in the native protein, nor will it have any complicated 
secondary structure, allowing for good access of the antibody. The antigenic peptide 
was injected into New Zealand white rabbits initially as a stable emulsion with complete 
Freund's adjuvant (CFA) (Sigma-Genosys). CFA allows for the slow release of the 
antigen so it is more readily trapped by macrophages, and contains inactivated 
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mycobacteria that stimulate both the humoral and cell-mediated immune response. 
Following the initial immunisation, rabbits were immunised once a week with antigen 
using incomplete Freund's adjuvant (IFA), which does not contain mycobacteria, for 4 
weeks before antiserum collection (Sigma-Genosys). Antiserum refers to the blood from 
the immunized host that has had red blood cells and clotting proteins removed. 
Typically antisera contain between 5 and 10 mg ml-1 of IgG, with approximately 0.1 mg 
ml'' of specific antibody (information provided by Sigma-Genosys). Serum taken before 
the initial injection was retained for use as a negative control (preimmune). Antisera 
were aliquoted and stored at -20°C or -80 °C for longer periods of time. 
Antibody Dialysis 
Manufacturers supply custom-made antisera in buffers that contain 0.1% sodium azide 
to extend the shelf life and protect against bacterial growth; however this can prevent 
the use of the antibody in some assays. For example, sodium azide is a metabolic poison 
so may interfere with assays involving cell culture. To remove sodium azide and other 
small molecules, anti-sera were dialysed against PBS. Dialysis membranes (Scientific 
Laboratory Supplies Ltd, UK) were cut into 10 cm lengths and boiled for 10 minutes in 
0.1 M NaHCO3. Membranes were then washed in distilled water (dH2O), and boiled for 
a second time. Finally, membranes were washed in dH2O and stored at 4°C in 25% 
ethanol. For antibody dialysis, membranes were removed from ethanol storage and left 
to soak in PBS until flexible, and then checked for leaks by filling with a small volume 
of PBS and clamping both ends. The tubing was then filled with 1 ml of preimmune or 
TM3E3 antiserum, clamped, and placed into a beaker filled with PBS at a volume 500 
times that of the sample (500 ml PBS). Samples were left for 48 hours at 4°C, as low 
temperatures improve antibody stability, with gentle stirring to allow exchange. During 
this dialysis period, the buffer was changed a total of 3 times. Dialysed samples were 
aliquoted to sterile eppendorfs and stored at -20°C. 
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Figure 2.1. E3 Targeting Schematic of an antibody targeted to the 3`' extracellular 
loop of an ion channel. S l-S6 refer to the 6 transmembrane domains, and the N- and C- 
termini are indicated by N and C respectively. E3 donates the 3rd extracellular loop, and 
AB the E3-targetted antibody (not to scale). 
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Enzyme linked immunosorbant assay 
Sodium carbonate buffer: 50 mM Na2CO3, pH 9.6 
Blocking solution: 5% non-fat milk powder (Marvel) in PBS 
Antibody dilution buffer: 1% non-fat milk powder, 0.05% Tween-20 in PBS 
Phosphate citrate buffer: 60 mM citric acid, 25 mM Na2HPO4 
ABTS reagent: 0.055% 2'2-azido-bis (3-ethylbenzthiazoline-6-sulfonic 
acid) (ABTS) and 0.01 % H2O2 in phosphate citrate buffer 
The specificity and titre of antisera were determined by enzyme-linked immunosorbant 
assay (ELISA). Wells in 96-well MAXI-SORP plates (NUNC) were coated with 50 µl 
of antigenic peptide diluted to 4 µg ml-1 in sodium carbonate buffer. No-peptide (NP) 
control wells were left blank, and plates were incubated overnight at 4°C to allow 
peptide to adsorb to the well surface. The following day, wells were washed 3 times 
with PBS/Tween to remove unbound peptide. Blocking solution (300 Al) was added to 
each well for 1 hour at 37°C to block non-specific adsorption of other proteins to the 
plate. Following a further PBS/Tween wash, serial dilutions of preimmune and TM3E3 
antisera were made in antibody dilution buffer (1: 500,1: 1000,1: 2000,1: 4000,1: 8000, 
1: 16000,1: 32000) and added to corresponding wells. Each dilution was assayed in 
duplicate. Plates were incubated for 2 hours at 37°C to allow antibody present in the 
diluted serum samples to specifically bind to its antigenic peptide. Wells were again 
washed with PBS/Tween, leaving antibody-antigen complexes attached to the well 
surface. A secondary, enzyme-linked antibody directed against the host animal's 
immunoglobin, was then applied. Horseradish peroxidase (HRP)-conjugated goat anti- 
rabbit IgG (Abcam) was added to each well (50 µl) and incubated for 1 hour at 37°C. 
After a final wash with PBS/Tween, 50 µl of the ABTS reagent was added to each well 
and plates were incubated for 30 min at room temperature in the dark. This allowed 
ABTS, the substrate for HRP, to be oxidised in the presence of H202. Oxidation caused 
a permanent colour change due to the formation of a green reaction product. The 
absorbance at 405 nm for each well was read on a plate reader, the intensity of which 
was directly related to the amount of antibody bound to the surface-bound peptide. 
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Calcium Imaging 
Microscope-based System 
Cells were split onto poly-L-lysine coated coverslips and transfected with TRPM3 24- 
48 hours before recording. The UV-light excitable, ratiometric Ca2+ indicator dye fura-2 
(Calbiochem) was used to measure intracellular calcium. Fura-2 is supplied as an 
acetoxymethyl ester that can easily pass into the cell cytosol where it is cleaved by 
endogenous, non-specific esterases to produce free carboxyl groups that covalently bind 
Ca2+ ions. Upon binding Ca2+, fura-2 displays a shift in absorption that can be observed 
at excitation wavelengths of 340 and 380 nm. This spectral shift is proportional to the 
Ca2+ concentration. When intracellular Ca2+ concentration is low, the ratio of 340/380 is 
low. When the Ca2+ concentration is high, this ratio is high (Figure 2.2). Cells on 
coverslips were incubated in a non-C02 incubator with 4 µM fura-2 AM at 37 °C for 1 
hour in standard bath solution (SBS). Exclusion of CO2 from this step is necessary as 
SBS is not bicarbonate-buffered, and the diffusion of CO2 into the buffer would have 
resulted in acidity. Cells were then washed for half an hour in SBS at room temperature 
before coverslips were fixed onto the recording chamber with vacuum grease and placed 
onto the microscope stage. Solutions were continuously perfused over cells in the 
recording chamber during recordings using a standard perfusion system with a4 ml 
min' flow rate. Fluorescence within cells was observed using an inverted microscope 
(Zeiss, Germany) through a 40x Fluar oil-immersion objective (numerical aperture, NA 
= 1.30) with excitation light at 340 and 380 nm provided by a xenon arc lamp, the 
wavelength of which was controlled by a monochromator (Till photonics, Germany). 
Emitted light at 510 nm was collected via an emission filter and Fura-2 images were 
captured every 10 seconds by a CCD camera (Hamamatsu, Japan), for the two 
excitation wavelengths of 340 and 380 nm, allowing a ratio image to be produced. 
Imaging was controlled using Openlab 2 software (Image Processing and Vision 
Company Ltd, UK). Recordings were made alternately from test and control cells at 
room temperature and analysed offline by selecting regions of interest (ROI). Changes 
in Ca2+ are displayed as changes in the ratio of the emission recorded for both 340 and 
380 excitation (OR3aa38o) for Fura-2. 
For antibody experiments, anti-sera at the desired dilution were present for 2 hours in 
the cell culture media, during loading and washing stages, but not during recording. 
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340 380 510 
Wavelength (nm) 
Figure 2.2. Excitation spectrum for Fura-2 Excitation spectra are shown for 340 nm 
(green) and 380 nm (red) for Fura-2, with emission spectra denoted as a dashed line. 
The spectrum shifts to the left (shown by arrow) when Ca 2+ is increased. This spectral 
shift is proportional to the change in Ca'+concentration. 
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FlexStation 11384 
The FlexStation 11384 benchtop scanning fluorometer (Molecular Devices) incorporates 
an integrated 8-channel robot to allow for high throughput Cat+-imaging (Figure 2.3). 
The machine contains separate compartments for the cell plate, compound plate and tips 
and can be programmed by the user to perform kinetic fluorescence experiments 
independently of user intervention. A Xenon-lamp light source and dual 
monochromators allow changes in Ca2+ to be monitored with either single or dual 
wavelength ratiometric calcium indicators. Generally ratiometric dyes are preferred as 
the fluorescence signal is not dependent on the dye concentration, so problematic effects 
such as uneven loading, leakage and photo bleaching are minimised. Ratiometric dyes 
also tend to show increased sensitivity and a better signal to noise ratio. Dye loading 
can be improved with pluronic acid (Invitrogen), a non-ionic, surfactant polyol that 
facilitates the solubilisation of calcium dyes and prevents compartmentalisation. Stable 
cell lines were cultured in 96-well, poly-D Lysine coated, black walled, clear-bottomed 
plates (BD Bioscience or Corning), and primary cells were plated into Ce1IBIND 
(Corning) 96-well plates. Cells in each well were loaded with 50 µl of 4 µM Fura-2 AM 
in SBS and incubated in the dark at 37°C for 1 hour. Cells were washed for half an hour 
in 100 µl of SBS, and then filled with SBS so that the final volume of recording buffer 
in each well was 200 µl. Compound addition to cells resulted in a 1: 5 dilution; therefore 
compound plates (Greiner) were made up at 5 times the required final concentration. 
Fluorescence emission was recorded every 10 seconds for 340 and 380 nm excitation, 
with compound addition after at least 1 minute to provide a baseline for analysis. 
Responses were displayed as the change in the excitation ratio (OR3401380), as calculated 
by SoftMax Pro® software. 
Where indicated, thapsigargin (1 µM), verapamil (10 µM) or methyl ß-cyclodextrin (10 
mM) was present in the bath solution during the washing step. For experiments 
performed in the absence of extracellular Ca2', CaC12 was omitted from standard bath 
solution, and replaced with 0.4 mM EGTA. For antibody experiments, anti-sera at the 
desired dilution were present for 2 hours in the cell culture media, during loading and 
washing stages, but not during recording. For cholesterol enrichment experiments, 
cholesterol (1 mM) was present during fura-2 loading and for an hour long wash step at 
37°C. The TRP channel inhibitors 2-APB (75 µM) and gadolinium (100 µM) were 
present during the washing step and throughout recordings in the loading buffer. 
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Figure 2.3. A high throughput fluorimeter Photograph of FlexStation II384 benchtop 
fluorimeter. The cell culture plate (bottom drawer), compound plate (centre) and tips 
(top) are inserted into the machine, which then performs fluorescent measurements as 
instructed by SoftMax Pro software. Reproduced from www. moleculardevices. com. 
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FLIPR 
In addition to the FlexStation, a second fluorometric imaging plate reader, the FLIPR 
system (Molecular Devices), was also used for the high throughput analysis of calcium 
responses (AstraZeneca). In contrast to the FlexStation, the FLIPR can record 
fluorescence from each well of a 96-well plate simultaneously; however due to the 
absence of a xenon light source, can only be used with single wavelength calcium 
indicators. Unlike ratiometric calcium dyes, for single wavelength indicators the 
intensity of the fluorescence recorded is dependent on the Caz+ concentration. 
Stable TRPM3 cells were cultured in 96-well, poly-D Lysine coated, black walled, 
clear-bottomed plates (BD Bioscience) for analysis with a FLIPR (Molecular Devices). 
Cells were counted using a COULTER® A`"TTM Hematology Analyzer and plated at 
50,000 cells per well unless otherwise indicated. Tet+ and Tet- cells were included 
within the same plate for direct comparison. Cells were loaded with 4.5 µM Fluo-4 AM 
(Sigma) in the presence of 2.5 mM probenecid (Sigma) and 0.01% pluronic acid 
(Molecular Probes) to facilitate dye loading. Although fluo-4 AM is lipophilic and 
readily passes across membranes, it will form micelles in aqueous media that can 
impede its passage. Dye dispersion was enhanced by 0.01% pluronic acid (F-127), a 
non-ionic detergent that prevents micelle formation, and retention with the addition of 
2.5 mM probenecid, an organic anion transport inhibitor that prevents the removal of 
dye from the cytoplasm (Di Virgilio et al., 1990). Prolonged loading in the presence of 
pluronic acid decreases dye loading (Maruyama et al., 1989) and was avoided. Cells 
were washed 3 times with 100 µl SBS, then filled with a final volume of 50 µl. 
Compound addition (50 µl) to cells resulted in a 1: 2 dilution; therefore compound plates 
were made up at double the required final concentration. 
Before recordings, a signal test was performed to indicate loading efficiency, and wells 
displaying poor loading were disregarded. Fluorescence emission at 516 nm was 
recorded for an excitation wavelength of 488 nm using one of 2 protocols; Fluorescence 
measurements for single addition protocols consisted of a baseline of 5 points taken 
every 2 seconds, followed by compound addition at 10 seconds, a 1st interval of 60 
readings every second (total 1 min), followed by a 2nd interval of 60 readings every 5 
seconds (total 5 min). For 2 addition protocols, fluorescence measurements consisted of 
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a baseline of 5 points taken every 2 seconds, followed by test compound addition at 10 
seconds, a 1s` interval of 15 readings every 2 seconds and a 2"d interval of 40 readings 
every 5 seconds (total 4 min), followed by second 5 point baseline reading, then 
addition of the positive control PregS at 4.2 minutes with a 1s` interval of 60 readings 
every second (total 1 min) and a 2nd interval of 20 readings every 5 seconds (total 1.7 
min). Total runtime was 6.8 minutes (Figure 2.4). 
When necessary, cells were exposed to ß-cyclodextrin or methyl ß-cyclodextrin in the 
bath solution for a half hour wash step before the addition of recording buffer. For 
antibody experiments, anti-sera at the desired dilution were present for 2 hours in the 
cell culture media, during loading and washing stages, but not during recording. 
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12 
(60 sec) (100 sec) 
Time 
Figure 2.4. FLIPR 2-addition protocol Initial baseline recording indicated in red. Blue 
arrows signify time point of test compound and PregS positive control addition. 
Recordings were divided into 2 intervals (indicated as 1 and 2). 
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Patch Clamping 
Internal solution: 75 mM CsCI, 10 mM NaCI, 70 mM CsF, 2 MM M902, 
10 mM EGTA, 10 mM HEPES, pH 7.2 with KOH. 
Osmolarity is adjusted to 320 mOsm with mannitol. 
Pipette solution: 135 mM CsCI, 1 mM EGTA, 2 mM MgCl2 10 mM 
HEPES, 5 mM NaATP and 0.1 mM Na2GTP, pH 7.2 with 
CsOH. Osmolarity is adjusted to 290 mOsm with 
mannitol. 
External K+ solution: 160 mM NaC1,4.5 mM KC1,1 mM MgC12,2 mM CaC12, 
5 mM D-Glucose monohydrate, 10 mM HEPES, pH 7.4 
with NaOH. Osmolarity is adjusted to 340 mOsm with 
mannitol. 
Seal enhancer: 105 mM NaCl, 4.5 mM KCI, 1 MM M902,40 mM 
CaC12,5 mM D-Glucose monohydrate, 10 mM HEPES, 
pH 7.4 with NaOH. Osmolarity is adjusted to 340 mOsm 
with mannitol. 
Cell preparation 
Planar patch clamp recordings were made using a benchtop NPC-1 Port-a-patch and the 
automated higher throughput NPC-16 Patchliner (Nanion, Germany). TRPM3 cells 
were incubated with tetracycline 24 hours prior to experiments, and grown to 70% 
confluence in a 10 cm culture dish (Starstedt, US). The cell media was removed and 
cells were washed with PBS before being gently detached with trypsin. Fresh, 
prewarmed media was added and the cell solution was agitated to disperse cell clumps. 
The cell solution was then centrifuged for 2 min at 100g to form a cell pellet. The 
supernatant was removed, and the pellet resuspended in external K+ solution. After a 
second centrifugation step, supernatant was discarded and the pellet resuspended in 300 
p1 external K+ solution. 
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Port-a-Patch 
The Port-a-Patch allows for patch clamp recording using planar patch clamp chips under 
the control of HEKA software (Brueggemann et al., 2004). For Port-a-Patch recordings, 
internal solution was applied to the inside face of the chip, and SBS to the outer face. 
The chip was then screwed into place and covered with a Faraday cap. Cell solution (5 
µl) was applied to the surface of the chip, and the software instructed to apply negative 
pressure in order to attract a single cell to the aperture in the chip, so that it was exposed 
to both external and internal solution (Figure 2.5 A). Seal enhancer solution was added 
to encourage formation of a gigaseal (seal resistance >1 GS1). A stronger suction pulse 
was then applied to rupture the cell membrane to achieve whole cell. The software was 
then paused, the chip was unscrewed (with the cell still attached), and the internal 
solution replaced with pipette solution. The chip was replaced and the programme was 
restarted to maintain whole cell configuration. For experiments, solution exchange was 
performed by direct addition of test solution using a pipette, and removal of the 
previous solution. This addition/removal step was repeated 3 times to ensure sufficient 
exchange. Recordings were made using an EPC-10 amplifier (HEKA electronic). Data 
were acquired using Patchmaster software and analysed using Fitmaster software 
(HEKA). Data were sampled at 1 kHz. Currents were measured during voltage ramps 
from -100 mV to +100 mV for is every 10s from a holding potential of 0 mV. (Figure 
2.5 B). 
Patchliner 
Voltage-clamp recordings were performed on a NPC-16 Patchliner (Nanion 
Technologies), a high throughput planar patch clamp technique that allows parallel 
investigation of 8 cells within separate compartments on the same chip (Bruggemann et 
al., 2006). Unlike the Port-a-Patch, the whole experiment is automated. Cells and 
solutions are transferred by a robotic pipettor into the chip, and old solutions are 
decanted, allowing for fast and efficient exchange of both the external and internal 
solutions. Patchliner experiments were kindly performed by C. Milligan, using the 
same software parameters as for Port-a-Patch. 
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A 
reference electrode 
test electrode 
B 
chip 
+100 mV 
0 mV 
-100 mV 
0 mV 
Figure 2.5. Planar patch clamp set-up The benchtop NPC- I Port-a-patch is capable of 
automated patch clamp recordings. A. Schematic of planar patch clamp chip. The 
default configuration for a cell is cell attached. The application of negative pressure, or 
suction, is required to achieve whole-cell. B. Ramp protocol used for whole cell voltage 
clamp recordings for both Port-a-Patch and Patchliner. Cells were held at 0 mV. 
Hyperpolarisation to -100 mV was followed by a ramp to +100 mV before returning to 
0 mV. 
standard bath solution 
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Polymerase Chain Reaction (PCR) 
cDNA preparation 
The isolation of total RNA from HEK 293 and primary HSV smooth muscle cells was 
performed using the phase-separation method. Cells were grown to -80% confluency in 
6-well plates (Nunc), removed from the culture dish surface using PBS, and spun in a 
centrifuge at 2500 rpm for 5 minutes to form a pellet. The supernatant was discarded 
and the pellet resuspended in 1 ml of TRI Reagent (Sigma, UK). TRI reagent contains 
guanidine thiocynate to lyse cells and denature endogenous RNases, and phenol to assist 
phase separation of cellular protein, DNA and RNA into distinct phases. Additionally 
100 tl bromochloropropane (BCP) was added to the TRI reagent/cell mixture and 
incubated at room temperature for 15 minutes. The solution was then centrifuged at 13 
rpm for 15 minutes at 4°C allowing the formation of 3 separate phases. For RNA, the 
colourless upper aqueous phase was transferred to a fresh eppendorf. Glycogen was 
added to act as a carrier, and the mixture briefly vortexed before the addition of an equal 
volume of ice cold isopropanol to precipitate RNA. After a final 10 minute incubation 
on ice and 20 minute centrifugation step, the resulting pellet was washed with 75% 
ethanol and allowed to air dry before being resuspended in molecular grade water. The 
total RNA yield was quantified by A. Cheong using a real-time fluorimeter (Roche) to 
perform a Ribogreen assay (Molecular Probes, UK). Ribogreen dye associates with 
nucleic acids and emits at a wavelength of 530 nm following excitation at 470 nm. The 
resulting fluorescence values can be used to quantify total RNA in a sample by 
comparison with a standard calibration curve. 
Oligo dT Reverse Transcription 
The RNA isolated from HEK 293 or HSV SMC as described was transcribed using 
AMV-reverse transcriptase (Promega) to produce cDNA. RNA (1 µg) was combined 
with primer (0.5 µg), 25 mM dNTPs (final concentration 0.63 mM each), 30 U AMV- 
reverse transcriptase plus 5X reaction buffer, and made up to 40 µl with molecular 
grade water. The mixture was incubated at 42°C for 1 hour, followed by heat 
inactivation at 94°C for 5 min. 
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Primer design 
Forward and reverse primers were designed to be complementary to the target DNA 
sequence for individual human TRPM3 splice variants according to sequences 
deposited in Genbank under the following accession numbers: TRPM31325 (AJ505026); 
TRPM3a (AF536748); TRPM3b (AF536749); TRPM3c (AF536750); TRPM3d 
(AF536751); TPRM3e (AF536752); and TRPM3f (AF536753). Primers specific for 
variant TRPM31325 were directed to the unique N-terminal region (TRPM31325), while 
primers spanning exon 4 of the TRPM3 gene were designed to identify the TRPM3f 
variant (TRPM3f). A primer pair spanning exons 11-12 & 14-15 was intended to give 4 
products of similar sizes, relating to TRPM3b, TRPM3e, TRPM3d and all remaining 
variants (TRPM3bed). Primers spanning a 12 amino acid sequence that is only present 
in the TRPM3c variant were designed to identiy the TRPM3c variant (TRPM3c) 
(Figure 2.6). It was not possible to design primers specific for variant TRPM3a due to 
the absence of any splice-specific, unique regions. Primers directed to human ß-actin 
cDNA (Genbank accession number BC004251) were created by A. Dedman. Primer 
sequences and predicted products are given in Table 2.1. 
Primers were chosen to avoid high GC content, were predicted to have low secondary 
structure content, and had a melting point (Tm) close to 60°C. A nucleotide-nucleotide 
BLAST search of the homo sapien database (www. ncbi. nlm. nih. govBLAST) was 
performed to ensure primers were specific for TRPM3. Primers were synthesised by 
Sigma-Genosys and stored in stock solution of 100 mM in water at -20°C. Working 
stocks of 20 mM were stored at 4'C. 
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Conventional (solution) PCR 
PCR allows for amplification of a single DNA strand through a series of cycles using 
specific primers. Each cycle consists of a high temperature denaturation step to allow 
separation of the double stranded DNA, an annealing step in which primers can anneal 
to their target DNA sequence. and a final extension step in which the 3' end of each 
primer is extended. Extension is catalysed by a thermostable DNA polymerase that 
incorporates dNTPs into the new DNA strand. DNA amplification is exponential, as 
primers can bind both template DNA and the newly formed PCR products to yield 
further PCR products. A 10 µl PCR reaction consisted of I µl template cDNA, 0.5 µM 
of both forward and reverse primers, 0.25 U Taq DNA polymerase (Promega) and 
supplied buffer. 1.5 m. MM MgC12 as a catalyst, and 250 itM dNTPs, made up to 10 µl with 
PCR grade water. A standard protocol of denaturation at 94°C for 30 seconds, annealing 
for 45 seconds (at a temperature 5'C below Tm), and elongation at 72°C for 45 seconds 
for 40 cycles was performed on a PCR block thermocycler (Eppendorf). 
PCR products were analysed by agarose gel electrophoresis alongside a DNA ladder as 
described previously. Where necessary, separated PCR product bands were visualised 
using a UV transilluminator and single bands excised using a sterile scalpel blade. 
Individual PCR products were cleaned using the QlAquick Gel Extraction. (Qiagen) as 
per manufacturer's instructions. The resulting product was used as the template for a 
subsequent PCR reaction to provide sufficient DNA for sequencing, which was 
performed in house (Astbury Building, University of Leeds). 
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Western blotting 
Resolving gel (6%). - 
1120 53 ml 
30% acrylamide mix 2 ml 
1.5 r1 TR1S (pH 8.8) 2.5 m1 
10% SDS 100 µ1 
10% ammonium persulphate 100 µl 
TFNED 8 µ1 
Stacking gel (5%): 
H2O 1.4 ml 
30% acrylamide mix 330 Id 
0.5 NI TRIS (p116. ß) 250 pl 
10% SDS 20 pi 
10% ammonium persulphatc 20 pi 
TEMED 2 pl 
SDS sample buffer: 100 mM TRIS-HCL (pH 6.8), 4% sodium dodecyl 
sulphate (SDS) and 20% glycerol 
Running buffer. - 25 mM TRIS, 192 mM glycine and 0.1% SDS (w/v). 
Transfer buffer 0.068 mM TRIS, 77.2 mNI glycine, SDS (0.037%), and 
methanol (25%). 
Protein extraction 
HEK-TRPMM3 cells were grown to confluence on a6 well plate (NUNC), removed from 
the incubator and left on ice. Media was aspirated and cells washed with ice cold PBS. 
Cells were then lysed using 100 gl ice cold sample buffer containing a protease inhibitor 
cocktail (Roche Diagnostics) as per manufacturer's instruction. Samples were then 
transferred into eppendorfs and left on a heat block set at 100°C for 5 minutes before 
protein quantification and storage at -20°C . 
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Protein quantification 
The concentration of protein in samples was determined using the DC Protein Assay 
(Bio-Rad). The colorimetric assay consists of 2 steps in which the protein in the sample 
reacts with an alkaline copper tartrate solution and then reduces a Folin reagent to 
produce blue reduced species with maximum absorbance at 750 nm. Comparisons with 
a standard curve comprised of several dilutions of a BSA protein standard allow 
determination of the protein concentration within a sample. 
Western blotting 
Western blotting can be used to detect a single protein within a cell lysate by 
incorporating SDS polyacrylamide gel electrophoresis (SDS-PAGE) to separate proteins 
on the basis of their molecular weight. SDS is an anionic detergent that denatures 
protein and applies an overall negative charge by binding to polypeptide chains via a 
hydrophobic tail. Proteins can be further denatured using a suitable reducing agent to 
reduce disulfide linkages. When an electric charge is applied across an SDS-PAGE gel, 
proteins of a similar molecular weight will migrate the same distance towards the 
positive electrode. regardless of their secondary structure. Larger proteins will take 
longer to migrate through the gel, as they encounter more resistance due to their size. 
Negatively charged proteins resolved on the SDS-PAGE gel can then be transferred 
onto a special membrane using electrophoresis and detected using specific antibodies. 
Protein samples were thawed on ice then combined with bromophenol blue (0.1 %) and 
the reducing agent dithiothreitol (DTT, 100 m. M). In addition, samples were heated to 
100°C to ensure complete denaturation of protein. Protein (20µg) was then loaded 
alongside markers (Bio-Rad) onto an SDS-PAGE gel composed of a 6% resolving gel 
and 5% stacking gel. Electrophoresis was carried out for one hour at 200V in running 
buffer to allow full separation of proteins within the sample. Protein gels were then 
transferred onto Immobilon-P polyvinylidene fluoride (PDVF) membrane (Millipore), 
pre-soaked in 100% methanol for 1 minute and transfer buffer for 5 minutes, for 1 hour 
at 0.03 A using a Trans-Blot SD semi-dry transfer cell (Bio-Rad). Membranes were 
washed for 1 minute in 100% methanol and allowed to air dry before being incubated in 
5% non-fat milk (Marvel) in PBS tween overnight at 4°C to block non-specific binding 
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sites. The membrane was then transferred into a primary antibody solution (1: 2000 
dilution in 5% milk/PBS tween) for 1 hour at RT. The membrane was washed x3 in 
PBS tween and incubated with a horse radish peroxidise (HRP)-conjugated goat anti- 
rabbit secondary antibody (diluted 1: 20000 in 5% milk/PBS tween) for 1 hour at RT. 
The membrane was washed a further 3x in PBS tween before being developed using the 
ECL plus kit (Amersham Biosciences). ECL solution was applied evenly to the surface 
of membrane and incubated for 1 minute in the dark to allow chemiluminescene to 
develop before excess solution was drained. Exposure of the developed blot to 
photographic paper (Kodak) for 1-5 minutes was used to detect chemiluminescence, 
followed by 4 minutes in developing solution to develop the film, a brief wash, and 5 
minutes in fixing solution (Photosol). After a final brief wash, blots were allowed to dry 
before being scanned and analysed using Image) software (http: //rsb. info. nih. govrij/). 
Immunolluocescence staining 
Antibody diluting solution: PBS, 1% bovine serum albumin (BSA) and 0.1% sodium 
azide 
Cells were split onto poly-L-Iysine coated coverslips 48 hours prior to experiments. For 
HEK-TRPM13 staining, cells were induced with tetracycline 48 hours prior to 
experiments. Cells were washed 3 times with PBS before fixing with 2% 
paraformaldehyde (PFA) for 5 minutes. Permeabilisation was not necessary as TM3E3 
targets an extracellular epitope. Cells were washed 3 times with PBS and transferred 
into blocking solution (1% BSA) for 30 minutes to block non-specific binding sites. 
Following the blocking stage cells were incubated overnight at 4°C in the primary 
antibody, TA13E3, diluted 1: 1000 in antibody diluting solution. Antibody pre-adsorbed 
to its antigenic peptide (prepared 24 hours prior to experiments), or exclusion of the 
primary antibody were used as negative controls. The next day cells were washed 3 
times in PBS and then incubated in a 1: 40 dilution of the secondary antibody, FITC- 
conjugated goat anti-rabbit IgG (Abcam), for 1 hour at room temperature. After a final 
wash step with PBS. coverslips were mounted cell-side down onto glass slides using 
DAPI Hard-Set mounting medium (VectaShield). Slides were stored at 4°C until viewed 
by laser-scanning confocal microscopy. 
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Confocal Microscopy 
Confocal microscopy provides a high resolution image from light emitted from a single 
plane through a specimen. Images were taken using a Zeiss LSM 510-META laser 
scanning inverted confocal microscope controlled by Zeiss LSNI imaging software, with 
an oil-immersed 63x (NA = 1.40) or 40x objective lens (NA = 1.30), or an air-exposed 
20x objective lens (NA = 0.80). FITC (494 nm excitation, 519 nm emission) was 
excited using argon laser fitted with 488 nm filters. DAPI (excitation 360 nm, emission 
460 nm) was excited using a diode laser fitted with 405 nm filters. 
Immunohistology Staining 
Immunohistology staining of human saphenous vein sections was performed by S. 
Piruthivi. Briefly. tissue samples in paraffin wax were prepared using a Leica ASP 300 
automated tissue processing unit (Leica Microsystems, UK). For immunohistology 
investigation. sections 8 pm thick were mounted onto polylysine slides (VWR 
International, UK). Samples were dewaxed and rehydrated, and immunostaining was 
performed using the rabbit ABC kit (Vector Laboratories Ltd, UK). Primary antibody or 
the preadsorbed peptide control was added overnight at 4°C. The following day slides 
were incubated with biotinylated secondary antibody was for 30 minutes. Following 
application of ABC solution, sections were saturated with DAB solution for 5-10 
minutes to allow colour development. Tissue sections were then dehydrated and 
mounted in DPX. 
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Gelatin Zymography 
Separating gel buffer: 1.5 Ai Tris-base (pH 8.8) 
Stacking gel buffer: 0.5 ht Tris-base (pH 6.8) 
2x non reducing sample buffer: 20 mM TRIS (pH 6.8), 45 % glycerol, 10% SDS 
and 0.025% bromophenol blue 
5x running buffer: 25 mMi TRIS, 200 mNI glycine, 0.1% (w/v) SDS. 
Stock solution diluted 1: 5 with dH20 before use. 
Washing buffer: 2.5% Triton X-100 
lO x incubation buffer: 50 mbl Tris-base (pH 7.6), 10% CaC12 2H2O, 50 
NI NaCI and 0.005% Brij-35. Stock solution 
diluted 1: 5 with dH2O before use. 
Coomassie brilliant blue: 25% methanol, 10% glacial acetic acid and 0.02% 
Coomassie blue R-250 
Matrix metalloproteinases (AMMPs) are responsible for the degradation of extracellular 
matrix molecules. MMP-2 and AIAMP-9 are more commonly known as gelatinases due to 
their role as gelatin degrading proteases. 
Cell treatment 
Cells were serum starved for 48 hours before a 48-hour treatment with conditioned 
media (0.4% serum) containing 100 n. M phorbol ester (TPA), plus SPH or PregS alone, 
or in the presence of TM3E3 or peptide control. Non-treated 0.4% serum media was 
included as a negative control. Media was removed and centrifuged at 5000 rpm for 5 
minutes to pellet any cell debris. The supernatant was collected and snap frozen in 
liquid N2 before storage at -20°C. 
73 
Gelatin Zymography 
Gelatin Zymography uses SDS polyacrylamide gel electrophoresis (SDS-PAGE) to 
separate gelatinise matrix metalloproteinases (NIMPs) on the basis of their molecular 
weight. It is important that proteins are not reduced as their native structure and activity 
is important to the method. Media samples were defrosted on ice and mixed 1: 1 with 2x 
non-reducing sample buffer. Samples were then run on a 7.4% acrylamide gel, 
containing 1.0 mg ml's gelatin, at 120 V for 105 minutes alongside conditioned medium 
from IIT-1050 cells. This media was used as a positive control to indicate the position 
of MMP-2 at 72 kDa, and of MMP-9 at 92 kDa. Gels were removed from glass plates 
and washed with 2.5 % Triton X-100 for 1 hour to remove SDS and to allow 
fractionated proteins to renature. Incubation at 37°C for 6'h hours allowed for the 
digestion of gelatin at the location of gelatinase bands in the gel. MMP proteins were 
detected as bands of clear lysis on a blue background following staining with 
Coomassic brilliant blue for 1 hour at room temperature on a rocking platform. Gels 
were scanned into the computer to allow analysis of band density using Image) 
software. 
Colorimetric sandm ich ELISA 
MMP-9 secretion was further investigated using the Quantikine ELISA Kit (R&D 
Systems, UK). The kit measures total MMMP-9, i. e. both active and pro forms of the 
MMP-9 protein. Briefly. microplates were supplied pre-coated with a monoclonal 
antibody specific for MMP-9. Conditioned media samples prepared for zymography 
experiments were applied to wells and MMP-9 present was able to bind to the surface- 
bound antibody. A secondary, HRP-conjugated polyclonal antibody against MMP-9 
was added. followed by addition of a substrate solution. The resulting colour change 
was proportional to the amount of MMMP-9 in samples. Plates were read at Aq, nm using 
a plate reader with correction set to 540 nm (to allow for background readings in the 
plate). Samples were assayed in duplicate. MMP-9 concentration within samples was 
determined by comparison with a standard curve. 
Additionally, the secretion of interleukin-6 (IL-6), a cytokine known to influence MMP- 
9 secretion, was measured using a PeliKine-compact`. ELISA kit (Sanquin, 
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Netherlands). Briefly, 96-well 1bIAXI-SORP plates (NUNC) were coated with an 
antibody against human IL-6 overnight at 4°C. When conditioned media was applied, 
any IL-6 present was able to bind to the surface-bound antibody. In turn, a secondary 
biotinylated sheep antibody was added, which bound to the IL-6-antibody complex. 
Addition of HRP-conjugated streptavidin followed by a substrate solution caused a 
colour change directly related to the concentration of IL-6 present in the sample. The 
colour change was read at A45o nm using a plate reader. As the IL-6 concentration 
present in media samples was high, samples were diluted 1: 100 in dH2O before ELISA 
analysis, and assayed in duplicate. IL-6 concentration within samples was determined 
by comparison with a standard curve. 
Data Analysis 
Data were analysed and presented using the Origin 7 Software package. For 
conventional Cat -imaging using the microscope based system, 'n/N' represents the 
number of coverslips/total number of individual cells. For FlexStation and FLIPR 
experiments, 'n , N' represents the number of independent experiments/the number of 
individual wells. For experiments performed on HSV smooth muscle cells, each 
independent experiment was performed on cells obtained from different patients. 
If a representative trace is shown, error bars represent the standard error of the mean 
(SEMI), where the mean (p) is given by. 
Ex 
N 
And SEM is given by: 
SEM=a 
JN 
Where N is the sample size (i. e. the number of individual wells or cells measured) and x 
is the value of each sample, and a is the standard deviation. For all other cases, SEM is 
calculated using n. the number of independent experiments. 
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Dose response curves were produced using the Hill equation: 
Y=V, t, a, ý Xý 
k"+x" 
Where V. is the maximum response to an agonist, x is the concentration of the 
agonist. k is the EC50 for half-maximal response to the agonist, and n is the slope of the 
curve. referred to as the Hill coefficient. 
The statistical significance is determined by analysing the probability (p) that an 
experimental result occurred by chance. The reliability of such an observation is 
represented by the p-value. The higher the p-value, the greater the probability the result 
occurred simply by chance. Statistical significance was investigated using a two-tailed 
student's t test, which is derived from the normal distribution, and significant difference 
is given by pc0.05. 
Sequence alignment 
Protein and DNA sequences were obtained from Genbank (www. ncbi. nlm. nih. gov/) and 
aligned with each other or with sequencing results using ClustalW software 
(www. cbi. ac. uk/Tools/clustalwl). This allowed for the identification of conserved 
regions within the protein sequence of TRP family members, and also to check the 
results of the DNA sequencing used to identify PCR products. 
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Chapter 3 
Development of an externally-acting specific blocker of TRPIN13 
Although there is currently an abundance of drugs commercially available for use as ion 
channel modulators, many are nonselective, and lack the ability to differentiate between 
structurally related proteins. TRP ion channel antagonists have also proven to be non- 
specific, blocking not only members of the same subfamily, but also a broad range of 
calcium channels. The generation of peptide-specific antibodies is emerging as a 
reliable method for the design of subtype specific channel blockers. Antibodies targeted 
to extraccllular regions of ion channels, most commonly the third extracellular loop, 
have proven to be selective blockers for a variety of ion channels. 
The first instance of a rational method to develop specific channel blockers used 
polyclonal antibodies to inhibit whole-cell currents relating to the voltage-gated K+ 
channels K, 1.2 and K3.1. and established that Kj. 2 contributes to endogenous 
neuronal cell currents (thou et a!., 1998). When applied to TRP channels, such 
antibody design revealed a role for TRPCI as a store-operated Ca2+ channel of vascular 
smooth muscle (Xu et A. 2001), and demonstrated a physiological relevance for 
TRPC5 in rabbit arterioles (Xu et a!.. 2006a). Polyclonal antibodies have also been used 
to inhibit both proton and chemical activation of TRPV I (Klionsky et al., 2006), and to 
block Na` current through the voltage gated Na` channel, Nay 1.5 (Xu et al., 2005b). 
More recently, the first study to use monoclonal antibodies has shown specific 
inhibition of the voltage-gated K` channel hEag 1, and suggested a function for the 
channel in modulating tumour cell growth (Gomez-Varela et al., 2007). 
The development of such selective inhibitors for TRP channels in particular does not 
appear to be complicated by their diverse methods of activation, which range from both 
infra and extracellular ligands to changes in pH or temperature. Lipid-mediated 
regulation is a common mechanism for the activation of the TRP superfamily, and lipid- 
regulated currents have been identified for a number of TRP channel family members. 
Lipids are a diverse range of naturally occurring compounds, and include fatty acids, 
their naturally occurring derivatives, esters and amides, and functionally or 
biosyynthetically related compounds, such as alcohols and cholesterol. The major 
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structural compounds of cell membranes are sphingolipids. The reversible hydrolysis of 
sphingomyelin, the most abundant sphingolipid in human plasma, to ceramide occurs 
via the sphingomyelin pathway (Auge et a!., 1996). Several intermediates of this 
pathway, including sphingosine-1-phosphate, sphingosylphosphorylcholine and 
sphingosine, are common lipid mediators involved in many cell-signalling pathways, 
including acting as modulators of TRP channels (Xu et a!., 2006b). The TRPM3 splice 
variant TRP. M31325 is activated by D-etythro-Sphingosine (SPH) and its analogues 
(Grimm et a!., 2005). TRPM3 is a relatively newly discovered member of the TRPM 
subfamily, and its function remains elusive. Studies by means of over-expression 
demonstrate non-specific inhibition of TRPM3 by the TRP channel blockers gadolinium 
(Gd; ') and 2-aminoethoxydiphenylborate (2-APB) (Grimm et a!., 2005; Xu et a!., 
2005a). However, a subtype specific channel blocker would prove a useful tool for 
further characterisation of the channel, and enable investigations into native channel 
expression and physiological function. 
The aim of this study was to use E3 targeting (Xu et al., 2005b) to design and develop 
an antibody as a selective inhibitor for the TRPM3 ion channel. Western blotting and 
immunocytochemistry were necessary to confirm the antibody was able to specifically 
bind the epitope expressed by the channel. Calcium imaging was used to ascertain the 
inhibitory effect of the antibody in live cells against known activators of TRPM3, and to 
explore its selectivity. The development of a stable TRPM3 cell line allowed for the use 
of high throughput technologies to further characterise the channel, and led to the 
discovery of a novel activator of TRPM3. 
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TRPM3 expression in HHEK 293 cells 
TRPM3 cDNA clone (a gift from C. Harteneck) contains yellow fluorescent protein 
(YFP) fused to the 3' end of the TRPM3 ORF. After transfection, the fusion construct is 
expressed by host cells as TRPM3 protein with a C-terminal YFP tag, resulting in 
specifically labelled protein in live cells. Western blotting with a TRPM3 specific 
antibody confirmed that transfection with the YFP-tagged cDNA causes a marked 
increase in TRPM3 protein levels (Grimm et aL, 2003). 
In order to study the effect of a peptide-specific antibody as a blocker for TRPM3, the 
channel was over-expressed in HEK 293 cells. Cells loaded with the ratiometric calcium 
indicator dye, fura-2. were visible at an excitation wavelength of 380 nm. Successfully 
transfected cells expressing YFP-tagged human TRPM3 were identified by their YFP- 
fluorescence at 480 nm (Figure 3.1). Following extensive optimisation of the method, 
transfection efficiency was typically 30%. The identification of transfected cells 
allowed for regions of interest to be selected in order to minimise background signals 
and measurements from non-transfected cells, and gave an indication of the location and 
distribution of tagged protein within the cell. 
The data show that TRPM3 can be successfully transfected into HEK 293 cells to give a 
roughly equal distribution of the protein throughout the cell. 
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Figure 3.1. TRPM3 expression in HEK 293 cells The YFP tag allows for the 
identification of successfully transfected cells. A. Fura-2 loaded cells visible at 
excitation wavelength 380 nm. B. In the same cells, TRPM3-expressing cells were 
identified by their YFP fluorescence at 480 nm excitation. C. Merged image. Scale bar 
represents 10 Nm. 
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SPH increases intracellular Ca 2+ in TRPM3-expressing cells 
Fluorescence microscopy experiments using the ratiometric Ca2+ dye fura-2 were used 
to investigate Ca2+ entry in TRPM3-expressing cells. This was necessary to confirm the 
channel identified by its YFP-tag was both functional and expressed at the plasma 
membrane. Known modulators of TRPM3 were tested on TRPM3-YFP-transfected and 
YFP-transfected control cells, including the sphingolipid D-erythro-sphingosine (SPH), 
an intermediate in the sphingomyelin pathway (Figure 3.2 A). 
SPH is reported to activate TRPM3 independently of PKC or depletion of intracellular 
Ca2+ stores (Grimm et al., 2005). In this study, SPH (20 µM) caused a significant 
increase in intracellular Ca2+ in HEK-TRPM3 cells within 2 min of application (Figure 
3.2 B). Ethanol (the solvent for SPH) was kept constant at 0.1% in recording solutions 
throughout experiments and failed to elicit a significant Ca2+ signal in the absence of 
SPH. The response to SPH in control HEK-YFP cells was much less, and the mean data 
show that after 5 min the Ca2+ response in HEK-TRPM3 cells was 7 times larger than 
that in HEK-YFP cells (Figure 3.2 Q. 
The data suggest that TRPM3 protein can be successfully exogenously expressed at the 
plasma membrane, and serves as a functional calcium channel in HEK 293 cells, in 
agreement with previous reports. 
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Figure 3.2. D-erythro-sphingosine (SPH) increases CaZ+ signals in TRPM3- 
expressing cells CaZ+ signals were measured as the 340/380 nm ratio of emission in 
fura-2 loaded HEK 293 cells. Cells were transfected with TRPM3 or YFP as a control. 
Ethanol (vehicle) was present throughout recordings. A. Structure of SPH. B. 
Representative traces from single cells. SPH causes an increase in CaZ+ in TRPM3- 
YFP-expressing cells compared to YFP-expressing control cells (grey trace). C. Mean 
data (±SEM) showing a significant increase in CaZ+ 5 min after SPH application 
(TRPM3 n/N=6/28, YFP n/N=3/16). 
OH 
NH2 
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An analogue of SPH increases Ca2+ in HEK-TRPM3 
The SPH precursor D-erythro-dihydrosphingosine (DHS) is a sphingosine kinase 
inhibitor and prevents the conversion of SPH to sphingosine-1-phosphate. DHS, also an 
intermediate in the sphingomyelin pathway, is a saturated analogue of SPH, lacking the 
double bond at position 4 (Figure 3.3 A). Esterification of DHS results in the formation 
of ceramide, which is then converted to SPH by ceramidases (Auge et al., 1996). 
DHS has previously been shown to activate TRPM3 (Grimm et al., 2005). Likewise, I 
found that DHS (20 µM) caused a significant increase in Ca2+ entry in TRPM3- 
expressing cells within 2 min of application (Figure 3.3 B). DHS also caused a small 
increase in Ca2+ entry in HEK-YFP cells. However, the mean data indicate that after 5 
min the response in HEK-TRPM3 cells was 3 times larger than that of HEK-YFP 
(Figure 3.3 Q. 
The data provide further evidence that the TRPM3 protein is functional when over- 
expressed in HEK 293 cells, and confirm the results of (Grimm et al., 2005). 
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Figure 3.3. D-erythro-dihydro-sphingosine (DHS) also increases Ca 2+ signals in 
TRPM3 expressing cells Ca2+ signals were measured as the 340/380 nm ratio of 
emission in fura-2 loaded HEK 293 cells. Cells were transfected with TRPM3 or YFP 
as a control. Ethanol (vehicle) was present throughout recordings. A. Structure of DHS. 
B. Representative traces from single cells. DHS causes an increase in Ca2+ in TRPM3- 
expressing cells compared to YFP-expressing control cells (grey trace). C. Mean data 
(±SEM) showing a significant increase in Ca2± 5 min after DHS application (TRPM3 
n/N=3/22, YFP n/N=3/19). 
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Hypotonic shock also activates TRPM3 
Reducing extracellular osmolarity is also reported to activate TRPM3 (Grimm et al., 
2003). Activation is believed to be the result of cell swelling, leading to stretch of the 
membrane, which suggests volume-regulated activity of the channel. 
Replacing bath solution with hypotonic solution in order to decrease the osmolarity 
from 300 to 200 mOsm caused a significantly larger Ca2+ signal in TRPM3-expressing 
cells than YFP-control cells (Figure 3.4 A). In contrast to the Ca2+ response to the lipid 
activators, SPH and DHS, the Ca2+ response to hypotonic shock was transient and had 
faster onset. Hypotonic shock also induced Ca2+ entry in HEK-YFP cells; however the 
response was slower and not statistically significant at the time points indicated. After 2 
min, the response in HEK-TRPM3 was 4 times larger than that of HEK-YFP (Figure 
3.4 B). 
In summary, hypotonic solution causes small but significant activation of over- 
expressed TRPM3. 
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Figure 3.4. Hypotonic solution activates TRPM3 Ca2+ signals were measured as the 
340/380 nm ratio of emission in fura-2 loaded HEK 293 cells. Cells were transfected 
with TRPM3 or YFP as a control. A. Representative traces from single cells. Switching 
bath solution osmolarity from 300 to 200 mOsm causes an increase in Ca2+ in TRPM3- 
expressing cells larger than the Ca2+ increase in YFP-expressing control cells (grey 
trace). B. Mean data (±SEM) showing a significant increase in Ca2+ 2 min after 200 
mOsm application (TRPM3 n/N=5/22, YFP n/N=3/21). 
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Hydrophilicity analysis of the TRPM3 amino acid sequence 
Kyte-Doolittle analysis maps the hydrophobic and hydrophilic nature of amino acids 
within a protein sequence in order to locate surface exposed and membrane embedded 
regions of the protein (Kyte et al., 1982). Such hydrophilicity analysis allowed for the 
determination of the location and sequence of a region likely to be the 3`d extracellular 
loop (E3) of TRPM3 (Figure 3.5). This sequence is conserved for all reported human 
TRPM3 splice variants, and for several species including human, rat and mouse, and 
was used to engineer a peptide for peptide-specific antibody generation. The peptide 
[C]LFPNEEPSWKLA was conjugated to keyhole limpet hemacyanin via the N- 
terminal cysteine residue, which is not present in the native protein sequence, and used 
to immunise rabbits to induce an immune response (Sigma-Genosys). Anti-sera 
containing anti-peptide polyclonal antibodies, TM3E3, were harvested. Preimmune sera 
taken before the initial injection were retained as a control. 
Alignment of the amino acid sequence from the third extracellular loop of TRPM 
subfamily members indicates TRPM3 shares -70% sequence homology in this region 
with its closest relative, TRPM1 (Figure 3.6). In addition, the alignment shows that only 
9 residues in the peptide sequence used for antibody design are conserved between 
TRPM3 and TRPM 1, and even less for other family members. A BLAST search 
performed using the peptide sequence indicated that, excluding TRPM3 splice variants, 
no other proteins contain this specific peptide sequence. 
In summary, the third extracellular loop of TRPM3 is a good target for antibody design. 
The unique peptide sequence of this region suggests that the polyclonal antibodies 
directed against it will specifically bind the TRPM3 protein. 
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Figure 3.5. Hydrophilicity Analysis Kyte-Doolittle plot of amino acid sequence for 
TRPM3 produced using Lasergene software (DNAStar). S1-S6 refer to the predicted 6 
transmembrane domains. E3 donates the 3rd extracellular loop. 
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Determination of TM3E3 specificity and titre 
As the TM3E3 antiserum was intended for use in cell culture experiments, dialysis was 
performed on a quantity of sample to remove sodium azide preservative and other small 
particles. The specificity and titre of TM3E3 antisera before and after dialysis was 
determined by an enzyme-linked immunosorbant assay (ELISA) (Figure 3.7 A). Wells 
not coated with antigenic peptide (NP) were included as a negative control, as were 
preimmune sera. 
Serial dilutions of dialysed antiserum samples were compared to the original, non- 
dialysed samples. The dialysed antibody serum was less potent, possibly due to dilution 
or damage to antibody as a result of the dialysis procedure. Application of the Hill 
equation to ELISA absorbance data (Figure 3.7 B) gave the dilution for half maximal 
activity for TM3E3 as 1: 3571 (Hill coefficient 1.50), and for dialysed TM3E3 this was 
reduced to 1: 1923 (Hill coefficient 1.42). 
Preadsorption of the non-dialysed antibody to its antigenic peptide significantly reduced 
activity of antisera at 1: 4000 dilution (Figure 3.7 C) indicating pre-adsorption to the 
antigenic peptide is a useful control for preventing the antibody binding its epitope. 
It is important to use a suitable concentration of antibody in order to reduce non-specific 
effects of an antibody. Therefore, based on the ELISA result, for functional 
experiments, TM3E3 should be used at a dilution of 1: 4000, and dialysed TM3E3 at a 
dilution of 1: 500. 
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Figure 3.7. Antibody specificity and titre ELISAs were performed on antisera before 
and after dialysis. The amount of antibody bound to wells was determined by reading 
the absorbance at 405 nm (A405). A. Image of ELISA plate layout; NP denotes no 
peptide control wells. B. Hill plot fitted to original (TM3E3) and dialysed (TM3E3d) 
antisera activity to calculate the concentration for half maximal activity. C. Mean data 
(±SEM) from duplicate readings in a single plate for TM3E3 with and without 
preadsorption to the antigenic peptide. 
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TM3E3 blocks SPH"activation of TRPM3 
E3-targeted antibodies have previously been used to selectively block TRP channel 
activity (Xu et al., 2001; Xu et al., 2005b). To determine whether the TM3E3 antibody 
could be used as a tool to inhibit TRPM3 function, Ca2+ imaging experiments were 
performed to investigate the effect of the antibody on the TRPM3 Ca2+ response. 
HEK-TRPM3 cells preincubated for 3.5 hours with non-dialysed TM3E3 antiserum at 
1: 4000 dilution show reduced Ca2+-entry in response to SPH, compared to cells 
preincubated with preimmune serum (Figure 3.8 A). Surprisingly, TM3E3 
preincubation also significantly reduced Ca2+-entry in YFP-transfected control cells 
(Figure 3.8 B). In addition, TM3E3 also caused a significant reduction in the starting 
baseline of TRPM3-expressing cells in 3 out of 4 experiments, although including all 
the data led to a lack of statistical significance. No change in baseline was evident for 
YFP-expressing cells. This trend indicates that the antibody can also block constitutive 
activity of TRPM3. 
The mean data indicate that TM3E3 inhibited SPH-induced Ca2+ entry in HEK-TRPM3 
by -47%, and in HEK-YFP by -80% (Figure 3.8 Q. 
In summary, an antibody targeted to the 3`d extracellular loop of TRPM3 inhibits 
constitutive TRPM3 activity, and SPH-induced Cat+-entry, through native TRPM3 
channels and channels over-expressed in HEK 293 cells. 
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Figure 3.8. T\13E3 inhibits SPH-activation of TRPM3 Ca 2+ signals were measured 
as the 340/380 nm ratio of emission in fura-2 loaded HEK 293 cells. Cells were 
transfected with TRPM3 or YFP as a control. Ethanol (vehicle) was present throughout 
experiments. A. Representative mean data (±SEM) showing Ca 2+-entry induced by SPH 
is inhibited by preincubation of HEK-TRPM3 with TM3E3, compared to preincubation 
with preimmune serum (pre) (pre n/N=3/29, TM3E3 n/N=3/22). B. Representative 
mean data (±SEM) showing effect of TM3E3 on YFP-expressing control cells (pre 
n/N=3/29, TM3E3 n/N=3/39). C. Mean data (±SEM) normalised to HEK-TRPM3 
maximum preimmune response 6 min after SPH addition (TRPM3-YFP: TM3E3 
n/N= 11/85, pre n/N=1 1 /90, YFP alone: TM3E3 n/N=3/39, pre n/N=3/30). 
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TREND expression in wild type HEK 293 cells 
Several TRP channels are endogenously expressed in HEK 293, and in particular 
members of the TRPM subfamily TRPM4 and TRPM7 have been detected (Launay et 
al., 2002; Nadler et al., 2001). In this study, control HEK 293 cells displayed a Cat+- 
response to TRPM3 activators, and in particular the response to SPH could be inhibited 
by preincubation with TM3E3. This suggests that either HEK 293 cells natively express 
a SPH-sensitive variant of TRPM3, or that TM3E3 affects another channel that is also 
activated by SPH. For this reason, RT-PCR was used to search for TRPM3 mRNA in 
HEK 293 cells. 
Primers were designed to detect the TRPM3 splice variant TRPM31325, the variant 
reportedly activated by SPH and hypotonic stimulation and used in this study. As 
TRPM3 is highly expressed in brain (Lee et al., 2003a), human brain cDNA was 
included as a positive control for TRPM3 expression. Primers directed against ß-actin 
were used to probe HEK 293 cDNA as a second positive control. ß-actin is one of 6 
different actin isoforms that contribute to the actin cytoskeleton, and high levels are 
expressed by most cell lines. PCR products were resolved by agarose gel 
electrophoresis. 
PCR amplified a 335 bp product corresponding to TRPM3 from both HEK 293 and 
brain cDNA using the TRPM31325 primer pair (Figure 3.9). The ß-actin primer pair 
amplified a 194 bp product from HEK 293 cDNA, as predicted. 
In summary, solution PCR amplification revealed TRPM3 mRNA is present in HEK 
293 cells, which could account for the Cat+-responses to TRPM3 activators that were 
observed in control cells. 
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Figure 3.9. TRPM3 expression in HEK 293 cells DNA gel stained with ethidium 
bromide. PCR was performed using primers designed to amplify reverse transcribed 
TRPM3 mRNA from human brain or HEK 293 cDNA. M depicts 100 bp marker. Low 
molecular weight hands designated by are most likely a consequence of the extension 
of self-annealed primers (primer dimers). 
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Pregnenolone sulphate is a novel activator of TRPM3 
It has been reported that pregnenolone sulphate (PregS) activates the mouse TRPM3a2 
variant (J. Oberwinkler, personal communication). The effect of PregS on the human 
TRPM31325 variant was therefore examined. 
PregS is a neurosteroid endogenous to mammalian tissues such as the gonads, adrenal 
gland and brain, and is a precursor for the biosynthesis of steroid hormones (Gibbs et 
al., 2006). PregS itself is synthesized from cholesterol by removal of the non-polar 
hydrocarbon chain, and is therefore similar in structure to cholesterol (Figure 3.10 A). 
Fluorescence-microscopy based Ca2+ imaging was used to show that PregS (25 µM) 
activated a large and robust Ca2+ signal in HEK-TRPM3 cells, but not HEK-YFP cells 
(Figure 3.10 B). Compared to Ca2+ responses induced by other TRPM3 activators, the 
response to PregS was rapid, sustained and of much greater magnitude. After 2 min, 
responses in HEK-TRPM3 were 20 times larger than the YFP-control response, 
confirming PregS is a novel and strong activator of human TRPM3. 
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Figure 3.10. Pregnenolone sulphate (PregS) increases Ca 2+ signals in TRPM3- 
expressing cells Ca2+ signals were measured as the 340/380 nm ratio of emission in 
fura-2 loaded HEK 293 cells. Cells were transfected with TRPM3 or YFP as a control. 
DMSO (vehicle) was present throughout recordings. A. Structure of PregS. B. 
Representative traces from single cells. PregS (25 µM) causes an increase in Ca2+ in 
TRPM3-expressing cells compared to YFP-expressing control cells (grey trace). C. 
Mean data (±SEM) showing a significant increase in Ca2± 2 min after PregS application 
(TRPM3 n/N=3/26, YFP n/N=3/50). 
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A tetracycline-inducible stable TRPM3 cell line 
A tetracycline-inducible TRPM3-expression system in HEK 293 cells was developed by 
F. Zeng to allow for the high-throughput analysis of TRPM3 Ca2+ signals. The YFP-tag 
was removed for this system. An inducible system is ideal for identification of specific 
TRPM3 responses as opposed to endogenous cell activity, as TRPM3-expressing and 
control cells come from the same population of cells. 
To determine whether the TRPM3-specific antibody TM3E3 could specifically detect 
its target antigen in tetracycline-induced (tet+) cells, and to demonstrate a marked 
increase in protein expression compared to non-induced cells, western blotting was 
performed. Dialysed TM3E3 was used at a dilution of 1: 4000. The calculated molecular 
weight for TRPM3 is 157 kDa, and published western blot data give an apparent 
molecular mass of 160 kDa (Grimm et al., 2003). In this study, TM3E3 recognised a 
protein of approximately 150 kDa (Figure 3.11 A). This 150 kDa band was absent 
following pre-incubation of TM3E3 with 10 µM of the antigenic peptide. Line scan 
analysis of individual lanes shows other low molecular weight bands detected by 
TM3E3 were not completely blocked by pre-incubation with peptide, indicating these 
bands are not related to TRPM3 (Figure 3.11 B). 
TRPM3 expression was further confirmed using immunocytochemistry. The nuclear 
staining agent DAPI was used to locate cells. Dialysed TM3E3 at a dilution of 1: 4000 
was able to detect TRPM3 in tetracycline-induced (tet+) cells (Figure 3.12), and no 
staining was observed when the primary antibody was omitted or when TM3E3 was 
preadsorbed to its antigenic peptide. Additionally, there was a small amount of faint 
staining observed in non-induced (tet-) control cells, consistent with native expression. 
In summary, TM3E3, an antibody targeted to the 3`' extracellular loop of TRPM3, binds 
TRPM3 protein. In addition, the data confirm that tetracycline-induction causes a clear 
increase in TRPM3 protein levels. 
98 
A 
TM3E3 TM3E3 
B 
+ pep 
tet+ tet- tet+ 
Relative Intensity 
0 20 40 60 80 
KDa KDa -A---J 
ý 
250- ý. , :ýý 250 
full length 
TRPM3 150 
Lý I ý-j 
f-TRPM3 
Figure 3.11. Detection of TRPM3 protein Western blotting on lysates of tetracycline- 
induced (tet+) or non-induced (tet-) HEK-TRPM3 cells. A. Lysates were blotted with 
dialysed TM3E3 antibody or TM3E3 preadsorbed to its antigenic peptide (TM3E3 + 
pep) as a negative control. B. Line scan analysis of individual western blot lanes shows 
TRPM3 signal present in tet+ lane (black line) is not present in peptide-adsorbed (green 
line) or tet- (red trace) control lanes. 
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Figure 3.12. Immunofluorescence detection of TRPM3 Immunocytology performed 
on non-permeabilised, tetracycline-induced (tet+) or non-induced (tet-) HEK-TRPM3 
cells. Cells were co-stained with DAPI and TM3E3 antibody plus a FITC conjugated 
secondary antibody. For negative controls, TM3E3 was preadsorbed to its antigenic 
peptide (TM3E3 + pep) or primary antibody was omitted. Scale bar represents 20µm. 
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A stable cell line allows for high throughput fluorimetry 
High throughput technologies such as the FlexStation are commonly used in drug 
discovery to screen large compound libraries for modulators of a particular protein or 
physiological function. Although such systems are rapid and cost effective, the 
downside is they require large numbers of cells, a high percentage of which must 
express the protein of interest. Standard transfection techniques often do not display 
sufficient efficiency of expression. As the user is restricted to monitoring a population 
of cells rather than selecting regions of interest, cellular responses can appear small or 
undetectable. The development of a stable TRPM3 cell line allowed for rapid and 
efficient channel expression, ideal for high-throughput systems. 
FlexStation fluorimetry of fura-2 loaded cells was used to confirm that TRPM3 
expression induced by tetracycline produced functional channels at the membrane. The 
TRPM3 activator PregS (25 µM) activated a rapid and sustained Ca2+ response in cells 
expressing TRPM3 (tet+) but not in non-induced cells (tet-) (Figure 3.13 A). The mean 
data show that after 1 min, PregS-induced responses in tet+ cells were significantly 
larger than tet- cells (Figure 3.13 B). 
The FlexStation also enables fast and accurate determination of dose response data for a 
given agonist. Different concentrations of agonist can be applied to separate wells of 
test and control cells within the same plate, allowing for direct comparison. Dose 
response data were produced in this way for PregS activation, and a Ca2+ response was 
activated by concentrations of PregS >_ 0.3 µM (Figure 3.13 Q. Responses increased in 
magnitude with higher concentrations of PregS, indicating the channel displays 
concentration-dependant activation. Fitting of the Hill equation indicated the 
concentration for half maximal activation, the EC50, was 1.83 tM (± 0.23), with a Hill 
coefficient of 1.03 (± 0.10) (Figure 3.13 D). 
The robust Ca2+ signals in response to PregS activation of TRPM3 were ideal for 
FlexStation fluorimetry. It is evident that PregS can activate TRPM3 in a concentration 
dependent manner, and when combined with a stable cell line, is a valuable tool for high 
throughput screening. 
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Figure 3.13. PregS increases Ca 2+ signals in tet+ TRPM3 cells Ca2+ signals were 
measured as the 340/380 run ratio of emission in fura-2 loaded HEK 293 cells. Cells 
were induced by incubation with tetracycline (tet+). Cells not treated with tetracycline 
were included as a control (tet-). DMSO (vehicle) was present throughout recordings. 
A. Mean data from 6 wells within a single plate. PregS (25 µM) causes an increase in 
Ca2+ in tet+ TRPM3 compared to tet- (open circles). B. Mean data (±SEM) showing 
significant increase in Ca2+ 1 min after PregS application (tet+ n/N=3/12, tet- 
n/N=3/12). C. Single trace representatives show dose-dependant activation of TRPM3 
expressing cells in response to PregS (0.1-30 µM). D. Mean dose response data (±SEM) 
taken 1 min after application from 3 independent experiments, analysed using the Hill 
equation. 
2468 10 
Time (min) 
PregS 
102 
Pregnenolone sulphate does not activate TRPC5 or TRPM2 
To determine the specificity of TRPM3 activation by PregS, its effect on other stable, 
tetracycline-inducible TRP cell lines was also investigated using fura-2 loaded cells and 
high-throughput Ca2+ fluorimetry. TRPM2 and TRPC5 stable cell lines were induced by 
tetracycline (tet+), and non-induced cells (tet-) were included in the same 96-well plate 
as controls. 
The lanthanide gadolinium (Gd3+) is a non-specific cation channel modifier that exerts 
dual effects on TRP channels in that it can be either excitatory or inhibitory. It is 
recognised as a TRPC5 channel activator at micromolar concentrations (Jung et al., 
2003). Gd3+ (100 µM) caused a significant increase in Ca2+ influx in tet+ TRPC5 cells, 
but PregS (25 µM) had no effect (Figure 3.14 A). The mean data show neither Gd3+ nor 
PregS caused any Ca2+ increase in non-induced cells (tet-) (Figure 3.14 Q. 
TRPM2 plays an important role in cell death induced by oxidative-stress, and can be 
activated by hydrogen peroxide (H202) (Wehage et al., 2002). H202 (1 mm) caused a 
significant increase in Ca2+ entry in tet+ TRPM2 cells, yet again PregS (25 µM) had no 
effect (Figure 3.14 B). The mean data show neither H202 nor PregS caused a Ca2+ 
response in tet- control cells (Figure 3.14 Q. 
In addition, PregS failed to elicit Ca2+ responses in TRPV4-expressing cells (C. Jones, 
AstraZeneca, personal communication). 
The data indicate PregS cannot activate TRPC5, TRPM2 and TRPV4, and may be a 
relatively specific activator for TRPM3. 
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Figure 3.14. PregS does not activate other TRP family members Ca2+ signals were 
measured as the 340/380 nm ratio of emission in fura-2 loaded HEK 293 cells. For 
PregS application, DMSO (vehicle) was constant throughout experiments. Traces 
correspond to data from a single well, representative of 6 wells within one plate 
(n/N=1/6). Arrow indicates time point of compound addition. A. Tetracycline-induced 
TRPC5 with PregS (25 µM) or positive control (100 gM Gd3+) addition. B. 
Tetracycline-induced tet+ TRPM2 with PregS (25 µM) or positive control (1 mM H202) 
addition. C. Mean data (±SEM) from 3 plates normalised to maximum response for 
positive control at 4 min after application (n/N=3/12). 
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Characterisation of PregS-induced Ca2+ responses 
Recognised TRP channel inhibitors were used to further characterise the PregS-induced 
TRPM3 response. Fura-2 loaded cells were preincubated for half an hour with inhibitors 
before analysis using high-throughput fluorimetry. 
Although known to activate TRPC5, gadolinium (Gd 3) is also useful as a blocker of 
most TRP channels, including TRPM3 (Lee et al., 2003a). Gd3+ (100 µM) completely 
inhibited PregS-induced Ca2+-influx in tetracycline-induced (tet+) TRPM3 cells (Figure 
3.15 A). The mean data indicate that at 1 min after PregS application, Gd3+ inhibited the 
PregS response in tet+ cells by 100%, but did not affect non-induced (tet-) cells (Figure 
3.15 Q. 
2-aminoethoxydiphenylborate (2-APB) was initially introduced as an inhibitor of the 
IP3 receptor; however it has become established as a blocker of store-operated Ca2+ 
entry (Bootman et al., 2002). More recently it has emerged as an inhibitor of several 
TRP family members, including TRPM3 (Xu et al., 2005a). 2-APB (75 µM) inhibits 
Ca2+-responses evoked by PregS (25 µM) in tet+ cells (Figure 3.15 B). The mean data 
show that at 1 min after PregS application, 2-APB inhibited PregS-induced Ca2+ 
responses by approximately 70%, with no significant effect in non-induced (tet-) cells 
(Figure 3.15 Q. 
To investigate if PregS causes Ca2+ influx across the membrane through TRPM3 
channels, rather than leading to Ca2+ release from stores, cells were exposed to 
thapsigargin (Tg). Tg empties intracellular Ca2+ pools by inhibiting the sarcoplasmic 
reticulum Ca2+-ATPase (SERCA), thus preventing refilling of Ca2+ stores following 
depletion. A 30 min preincubation with Tg (1 µM) reduced the amplitude of the 
response to PregS, but the overall response was the same as the control. The mean data 
show that the baseline ratio in both tet+ and tet- cells was increased in cells exposed to 
Tg, which is likely to be the result of activation of endogenous store-operated channels 
in this cell type (Figure 3.16 B). The mean data also show a significant reduction in the 
amplitude of the PregS response in TRPM3-expressing cells (Figure 3.16 Q. 
To further investigate the relationship between intracellular Ca2+ stores and the PregS 
response, experiments were performed in the absence of extracellular Ca2+. In the 
105 
absence of Cat' the PregS response was completely absent, demonstrating PregS causes 
Cat'influx (Figure 3.17 A& B). As a positive control, CCh was applied, and was seen 
to elicit a Cat' response, demostrating availability of stores for Cat'release (Figure 3.17 
C). 
In summary, the PregS response is due to TRPM3-mediated Ca2+ influx across the 
plasma membrane and does not involve Ca2+ release. 
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Figure 3.15. Characterisation of the PregS response Ca2+ signals were measured as 
the 340/380 nm ratio of emission in fura-2 loaded HEK 293 cells. Traces are 
representative mean data (±SEM) from 6 wells within a single plate. DMSO (vehicle), 
Gd3+ and 2-APB were present for the duration of recordings. A. Gd3+ (100 µM) 
completely inhibited the Ca2+ response. B. 2-APB also causes significant inhibition of 
the Ca2+ response. C. Mean data (±SEM) from 3 independent experiments taken 1 min 
after PregS application, with (n/N=3/9) and without inhibitors (n/N=3/9). 
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Figure 3.16. Effect of thapsigargin on the PregS response Ca2+ signals were 
measured as the 340/380 nm ratio of emission in fura-2 loaded HEK 293 cells. Traces 
are representative mean data (±SEM) from 6 wells within a single plate. DMSO 
(vehicle) was present throughout recordings. A. Preincubation for 1/2 hour with Tg (1 
µM) increases the baseline Ca2± ratio. B. Mean data (±SEM) showing change in 
baseline. C. Baseline subtracted mean data (±SEM) from 3 independent experiments 
taken 1 min after PregS application, with (n/N=3/9) and without Tg (n/N=3/9) 
preincubation. 
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Figure 3.17. The PregS response does not involve Ca2+ release from stores Ca" 
s12nals %%ere measured as the 340/380 nm ratio of emission in fora-2 loaded HEK 293 
cells. DMSO (vehicle) was present throughout recordings. A. Representative mean data 
(±SEM) from 3 wells within a single plate. PregS (25 uM) does not elicit a Ca2+ 
response in the absence of extracellular Cap+. B. Mean data (±SEM) from 3 independent 
experiments (n/N=3/9) taken 30 seconds after PregS application. 
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TM3E3 inhibits PregS-induced Ca 2+ responses 
Data previously presented in this chapter showed that the activation of TRPM3 by 
sphingosine was blocked by TM3E3. The antibody was therefore investigated as an 
inhibitor of PregS-induced Ca2+ entry. 
Preincubation with non-dialysed TM3E3 at a 1: 4000 dilution significantly inhibited the 
PregS response in TRPM3-expressing cells by an average of 26.1%, with no effect on 
tet- cells (Figure 3.18). To explore the selectivity of E3-targeted antibodies, a second 
peptide specific antibody targeted to the 3`d extracellular loop of TRPC1, TIE3, was 
directly compared to TM3E3 within the same microtitre plate. Preincubation with T1E3 
at a dilution of 1: 500, determined as the most suitable dilution by ELISA, did not inhibit 
PregS activation of TRPM3, nor did it have any effect on tet- cells (Figure 3.18). 
HEK 293 cells display an increase in Ca2+ in response to ATP due to activation of 
native purinergic receptors. To explore whether TM3E3 inhibits the TRPM3 channel 
directly, or has an overall effect on the cell as a whole, the ATP response in cells 
preincubated with preimmune or TM3E3 antisera was investigated. TM3E3 failed to 
inhibit the endogenous ATP-induced Ca2+-reponse in tet- cells (Figure 3.19 A and B). 
In addition, the mean data (Figure 3.19 B) confirm that ATP applied to tet+ cells does 
not cause a significant difference in the Ca2+ response in tet+ cells, suggesting ATP 
cannot activate TRPM3. 
To further confirm specificity of the antibody, the blocking ability of TM3E3 was 
examined for other TRP family members. TM3E3 did not inhibit H202-induced Ca2' 
responses in TRPM2, (Figure 3.20 A), Gd3+ activation of TRPC5 (Figure 3.20 B), or 
4aPDD activation of TRPV4 (Figure 3.20 Q. 
The data strengthen the idea that E3-targetted antibody design can be used to generate a 
highly specific ion channel blocker. 
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Figure 3.18. TM13E3, but not T1E3, inhibits PregS activation of TRPM3 Ca 2+ 
signals were measured as the 340/380 nm ratio of emission in fura-2 loaded HEK 293 
cells. Cells were induced by incubation with tetracycline (tet+); non-induced cells (tet-) 
were included as a control. Mean data (±SEM) from 3 individual experiments taken 30 
seconds after PregS application. Cells preincubated with antibody are indicated by grey 
bars. Preimmune controls are indicated by black bars. PregS (25 [IM) caused an increase 
in Ca 2+ in tet+ TRPM3 that was inhibited by preincubation with TM3E3 compared to 
preimmune control. Within the same plate, the PregS response was not inhibited by 
preincubation with the anti-TRPC I antibody, T1 E3 compared to its preimmune control. 
For each test group n/N=3/18. 
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Figure 3.19. TM3E3 does not inhibit the native ATP response Ca 2+ signals were 
measured as the 340/380 nm ratio of emission in fura-2 loaded HEK 293 cells. Traces 
are representative mean data (±SEM) from 6 wells within a single plate. A. ATP (10 
uM) caused an increase in Ca 
2+ in tet- TRPM3 that was not inhibited by preincubation 
with TM3E3 (open circles) compared to preimmune control (closed circles). B. Mean 
data (±SEM) taken 15 seconds after ATP application, for 3 individual experiments for 
tet- and tet+ TRPM3 cells preincubated with preimmune (black bars) or TM3E3 
antisera (grey bars). For each test group, n/N=3/18. 
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Figure 3.20. Specificity of TM3E3 Ca"' signals were measured as the 340/380 nm 
ratio of emission in fura-2 loaded HEK 293 cells. TRPM2 and TRPC5 cells were 
induced by incubation with tetracycline (tet+), non-induced cells (tet-) were included as 
a control. For TRPV4, the parent CHO cell line was included as a control. Traces are 
representative mean data (±SEM) from one independent experiment. A. H? O2 (I mM) 
caused an increase in Ca 2+ in tet+ TRPM2 (closed circles) that was not inhibited by 
TM3E3 (open circles). B. Gd3+ 100 uM) caused an increase in Ca 2+ in tet+ TRPC5 
(closed circles) that was not inhibited by TM3E3 (open circles). C. 4cLPDD (10 µM) 
caused an increase in Ca 2+ in TRPV4 (closed circles) that was not inhibited by 
preincubation with TM3E3 (open circles). D. Mean data (±SEM) from 3 independant 
experiments for each cell type, normalised to maximum response to agonist. Cells were 
preincubated with preimmune (black bars) or TM3E3 antisera (grey bars). TRPM3 
n/N=5/25, TRPM2 n/N=3/34, TRPC n/N=3/34, TRPV4 n/N=3/27. 
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TRPM3 inhibition by dialysed TM3E3 
As mentioned previously, TM3E3 antisera were dialysed to remove preservative and 
other small molecules. Analysis by ELISA confirmed dialysis decreased the amount of 
antibody in samples, reducing the EC50 for dialysed TM3E3 activity to 1: 500. It was 
therefore necessary to ensure the dialysed antibody was still effective at blocking the 
TRPM3 channel. 
Dialysed TM3E3 at a dilution of 1: 500 effectively inhibited PregS activation of 
TRPM3, and had no effect on non-induced cells (Figure 3.21 A). Mean dose response 
data for 4 dilutions of the antibody indicate only dilutions of 1: 1000 and 1: 500 caused 
significant block of the PregS response (Figure 3.21 B). Analysis of the dose response 
data using the Hill equation gives an extrapolated IC50 for dialysed antibody inhibition 
as 1: 454 dilution (Figure 3.21 Q. 
The data suggest that in order to achieve a significant inhibitory effect using the 
dialysed antibody, it must be used at a 1: 500 dilution. 
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Figure 3.21. Dialysed antibody dose response Ca 2+ signals were measured as the 
340/380 nm ratio of emission in fura-2 loaded HEK 293 cells. TRPM3 cells were 
induced by incubation with tetracycline (tet+), non-induced cells (tet-) were included as 
a control. A. PregS (25 uM) caused an increase in Ca 2+ in tet+ TRPM3 that is inhibited 
by preincubation with dialysed TM3E3 at 1: 500 dilution (open circles) compared to 
dialysed preimmune control (closed circles) n/N=1/3. B. Mean data (±SEM) from 3 
independant experiments for cells preincubated with TM3E3 (grey bars) or preimmune 
antisera (black bars). Data are normalised to maximum Ca 2+ response in preimmune- 
treated tet+ cells 1 min after PregS application (n/N=3/12). C. Mean data (±SEM) for 
TM3E3 block of tet+ PregS response analysed using the Hill equation. 
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PregS activated currents in TRPTN13-expressing cells 
To further investigate whether the antibody had direct blocking effect on the channel, 
electrophysiology was performed. This also served to further characterise the effect of 
PregS on the TRPM3 channel, and to build confidence that PregS effects are TRPM3 
mediated. 
The Port-a-patch benchtop system was used to perform whole-cell recordings using a 
voltage ramping protocol to investigate the current-voltage (I-V) relationship of 
TRPM3. Cells were held at 0 mV, followed by a step to -100 mV with a 200 ms ramp 
up to +100 mV, before returning to 0 mV. Series resistance was never greater than 20 
MS2. 
PregS (25 µM) applied to TRPM3-expressing cells led to the rapid development of a 
TRPM3-like current (Figure 3.22 A). The I-V was linear (Figure 3.22 B), and revealed a 
non rectifying current, with PregS activation shifting the reversal potential to an average 
value of -13.6 (±9.1) mV. This is consistent with the activation of a non-selective cation 
channel as described in the literature for TRPM3 (Grimm et al., 2005). 
Whole cell-voltage clamp was also performed using the Patchliner, an automated, 
planar patch clamp device. Experiments using the same ramping protocol as designed 
on the Port-a-patch show that PregS did not activate current in tet- cells (Figure 3.22 C 
and D). The overall increase in current at both -80mV and +80 mV was 10 times larger 
in tet+ cells than for tet- cells, 3 minutes after PregS application (Figure 3.22 E). 
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Figure 3.22. PregS activated TRPM3 currents Whole cell-voltage clamp performed 
using Port-a-Patch (A&B) or Patchliner (C-E). DMSO was present throughout 
experiments. A. Representative time-series data of whole cell currents at -80mV and 
+80 mV in a TRPM3-expressing (tet+) cell upon activation by PregS (25 µM). B. I-V 
relationship of a tet+ cell before and after PregS application. C. Representative time- 
series data of whole cell currents at -80mV and +80 mV in non-induced (tet-) cells upon 
application of PregS (25 µM). D. I-V relationship of a tet- cell before (black) and after 
(grey) PregS application. E. Mean data (±SEM) showing increase in current at +80mV 
and -80mV induced by PregS in tet+ (n=8) and tet- (n=3) cells. Patchliner experiments 
performed by C. J. Milligan. 
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TMM13E3 inhibits PregS-induced currents 
TM3E3 successfully inhibited Ca2+ responses in TRPM3-expressing cells. Further 
Patchliner experiments were performed to investigate the effect of TM3E3 on TRPM3 
currents activated by PregS. 
Application of dialysed TM3E3 at a 1: 500 dilution inhibited PregS-induced currents 
within 5 min of application (Figure 3.23 A). TM3E3 inhibited both outward and inward 
current (Figure 3.23 B). When preadsorbed to its antigenic peptide, TM3E3 had no 
inhibitory effect (Figure 3.23 C and D). The mean data for whole cell currents at 
+80mV and -80mV show that TM3E3 caused a significant 37% block of PregS-induced 
inward current, and 24% of outward current, but had no effect if predsorbed to its 
antigenic peptide (Figure 3.23 E). 
In summary, TM3E3 can significantly block PregS-induced current in TRPM3- 
expressing cells. The effect of the antibody does not appear to be voltage-dependent, as 
both the inward and outward current is inhibited. 
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Figure 3.23. TM3E3 inhibited PregS-activated currents Whole cell-voltage clamp 
performed using Patchliner, DMSO was present throughout the experiment. All cells 
were tet+. A. Representative time-series data of whole cell currents at -80mV and +80 
mV upon application of PregS (25 µM) and TM3E3 (1: 500). B. I-V relationship before 
(black) and after (grey) PregS and (light grey) TM3E3 application. C. Representative 
time-series data of whole cell currents at -8OmV and +80 mV upon application of PregS 
(25 pM) and TM3E3+pep (1: 500). D. I-V relationship before (black) and after (grey) 
PregS and (light grey) TM3E3+pep application. E. Mean data (±SEM) for currents at 
+80mV and -8OmV induced by PregS (n=12) and following TM3E3 (n=8) or 
TM3E3+pep (n=4) application. Experiments performed by Dr C. J. Milligan. 
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Discussion 
The data presented in this chapter demonstrate that extracellular application of the 
polyclonal antibody TM3E3 gives a partial but significant inhibition of the TRPM3 
cation channel, providing further evidence that peptide-specific antibody design can be 
used to create selective ion channel blockers, and demonstrating a new and important 
tool for the study of TRPM3. 
PregS is a novel TRPM3 activator 
The high percentage of TRPM3-expressing cells resulting from tetracycline-induction 
allowed for high throughput analysis of the TRPM3 Ca2+ response using a FlexStation 
fluorimeter. Published modulators of TRPM3, including sphingolipids and hypotonic 
solutions, produced small Ca2+ responses in TRPM3-expressing cells that, although 
significant, were not ideal for detailed studies. A novel, potent, and physiologically 
relevant TRPM3 activator was therefore necessary, and was found in PregS. PregS 
caused rapid, sustained Ca2+ responses and quickly activated currents in TRPM3- 
expressing cells (Figure 3.13). The concentration of PregS giving half maximal 
activation was determined as 1.83 µM, with the threshold for activation sitting at 
approximately the physiological levels in healthy individuals, which are the same for 
both sexes at -0.1 µM (de Peretti et al., 1983; Tagawa et al., 2000). This would suggest 
that physiological concentrations of PregS may be sufficient to activate TRPM3. 
Contrary to the effect on TRPM3, PregS has been reported to inhibit capsaicin-induced 
TRPVI currents in rat dorsal root ganglion neurons (Chen et al., 2004). Although the 
physiological relevance of PregS modulation of TRP channels is unknown, it will serve 
as a useful TRPM3 activator and positive control for future experiments, and may be 
used to identify TRPM3 channels in their native cells and tissues. 
PregS synthesis is believed to occur in the brain independently of other steroid 
generating organs, making it a neurosteroid and a precursor to many steroid hormones. 
Neurosteroid levels vary with age and during pregnancy or times of stress and 
depression, and PregS levels in particular have been shown to correlate with impaired 
memory function in rats (Vallee et al., 1997). In addition PregS levels are reduced in the 
brains of Alzheimer's patients (Weill-Engerer et al., 2002), and consequently PregS is 
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believed to have a neuroprotective role, and is commonly prescribed as a memory 
enhancing drug. The effect of PregS in the CNS as an allosteric modulator of ligand- 
gated ion channels is well characterised. It is established as an excitatory neurosteroid, 
acting as a negative modulator of the y-aminobututyric acid type A (GABAA) receptor, 
and a positive modulator the N-methyl-D-aspartate (NMDA) type of glutamate receptor. 
PregS acts as a non-competitive antagonist of the GABAA receptor, and the inhibition it 
causes is independent of GABA binding and receptor activation (Akk et al., 2001). 
Pregnenolone (Preg), the non-sulphated precursor to PregS, is not active at the GABAA 
receptor, and a study of GABAA in C. elegans describes an extracellular arginine 
residue necessary for PregS inhibition of the receptor (Wardell et al., 2006). This 
suggests the negative sulphate group of PregS is required for activity. Single channel 
recordings have shown that PregS acts directly on NMDA receptors as an allosteric 
modulator (Bowlby, 1993). Again Preg is ineffective, further evidence that the negative 
sulphate is essential. Interestingly Preg can also activate TRPM3, although it is less 
efficacious than PregS (J. Oberwinkler, personal communication). This suggests that 
unlike modulation of other ligand-gated ion channels, the sulphate group is not critical 
for TRPM3 activation, but may be beneficial. 
The non-selective, cation inhibitors Gd3' and 2-APB both reduced the PregS-induced 
Ca2+ response in TRPM3-expressing cells (Figure 3.15). Although the data are 
consistent with a direct effect of PregS on the TRPM3 channel, there is the possibility 
PregS works via a signalling pathway. The related steroids oestrogen and progesterone 
both have receptors in peripheral tissues, and there is evidence PregS binds to the 
oxytocin receptor (Grazzini et al., 1998). However another candidate for PregS binding 
is the sigma (a) receptor. Originally believed to be an opiate receptor, the a receptor is 
now known to be distinct from other receptors, and exists in 2 isoforms, a, and a2. The 
a, isoform is a single 223 amino acid polypeptide that is able to bind steroids, including 
PregS (Maurice et al., 1999). Although mainly expressed in the CNS, a receptors are 
also present in the periphery, and are believed to be involved in signal transduction. 
There is evidence that neurosteroids can increase glutamate release through a G; 
coupled a receptor, and despite possessing an N-terminal ER retention signal, activation 
of the a, receptor causes its translocation to the plasma membrane where it stimulates 
PLC via a G; protein (Morin-Surun et al., 1999). Additionally there are reports that the 
a, receptor can modulate channels at the plasma membrane, such as inhibition of Kv 1.4 
(Aydar et al., 2002) and voltage-dependent Ca2+ channels in rat neurons (Zhang et al., 
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2002). An argument against PregS modulating TRPM3 via a ß, receptor-related 
signalling pathway is that the Ca2+ response is fairly rapid. Furthermore, PregS can only 
activate TRPM3 from the extracellular side of the membrane (J. Oberwinkler, personal 
communication). Nevertheless it seems premature to rule out involvement of the ER 
bound ßi receptor. Perhaps PregS exerts its effect on the ßl receptor via changes in 
intracellular Ca2+ as a result of TRPM3 activation. The suggestion that PregS exerts its 
inhibitory effect on TRPV1 by inserting into the membrane and perturbing membrane 
lipids adjacent to the channel (Chen et al., 2004) presents an alternative mechanism of 
activation. Steroids are lipophilic, and insertion into the plasma membrane seems 
favourable, thus causing a non-direct effect on TRPM3 as a result of stretch of the 
membrane, or even managing to transverse the membrane completely to activate ßi 
receptors. Although they are less potent, the structurally related compounds Preg, 
DHEA and DHEAS can also activate TRPM3, perhaps by a common mechanism of 
membrane insertion (J. Oberwinkler, personal communication). Incorporation into the 
membrane resulting in stretch-activation of the TRPM3 channel may be similar to the 
mechanism of activation resulting from hypotonic shock-induced cell swelling. 
Although a TRPM3 splice variant is reported to be a store-operated channel (Lee et al., 
2003a), the variant TRPM31325 is reported to be unaffected by thapsigargin (Tg) 
(Grimm et al., 2005). It is interesting that in this study, preincubation with Tg reduced 
the amplitude of the PregS-response (Figure 3.16 Q. As the Ca2+ response was not 
completely inhibited, this suggests that the majority of the PregS-induced Ca2+ response 
in TRPM3-expressing cells results from Ca2+ influx across the plasma membrane 
through the TRPM3 channel. However the inhibition by Tg suggests store release 
cannot be completely disregarded as a contributor. PregS is known to activate nuclear a- 
receptors, therefore is able to cross the plasma membrane, and in theory could act on 
TRPM3 channels expressed in the membrane of intracellular Ca2+ stores. 
In addition to the inhibition of the PregS response, Tg also caused an increase in the 
baseline of resting cells, presumably as a result of the activation of endogenous store- 
operated channels (Figure 3.16 A). As the increase in baseline was of a similar 
magnitude in both non-induced and TRPM3-expressing cells (Figure 3.16 B), this is 
evidence that TRPM3 is not store operated. Therefore a possible explanation for the Tg 
effect is that the PregS response saturated, and due to the increased starting baseline the 
Ca2+ response to PregS in a Tg-treated cell was unable to increase by the same 
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magnitude as a control cell. If this was the case, Tg did not inhibit the PregS effect, and 
store release is not a factor in PregS activation of TRPM3. Repeating experiments in the 
absence of extracellular Ca2+ confirmed the PregS response was the result of Ca2+ 
influx, and does not involve Ca2+ stores (Figure 3.17). The inhibitory action of Tg may 
have been the result of changes in local intracellular Ca2+ concentration. Intracellular 
Ca2+ is a common regulator of TRP channels; TRPV6 is inhibited by intracellular Ca2+ 
(Bodding et al., 2002) and the activation of TRPM4 and TRPM2 is dependent on 
intracellular Ca2+ (McHugh et al., 2003). Therefore it is possible that TRPM3 is also a 
Ca2+ sensitive channel. 
RT-PCR revealed TRPM3 mRNA is present in HEK 293 cells (Figure 3.9), which was 
confirmed by immunostaning with the TM3E3 antibody (Figure 3.12). Native 
expression of TRPM3 would explain why SPH and DHS caused a Ca2+ response in 
control, YFP-transfected cells (Figure 3.2 C&3.3 Q. However, PregS did not activate 
Ca2+ entry or current in control cells (Figure 3.10). Although several splice variants are 
reported for TRPM3, few are fully characterised. Even small splicing events can change 
the selectivity of the ion pore while retaining conserved TRPM3 characteristics 
(Oberwinkler et al., 2005). Perhaps a novel splice variant, similar enough in sequence to 
be identified by the TRPM31325 primer pair, is responsible for a channel sensitive to 
SPH and DHS, but not PregS. Alternatively, endogenous TRPM3 PregS-responses may 
be inhibited in native cells. 
E3-targeting to generate a specific TRPM3 channel blocker 
A functional role for TRPM3 has yet to be determined. When over-expressed in HEK 
293 cells, TRPM3 is activated by hypotonic stimulation, most likely as a result of cell 
swelling (Grimm et al., 2003). Volume-regulation of TRP channels is common, and has 
been demonstrated for several family members, including TRPV4, TRPC1, TRPC6, 
TRPV2, TRPM2, TRPM4 and TRPP2 (Kraft et al., 2005; Muraki et al., 2003; Nilius et 
al., 2004b). The physiological relevance of SPH activation of TRPM3 is also unknown. 
Serum levels of free SPH are reported to be between 64-273 nM (Abnet et al., 2001), 
whereas the EC50 for SPH activation of TRPM3 is 12 pM (Grimm et al., 2005), well 
above the physiological range. Sphingosine is believed to result almost exclusively from 
the metabolism of ceramide by ceramidase, as de novo synthesis does not occur 
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(Cuvillier, 2002). Ceramidase is present at the plasma membrane (Tani et al., 2007), 
and is expressed at high levels in human kidney (El Bawab et al., 2000). Additionally, 
human sphingosine-l-phosphate phosphatase, responsible for the dephosphorylation of 
sphingosine-l-phosphate to SPH, is also expressed in most tissues (Johnson et al., 
2003). Therefore SPH cannot be completely ruled out as a physiological modulator of 
TRPM3, as the concentration it reaches locally to the TRPM3 channel is unknown, and 
may well be sufficient for activation. A specific inhibitor for the TRPM3 channel would 
serve as a useful tool for functional investigations. 
While existing, small molecule TRP channel antagonists are non-specific, many have 
still proven useful in the characterisation of the TRP family. Lanthanide ions are known 
to block Ca2+ permeable cation channels (Halaszovich et al., 2000), 2- 
aminoethoxydiphenylborate (2-APB) can inhibit store-operated calcium channels and 
some TRP isoforms (Bootman et al., 2002; Xu et al., 2005a), SKF96365 inhibits 
receptor-mediated calcium entry, and ruthenium red is a non-selective inhibitor of all 
TRPV and some TRPM channels (Gunthorpe et al., 2002). More recently, antibodies 
have emerged as selective channel blockers, designed to specifically recognise 
individual ion channel proteins by exploiting conserved or unique regions of sequence. 
It is the common properties of antibodies that make them ideal as tools to investigate 
ion channel function; they are highly specific, and in the case of externally targeted 
antibodies, do not require complicated intracellular delivery methods. 
TRP channel structure is believed to resemble that of voltage-gated potassium channels. 
Although a crystal structure is not yet available for TRP, hydrophobicity analysis gives 
a good indication of the location and amino acid sequence of TM domains and 
connecting intra- and extracellular loops. The third extracellular loop seems an ideal 
target for antibody generation as it is not glycosylated and tends to be of sufficient 
length to allow for good antibody access, while other extracellular loops are smaller 
with post translational modifications that could hinder antibody access (Xu et al., 
2005b). The method of E3-targeting was applied to TRPM3 to create an anti-TRPM3 
antibody capable of blocking both SPH and PregS activation of the channel. 
It is important to determine whether a custom made antibody is specific for its 
designated target. In this study, this was demonstrated by immunostaining and western 
blotting with the stable TRPM3 cell line. For immunostaining, cells were not 
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permeabilised prior to staining with TM3E3, indicating that the signal observed in 
TRPM3-expressing cells was due to the antibody binding an extracellular epitope as 
predicted (Figure 3.12). Non-induced control cells also exhibited a small degree of 
staining, consistent with native expression of TRPM3. TM3E3 also successfully 
identified a protein in western blotting similar to the predicted molecular weight for 
TRPM3 of 157 kDa (Figure 3.11). Often, a western blot signal will not exactly match 
the predicted size of the protein due to post-translational modifications or the formation 
of heteromers that gives an apparent increase in size. Western blotting with TM3E3 
revealed 2 bands at 150 and 100 kDa (Figure 3.11). As both bands were reduced in the 
peptide control lane, they are most likely not due to non-specific labelling. A possible 
explanation for the smaller molecular weight band is degradation of the protein sample 
by endogenous proteases to produce a truncated TRPM3 peptide that was still detected 
by the antibody. A useful, further control for antibody selectivity would be to compare 
staining or blotting in tissues known to express TRPM3 with those that don't, such as 
by using siRNA to transiently knockdown the TRPM3 mRNA, or by using tissues from 
a knockout animal. As yet, there is not a TRPM3 knockout available. 
E3-targeted antibodies are particularly suitable for functional experiments as there is a 
much reduced chance of non-specific interactions when cells are intact, allowing only 
extracellular regions of membrane-bound proteins to be exposed to antibody, and not 
the whole proteome. Preincubation of live cells with TM3E3 inhibits calcium entry and 
current, indicating TM3E3 can binds its extracellular epitope and exert a functional 
effect. Additionally, immunostaining and western blotting suggest that the antibody 
remains bound to the channel following washing steps; therefore despite not being 
present in solutions throughout actual recordings, it can be assumed that the antibody 
remained bound to TRPM3. 
In functional studies, TM3E3 appears specific for TRPM3, with the ability to inhibit 
Ca2+ responses to both the published TRPM3 modulator D-erythro-sphingosine (SPH), 
and the novel modulator pregnenolone sulphate (PregS) (Figures 3.8 & 3.18). It was 
necessary to confirm the antibody had a direct effect on the TRPM3 channel, rather than 
causing a non-specific effect on the cell as a whole. Preimmune serum is a good control 
as it contains exactly the same components as the antibody sera, except that it lacks the 
peptide-directed antibodies. Presumably any non-specific effects of sera would be 
apparent in preimmune sera as well. A further control was to preabsorb TM3E3 to its 
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peptide so that it was unable to bind its TRPM3 epitope, and this peptide-bound 
antibody had no inhibitory effect on PregS currents. The use of the antigenic peptide 
confirms the antibody does bind the correct epitope in TRPM3. In addition, TM3E3 
only inhibited TRPM3-related cellular responses, and did not affect endogenous ATP 
responses in non-induced cells, nor did a second E3-targeted antibody, T1 E3, have any 
effect on cell responses to TRPM3 activators (Figure 3.18). Also, the antibody had no 
effect on cells which do not present the antigen (Figure 3.20). It would appear from 
these experiments that the antibody only has an inhibitory effect when it is bound to the 
TRPM3 channel. Importantly TRPM3 and its close relative TRPM2 share 74% 
sequence homology in the 3rd extracellular loop, yet the antibody could successfully 
distinguish between the two, further demonstrating its specificity for TRPM3. 
TM3E3 typically blocked channel activity by 30-50% after a 0.5-3 hour preincubation. 
Although inhibition of channel activity is partial, this is sufficient to study TRPM3 in 
native cells and tissues, and the selectivity of the antibody compensates for an 
incomplete block. The native structure of TRPM3 may give a different arrangement of 
the extracellular loops than is indicated by a linear peptide representative, perhaps 
hindering antibody access and preventing a complete block of the channel. Also, 
accessibility may be an issue, as cells in culture are adhered to a flat surface and 
therefore some channels will not be exposed to antibody. However, in Patchliner 
experiments cells were in solution, and presumably were well exposed to antibody, yet 
still there was not a complete inhibition, although this is presumably due to a shorter 
duration of exposure to the antibody. A partial effect could occur as a result of only 
partial occlusion of the channel pore or an incomplete conformation change, as will be 
examined later in this discussion. There is little information as to the suitability of 
antibodies targeted to other extracellular regions of TRP channels, although antibodies 
to intracellular regions of potassium channels have been successful blockers, while 
antibodies to sodium channels can be inhibitory or stimulatory (Dallas et al., 2005). 
Future experiments may discover regions of the protein that serve as superior antibody 
targets that will provide a stronger or complete channel block. 
The antibody concentration used in experiments is important as it must give maximum 
inhibition while minimising non-specific background suppression (thou et al., 1998). 
For this reason, cells were preincubated with the antibody for a relatively short time 
prior to experiments to minimise changes to the native protein levels and cellular 
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localisation (Xu et al., 2001). The short incubation time did not appear to have an effect 
on blocking activity, as direct application in patching experiments shows a significant 
block can be achieved within 10 minutes, therefore a longer preincubation may be 
unnecessary. The antibody has further advantage in that it can inhibit TRPM3 function 
reasonably quickly with minimal effects on the cell as a whole. This is a common 
disadvantage with siRNA knockdown or knockout animals, which can result in other 
proteins compensating for the effects of the gene removal, masking the exact effect of 
the knockdown. 
Mechanism of antibody blockade 
The underlying mechanism of E3-antibody blockade has yet to be determined. 
Polyclonal antibodies present in sera are a mixture of structurally different IgG 
immunoglobins, each of which will recognise a different epitope on the sequence of a 
specific antigen. This means the exact polyclonal within the anti-sera that acts as a 
blocker, plus its epitope, is unknown. The simplest explanation for channel inhibition is 
that when bound to the channel, the blocking antibody can obstruct the pore. Rabbit IgG 
consist of 2 heavy and 2 light chain polypeptides, making them typically -160 kDa. 
Compared to the predicted size of TRPM3 of 157 kDa, this would certainly seem 
sufficient to obstruct the pore, but may be too large to actually fit into the pore. 
It has also been suggested that one or more different polyclonal antibodies must bind in 
order to achieve channel inhibition. This would explain why rabbit monoclonal 
antibodies targeted to the 3`d extracellular loop of human TRPV 1 did not cause 
inhibition, as a single species of IgG was insufficient to inhibit function (Klionsky et al., 
2006). In the same study, a polyclonal antibody generated against rat TRPV 1 was 
effective at blocking both proton and chemical activation of the channel, activation 
mechanisms known to be independent of each other, suggesting the antibody locks the 
channel in a closed state. This also implies E3 antibodies do not interact with the 
agonist binding site. Although the exact binding site and mechanism of activation for 
TRPM3 are unknown, like TRPV 1 it is unlikely the antibody would function as a 
competitive inhibitor agonist because it can inhibit activation by two structurally 
unrelated activators, SPH and PregS, which in all probability do not share a binding site. 
However if regulatory proteins are required for activation, and have binding sites 
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distinct to activator binding sites, perhaps the antibody masks their binding and thus 
prevents allosteric interactions required for normal channel function. 
TM3E3 binding to the TRPM3 protein may result in a conformational change in the 
channel to lead to obstruction of the pore, to lock the channel in the closed state, or even 
to mark the TRPM3 protein for internalisation and degradation. Alternatively the 
antibody could prevent a conformational change necessary for channel opening. If the 
antibody causes internalisation of TRPM3 channels, the number of channels present at 
the plasma membrane would be reduced, thus reducing the overall cellular response. 
However the YFP-tagged TRPM3 protein used in this study did not appear to exhibit 
different activation or function than the non-YFP tagged inducible TRPM3. This 
indicates that aC terminal protein addition was not sufficient to cause TRPM3 
internalisation, therefore perhaps neither would a bound antibody. 
Alternative splicing allows the TRPM3 gene to encode several different proteins. There 
are currently 7 reported variants of human TRPM3, seemingly with different functions. 
TRPM3 variants a-f vary in the pore domain and N terminus, and TRPM3a is store- 
operated (Lee et al., 2003a), while the variant TRPM31325 as used in this study has a 
shorter N terminus and longer C terminus, and is not store operated (Grimm et al., 
2005). Additionally, alternative splicing in the pore region of mouse TRPM3 changes 
the cation selectivity of the pore (Oberwinkler et al., 2005). This indicates alternative 
splicing could be a mechanism used to produce channels not only with different 
selectivity, but also different mechanisms of activation and cellular function. The 
antibody should in theory inhibit all TRPM3 variants, as for all those reported so far the 
3`d extracellular loop is conserved save for TRPM3c, which contains an extra 12 amino 
acids, although the antigenic peptide sequence is conserved fully and unaffected by 
splicing. It is acceptable to assume the antibody will not be able to distinguish between 
splice variants. 
Antisera containing polyclonal antibodies generated against the channel of choice is a 
finite supply - the exact polyclonal antibody acting as a blocker and its precise epitope 
on the channel structure are unknown, so future use of the same technique may not 
produce the same effective blocker again. Monoclonal antibodies (mAbs) however can 
be produced in recombinant systems, creating large amounts of pure antibodies. The 
unlimited diversity and exquisite specificity has meant that currently mAbs are very 
128 
popular, with over 350 now undergoing clinical trials against a broad range of different 
diseases and conditions. Yet a mAb directed against TRPV 1 was ineffective (Klionsky 
et al., 2006). Despite identifying 26 different mAbs that could bind the channel, none 
caused inhibition, indicating they did not target the correct epitope required for channel 
blockade. However polyclonal antibody serum directed against the same region of 
TRPVI was a successful inhibitor, perhaps because it bound the entire extracellular 
loop to which it was targeted, whereas the mAbs despite possessing higher affinity have 
smaller epitopes. A recent study has presented evidence to the contrary, developing the 
first monoclonal antibody to be a successful ion channel blocker (Gomez-Varela et al., 
2007). Their antibody specifically and potently reduces current through the hEagl ion 
channel. Furthermore the antibody implicates hEagl expression is linked to tumour cell 
growth, evidence for E3-targeted antibodies as tools to determine ion channel function. 
Summary 
In the near future, it is expected that custom-made antibodies will have further 
important therapeutic applications due to their specificity and unlimited diversity. 
Currently, an antibody that can specifically block a channel is a valuable tool for further 
study of the protein, particularly for those where the function remains elusive. TRPM3 
is one such functionally mysterious channel, and TM3E3 will be undoubtedly useful for 
further characterisation of the channel. 
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Chapter 4 
TRPM3 in human saphenous vein smooth muscle cells 
The previous chapter introduced TM3E3 as a specific blocker for the TRPM3 ion 
channel. The antibody is potentially an important tool for determining the native 
expression and localisation of TRPM3, and its effectiveness gives it the potential to 
specifically inhibit channel function in living cells and tissues. 
TRP channels are widely expressed in the vasculature and are activated by lipids and 
second messengers known to be present at increased concentrations in disease states 
such as atherosclerosis, a major contributing factor to heart disease. The longest vein in 
the human body is the great saphenous vein, and it is sections of this vessel that are 
commonly used as the graft tissue in coronary bypass surgery, a treatment for 
atherosclerotic occlusion of vessels. Like all blood vessels, human saphenous vein 
(HSV) consists of 3 layers; an outer layer of connective tissue termed the adventitia, a 
medial layer of smooth muscle, and an inner layer of endothelium, termed the intima. 
Surgical processes including bypass surgery, and also angioplasty, regularly lead to 
extensive vascular remodelling, resulting from smooth muscle cell proliferation and 
migration to invade the intima and occlude the vessels. This neointimal hyperplasia is 
instigated by a phenotypic switch in the smooth muscle from a contractile to 
proliferative state, which is associated with down-regulation of L-type Ca2' channels 
(Quignard et al., 1997). The loss of L-type channels is compensated by different types 
of Ca2+ channel in the proliferating cells. 
The in vitro culture of HSV has proved a useful model to demonstrate neointimal 
proliferation (Porter et al., 1996). The isolation and culture of human saphenous vein 
smooth muscle cells (HSV SMC) is also a useful model, and together these techniques 
have been used to show that inhibition of Ca2+ entry through TRPC channels can 
significantly reduce neointimal formation in human vein, and inhibit cultured SMC 
proliferation (Kumar et al., 2006). This suggests that TRP channels may play the role of 
the compensatory channel present in proliferating SMC. 
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The aim of this chapter was to investigate TRPM3 expression and function in vascular 
smooth muscle using immunocytochemistry, calcium measurement techniques and 
assays of HSV SMC secretion. Furthermore experiments would determine whether, in 
addition to over-expressed TRPM3 channels, TM3E3 could block endogenous channels 
in primary cell types, serving as a useful tool to elucidate native channel function. 
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Detection of TRPM3 in HSV SMC 
The expression of TRPM3 mRNA in smooth muscle cells isolated from human 
saphenous vein (HSV) was investigated using solution PCR. Alternative splicing is 
common for members of the TRP superfamily (Li et al., 2005), and TRPM3 is reported 
to exist in many splice variant forms (Lee et al., 2003a; Oberwinkler et al., 2005). The 
human splice variants TRPM3a-f vary in the pore domain and N terminal regions, while 
the variant TRPM31325 described in Chapter 3 of this study is unique in that it has a 
longer N terminus. Using the aligned gene sequences for all reported variants, small 
diffences in the amino acid sequences were exploited to design splice-specific primers 
to probe HSV SMC cDNA for alternatively spliced TRPM3 variants. A schematic 
depicting the alignment of TRPM3 splice variants, plus details of the primers used and 
the expected products are given in Chapter 2 (Figure 2.6 and Table 2.1). 
Primers directed to the N terminus of the TRPM3 splice variant TRPM31325 amplified a 
single amplicon of the predicted size 335 bp (Figure 4.1 A). Control reactions without 
reverse transcriptase (-RT) were also performed. 
HSV SMC cDNA was also probed for further splice variant mRNA (Figure 4.1 B). 
Product bands were excised from the gel, cleaned, subjected to further round of PCR to 
amplify DNA present, and sequenced. Primers specific for TRPM31325 were included as 
a positive control, and gave a single amplicon of 335 bp as previously described, 
confirmed by sequencing TRPM31325 (A). Primers spanning exon 4 of the TRPM3 gene, 
designed to identify the TRPM3f variant, produced a single product band of 
approximately 250 bp (B), which sequencing revealed was due to the TRPM31325 
variant. Primers spanning exons 11-12 & 14-15 were predicted to give 4 products of 
similar sizes, relating to TRPM3b, TRPM3e, TRPM3d and all remaining variants. A 
single product of approximately 300 bp was visible on the gel (C). Although amplicons 
of such similar sizes are difficult to resolve by electrophoresis, sequencing revealed the 
single band was due to TRPM31325. Finally, primers spanning a 12 amino acid sequence 
that is only present in the TRPM3c variant gave a single product of -200 bp (D), which 
again was revealed as TRPM31325 by sequencing. It was not possible to design primers 
specific for variant TRPM3a as there were no variations unique to this splice variant to 
exploit. Low molecular weight bands designated by * are most likely a consequence of 
the extension of self-annealed primers, (primer dimers). 
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Previously, immunostaining with an anti-TRPM3 antibody detected TRPM3 protein in 
the intimal and medial layers of human saphenous vein (B. Kumar thesis, 2004). The 
presence of TRPM3 protein was further confirmed in this study with 
immunocytochemistry, using the E3-targeted antibody TM3E3. HSV SMC were fixed 
with 2% PFA and exposed to TM3E3 at a 1: 4000 dilution. TRPM3 protein was detected 
throughout cells (Figure 4.2). Preincubation of TM3E3 with its antigenic peptide 
(TM3E3 + pep) or omission of the primary antibody were used as negative controls, and 
showed no staining. 
In summary, RT-PCR amplification identified TRPM3 mRNA is present in HSV SMC, 
and TRPM31325 is the predominant splice variant. In addition, TRPM3 protein is present 
in this primary cell type. 
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Figure 4.1. TRPN13 expression in HSV SMC DNA gel stained with ethidium 
bromide. M depicts 100 by marker. PCR was performed using primers designed to 
amplify different splice variant cDNA from reverse transcribed HSV SMC mRNA. 
Non-reverse transcribed mRNA (-RT) was included as a control. A. Variant TRPM31325. 
B. Variants TRPM3f (B), TRPM3b. e, d (C) and TRPM3c (D). TRPM31325 was included 
as a positive control (A). Gel is representative of 4 separate experiments on cDNA 
samples from 4 different patients. 
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Figure 4.2. Immunofluorescence detection of TRPM3 Staining was performed on 
non-permeabilised HSV SMC fixed with 217 PFA using DAPI to label nuclei (left hand 
panel) and with TM3E3 antibody with FITC conjugated secondary antibody to label 
TRPM3 protein (right hand panel). For negative controls, TM3E3 was preadsorbed to 
its antigenic peptide (TM3E3 + pep) or primary antibody was omitted. Scale bars 
represent 20µm. 
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SPH increases intracellular Cat in HSV SMC 
Experiments using the ratiometric Ca2' dye Fura-2 and a FlexStation fluorimeter were 
performed to investigate Ca2+ entry in HSV SMC. Known modulators of TRPM3 were 
used to search for functional TRPM3, starting with D-erythro-sphingosine (SPH). 
SPH (20 µM) caused an increase in intracellular Ca2+ in HSV SMC within 1 min of 
application (Figure 4.3 A). Ethanol (the solvent for SPH) was kept constant at 0.1% in 
recording solutions throughout experiments and failed to elicit a significant Cal' signal 
in the absence of SPH. The mean data from 4 different patients show that after 2.5 min, 
the Ca2+ response to SPH was significantly larger than the ethanol control (Figure 4.3 
B). 
As demonstrated in the previous chapter, the FlexStation high-throughput system allows 
for fast and accurate determination of dose response data. Increasing concentrations of 
SPH were applied to HSV SMC within the same plate, allowing for direct comparison 
between wells. Dose response data taken 2.5 min after SPH addition were analysed 
using the Hill equation (Figure 4.3 Q. The value for half maximal activation, the EC50, 
was determined as 15.8 ±1.67 µM, with a Hill coefficient of 2.4 ± 0.38. Data points for 
the dose response curve were limited due to the poor solubility of SPH at concentrations 
higher than 50 µM, and as a result the dose response curve did not plateau. Therefore 
the EC50 given may be an under-estimate of the true value. 
The data show that the TRPM3 activator SPH causes Ca 2+ responses in HSV SMC, 
possibly as a result of TRPM3-activation. 
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Figure 43. D-erythro-sphingosine (SPH) evokes Ca2+ responses in HSV SMC Ca2+ 
signals were measured as the 340/380 ratio of emission in fura-2 loaded HSV SMC 
using a FlexStation fluorimeter. Ethanol (vehicle) was present throughout recordings. A. 
Representative mean data (±SEM) from 5 wells within a single plate. SPH (20 µM) 
application (arrow) causes an increase in Ca2+ in HSV SMC compared to vehicle 
control (open circles). B. Mean data (±SEM) showing significant increase in Ca2+ 2.5 
min after SPH application (SPH n/N=4/25, EtOH n/N=4/19). C. Mean dose response 
(±SEM) data taken 2.5 min after SPH application from 4 independent experiments, 
normalised to 20 µM response, and analysed using the Hill equation. 
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TRPM3 activators increase intracellular Cat, in HSV SMC 
Further Ca2+ measurements were made using additional TRPM3 modulators D-erythro- 
dihydro-sphingosine (DHS) and D-erythro-N, N-dimethyl-sphingosine (DMS). 
Sphingosine-1-phosphate is an important intracellular second messenger for several 
plasma membrane proteins, and a TRP channel activator (Xu et al., 2006b). DHS and 
DMS are both potent sphingosine kinase inhibitors. Therefore in addition to probing 
TRPM3 function, they also served to ensure the activation they caused was not a result 
of their metabolism to SIP by endogenous sphingosine kinase. Ethanol (vehicle) was 
kept constant at 0.1 % throughout experiments which were performed at RT. 
DHS (20 µM) caused a rapid and transient increase in intracellular Ca2+ in HSV SMC 
(Figure 4.4 A). In the absence of DHS, the vehicle control failed to elicit a significant 
increase in Ca2+. The mean data from 5 different patients shows that after 2.5 min DHS 
caused a Ca2+ response that was significantly larger than the vehicle control (Figure 4.4 
B). Dose response data for DHS activation, taken 2.5 min after DHS addition, were 
analysed using the Hill equation (Figure 4.4 Q. The value for half maximal activation, 
the EC50, was determined as 11.3 ± 0.52 µM, with a Hill coefficient of 4.3 ± 0.87. 
DMS (20 µM) also caused an initial transient increase in intracellular Cat+, but this was 
followed by a sustained increase in Ca2+ (Figure 4.5 A). The mean data from 5 different 
patients shows that after 2.5 min, the Ca2+ response to DMS was not significantly larger 
than the vehicle control, however at 4 min after application the response was significant 
(Figure 4.5 B). For this reason dose response data for DMS activation were analysed 
using points taken 4 min after DMS addition (Figure 4.5 Q. The value for half maximal 
activation, the EC50, was determined as 19.9 t 4.94 µM, with Hill coefficient of 1.9 t 
0.32. Again, the dose response curve did not saturate, giving an under-estimation of the 
true EC5o. 
In summary, the TRPM3 activators DHS and DMS cause Ca2+ responses in HSV SMC, 
further evidence that the TRPM3 protein is functionally expressed in this cell type. In 
addition, the data indicate that Ca2+ responses to SPH do not result from its conversion 
to SIP, as structurally related, sphingosine kinase inhibitors also activate the channel. 
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Figure 4.4. D-erythro-dihydro-sphingosine (DHS) evokes Ca 2+ responses in HSV 
SMC Ca2+ signals were measured as the 340/380 ratio of emission. Ethanol (vehicle) 
was present throughout recordings. A. Representative mean data (±SEM) from 5 wells 
within a single plate. DHS (20 µM) application (arrow) causes an increase in Ca 2+ in 
HSV SMC compared to vehicle control (open circles). B. Mean data (±SEM) showing 
significant increase in Ca2+ 2.5 min after DHS application (DHS n/N=4/14, EtOH 
n/N=4/17). C. Mean dose response data (±SEM) taken 2.5 min after DHS application 
from a single experiment, normalised to 20 µM response, and analysed using the Hill 
equation. 
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Figure 4.5. D-erythro-N, N-dimethyl sphingosine (DMS) evokes Ca 2+ responses in 
HSV SMC Ca2+ signals were measured as the 340/380 ratio of emission. Ethanol 
(vehicle) was present throughout recordings. A. Representative mean data (±SEM) from 
5 wells within a single plate. DMS (20 µM) application (arrow) causes an increase in 
Ca2+ in HSV SMC compared to vehicle control (open circles). B. Mean data (±SEM) 
showing Ca2+ responses 2.5 min or 4 min after DMS application (DMS n/N=5/15, EtOH 
n/N=5/18). C. Mean dose response data (±SEM) taken 4 min after DMS application 
from a single experiment, normalised to 20 µM response, and analysed using the Hill 
equation. 
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Characterisation of SPH-induced Ca2+ responses in HSV SMC 
Thapsigargin (Tg), an inhibitor of sarco(endo)plasmic reticulum Cat+-ATPase (SERCA) 
and recognised TRP channel inhibitors were used to further characterise the SPH- 
induced Ca2+ response in HSV SMC. Fura-2 loaded cells were preincubated for 30 min 
with inhibitors before high-throughput fluorimetry was performed. 
Tg (1 µM) partially inhibited the SPH-induced Ca2+ response, suggesting that Ca2+ or 
Ca2+ stores may be involved in TRPM3 activation in HSV SMC (Figure 4.6 A). The 
mean data indicate that 2.5 min after SPH application Tg blocked the SPH response by 
52.6%, and was slightly more effective at 4 min after application, giving a 58.5% block 
of the response (Figure 4.6 D). 
The non-specific TRP channel inhibitors gadolinium (Gd3+, 100 µM) initially inhibited 
the SPH response, although the eventual size of the response was increased (Figure 4.6 
B). The mean data show that at 2.5 min after application, Gd3+ blocked SPH-induced 
Ca2+ responses by an average 46.5%, however at 4 min after application the Ca2+ 
response was significantly potentiated (Figure 4.6 D). 
2-aminoethoxydiphenylborate (2-APB, 75 µM) was also able to inhibit Ca 2+ -responses 
evoked by SPH with varying success. In the example trace shown, 2-APB inhibition 
was very effective (Figure 4.6 Q. However, the mean data reveal that 2-APB blocked 
Ca2+ responses by an average 47.7% at 2.5 min after application, and was less effective 
at 4 min, producing a 25.1% block at this time point (Figure 4.6 D). 
In summary, the data provide evidence that the SPH-induced Cat+-responses in HSV 
SMC in response to application of SPH are in part due to Ca2+ influx across the plasma 
membrane, most likely through functional TRPM3 channels. 
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Figure 4.6. Characterisation of the SPH-induced Ca 2+ response Ca2+ signals were 
measured as the 340/380 ratio of emission. Traces are representative mean data (±SEM) 
from 6 wells within a single plate. Ethanol (vehicle), Gd3± and 2-APB were present for 
the duration of recordings, which were performed at RT. A. SPH (20 µM) application 
caused an increase in Ca2+ in HSV SMC that was inhibited by preincubation with Tg (1 
µM). B. SPH-induced Ca2+ responses were inhibited by Gd3+ (100 µM). C. 2-APB (75 
µM) also inhibited Ca2+ entry. D. Mean data (±SEM) showing significant effects on 
Ca2+ responses with all 3 compounds at both 2.5 and 4 min after SPH application 
(control n/N=3/18, Tg n/N=3/14, Gd3+ and 2-APB n/N=3/17). 
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Figure 4.6. Characterisation of the SPH-induced Ca 2+ response Ca'- signals were 
measured as the 340/380 ratio of emission. Traces are representative mean data (±SEM) 
from 6 wells within a single plate. Ethanol (vehicle), Gd`+ and 2-APB were present for 
the duration of recordings, which were performed at RT. A. SPH (20 uM) application 
caused an increase in Ca" in HSV SMC that was inhibited by preincubation with Tg (1 
uM). B. SPH-induced Ca" responses were inhibited by Gd3+ (100 uM). C. 2-APB (75 
ýtM) also inhibited Ca'* entry. D. Mean data (±SEM) showing significant effects on 
Ca responses with all 3 compounds at both 2.5 and 4 min after SPH application 
(control n/N=3/18, Tg n/N=3/14. Gd`+ and 2-APB n/N=3/17). 
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PregS increases intracellular Ca2+ in HSV SMC 
In addition to known modulators of TRPM3, the novel TRPM3 activator, pregnenolone 
sulphate (PregS), was examined as an activator of native TRPM3 in HSV SMC. The 
effects of PregS, aside from those on the CNS, are not well characterised, and it is not 
known whether PregS is a physiological activator of TRPM3. 
PregS (25 µM) caused a rapid, transient increase in intracellular Ca2+ in HSV SMC 
within 30 sec of application (Figure 4.7. A). DMSO (the solvent for PregS) was kept 
constant at 0.1% throughout experiments, which were performed at RT. The mean data 
from 3 different patients shows that after 30 seconds the Ca2+ response to PregS was 
significantly larger than the DMSO control (Figure 4.7. B). 
The data show PregS can evoke Ca2+ responses in HSV SMC. 
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Figure 4.7. Pregnenolone sulphate (PregS) evokes Ca 2+ responses in HSV SMC 
Ca2+ signals were measured as the 340/380 ratio of emission. DMSO (vehicle) was 
present throughout recordings. A. Representative mean data (±SEM) from 10 wells 
within a single plate. PregS (25 µM) application (arrow) causes an increase in Ca2+ in 
HSV SMC compared to vehicle control (open circles). B. Mean data (±SEM) showing 
significant increase in Ca2+ 1 min after PregS application (PregS n/N=3/31, DMSO 
n/N=3/27). 
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Characterisation of PregS-induced Ca 2+ responses 
As previously described for SPH-induced Ca2+ responses, the PregS response was 
further characterised using the SERCA-inhibitor Tg and known TRP channel 
modulators. 
Preincubation with Tg (1 µM) partially inhibited the PregS-induced Ca2+ response, 
indicating not all of the Ca2+ response was due to Ca2+ influx (Figure 4.8 A). At 1 min 
after PregS application, Tg blocked 71.9% of the PregS-induced Ca2+ response. 
However, at 2 min, this was significantly less at only 28.8%, indicating that Tg is a 
better inhibitor of the initial PregS response (Figure 4.8 D). This would suggest that 
perhaps the PregS response occurs in 2 phases, an early phase dependent on Ca2+ stores, 
followed by a later phase due to Ca2+ entry across the plasma membrane. 
Gd3+ (100 µM) almost completely inhibited the PregS-induced Cat+-response, and also 
reduced the starting baseline compared to control cells, suggesting inhibition of 
constitutive channel activity (Figure 4.8 B). The mean data show that this inhibition was 
consistent, with Gd3+ causing an 83.6% PregS-induced Ca2+ responses after 1 min, and a 
57.3% inhibition after 2 min. 
2-APB (75 µM) was also an effective inhibitor of PregS-induced Cat+-responses and 
reduced constitutive channel activity (Figure 4.8 Q. The mean data reveal that 2-APB 
blocked Ca2+ responses by an average 57.1% 1 min after PregS application, and 
inhibition was reduced to 36.2% at 2 min. (Figure 4.8 D). 2-APB is recognized as a 
blocker of store-operated Ca2+ entry, which is reported to involve TRP channels, by 
blocking IP3-receptors (Bootman et al., 2002). If Ca2+ stores are involved with the 
PregS-response, this may explain why 2-APB appears to have had a stronger inhibitory 
effect at the earlier time point. 
In summary, the data provide further evidence for the functional expression of TRPM3 
in HSV SMC, and demonstrate that Ca2+ responses to PregS are in part due to Ca2+ 
influx, although the involvement of store operated Ca2+ release can not be ruled out and 
requires further investigation. 
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Figure 4.8. Characterisation of PregS-induced Ca 2+ response Ca 2+ signals were 
measured as the 340/380 ratio of emission. Traces are representative mean data (±SEM) 
from 6 wells within a single plate. DMSO (vehicle), Gd`+ and 2-APB were present for 
the duration of recordings, which were performed at RT. A. PregS (25 ttM) application 
caused an increase in Ca 2+ in HSV SMC that was inhibited by preincuhation with Tg (1 
uM). B. PregS-induced Ca'+ responses were inhibited by Gd3+ (100 LtM) C. 2-APB (75 
LiM) also inhibited Ca'` entry. D. Mean data (±SEM) showing significant inhibition of 
Ca'' with all 3 compounds, both I and 2 min after PregS application (control n/N=4/15, 
Tg n/N=4/18. Gd n/N= 3/11 and 2-APB n/N=3/16). 
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TM3E3 inhibits TRPM3 in HSV SMC 
Although compounds known to inhibit TRPM3 were effective at blocking SPH and 
PregS responses in HSV SMC, they are non-specific, and therefore do not prove the 
involvement of TRPM3. The effect of TRPM3 activators on other proteins in native 
systems is not fully understood and it is difficult to prove that a particular channel is 
involved. However, the highly-specific channel blocking antibody TM3E3 is ideal for 
this purpose. 
HSV SMC were preincubated with dialysed TM3E3 at 1: 500 dilution before 
experiments were performed at RT. SPH-induced Ca2+-entry in cells preincubated with 
TM3E3 was much reduced when compared to the preimmune control (Figure 4.9 A). 
Dialysed TM3E3 only produces significant inhibition at 1: 500 dilution, which is 
completely reversed by preadsorption of the antibody to its immunogenic peptide. 
(Figure 4.9 B), confirming it is a useful control. For 7 different patients, TM3E3 (1: 500) 
produced significant block in all but two (Figure 4.9 Q. The combined mean data show 
that TM3E3 gave significant 40% inhibition of the SPH response (Figure 4.9 D). The 
TRPC1-specific antibody T1E3 did not affect the SPH response, evidence for the 
selectivity of E3-targetted antibodies and suggesting TRPC 1 is not involved in the SPH 
response. 
TM3E3 also inhibited PregS-induced Ca2+-entry in HSV SMC compared to the 
preimmune control (Figure 4.10 A). For 6 different patients, TM3E3 produced 
significant block of the PregS-induced Ca2+ response in all but one (Figure 4.10 B). The 
mean data shows TM3E3 gave an average 45% inhibition (Figure 4.10 D). Interestingly 
the TRPC1-specific antibody T1E3 potentiates activation by PregS (Figure 4.10 C& 
D). This mechanism remains to be investigated. However as the SPH response was 
unaffected by TIE3, this would suggest TIE3 does not influence the PregS-response as 
a result of an effect on the TRPM3 channel. 
The data suggest that TRPM3 is present and functional in HSV SMC, and its activation 
by SPH and PregS can be specifically and significantly inhibited by TM3E3. 
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Figure 4.9. T`13E3 inhibits SPH-induced Ca 2+ response in HST' SMC Ca 2+ signals 
were measured as the 340/380 ratio of emission. Ethanol (vehicle) was present 
throughout recordings, which were performed at RT. A. Representative mean data 
(±SEM) from 9 wells within a single plate. SPH (20 uM) application caused an increase 
in Ca in HSV SMC that was inhibited by preincubation with dialysed TM3E3 
antiserum (closed circles) compared to preimmune serum (open circles). B. Antisera 
dilution data from 4 independent experiments for preimmune (black Kars), TM3E3 
(grey bars) and TM3E3 preadsorbed to antigenic peptide (dark grey bars). C. 
Normalised Ca response for 7 independent experiments with preimmune (black bars) 
or TM3E3 (grey bars) at 1: 500 dilution. D. Mean data (±SEM) showing significant 
inhibition of Ca response by TM3E3, but not TI E3,2.5 min after SPH application 
(TM3E3 n/N=7/76, Ti E3 n/N=6/47). 
148 
A PregS 
1.8 
0 M 1.6 
Ö 
1.4 
C 
1.8 
0 
Co 1.6 
Ö 
ä 1.4 
Time (min) 
PregS 
ýýýýT1E3 
TM3E3 
3456 12 
Time (min) 
B 
aý ý 1.2ý 
0.9 
'o 0.6 
0.3 
z 0.0 
D 
m = 1.2 
0 CL ý 0.8 
-o 
ý 0.4 
E 
ý ý Z 0.01 
n* 
I 
*** 
23 -« 
Patient Number 
* 
a,, ý 
Tý 
F. 1 
Figure 4.10. TMI3E3 inhibits PregS-induced Cat' response in HSV SMC Ca 2+ 
signals were measured as the 340/380 ratio of emission. DMSO (vehicle) was present 
throughout recordings, which were performed at RT. A. Representative mean data 
(±SEM) from 12 wells within a single plate. PregS (25 uM) application caused an 
increase in Cat` in HSV SMC that was inhibited by preincubation with dialysed TM3E3 
antiserum (closed circles) compared to preimmune serum (open circles). B. Normalised 
Ca" response for 6 different patients with preimmune (black bar) or TM3E3 (grey bar) 
at 1: 500 dilution. C. Representative mean data (±SEM) from 12 wells within a single 
plate shows that TIES (1: 500 dilution) preincuhation potentiates the PregS response 
(closed circles) compared to preimmune serum control (open circles). D. Mean data 
(±SEM) showing significant inhibition of Cal+ response by TM3E3, and potentiation by 
TI E3. I min after Pre, -, 
S application (TM3E3 n/N=6/44, TI E3 n/N=6/46). 
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TM3E3 is effective at physiological temperatures 
If an antibody was to be used as a therapeutic tool, it is important that it functions at 
physiological temperature. Previously in this chapter, although preincubation with 
antisera and fura-2 loading of cells was performed at 37°C, experimental recordings 
were made at RT. A low dilution of antibody would also be important in physiological 
studies to minimise non-specific effects. As the dialysed antibody was only effective at 
a 1: 500 dilution, non-dialysed antibody was used. 
In longer recordings performed for up to 25 minutes, the SPH response at 37°C was 
biphasic, with an initial transient increase in Ca2+ followed by a sustained increase that 
developed over 15 min (Figure 4.11 A). 
2-APB (75 µM) was still an effective inhibitor of the SPH-induced Ca2' response at 
physiological temperature (Figure 4.11 B). Inhibition of the both phases of the response 
was significant, with an 86.0% block observed at 1 min after SPH application, and a 
73.6% block at 10 min (Figure 4.11 D). 
Gd3+ (100 µM) also effectively inhibited the initial transient Ca2+ response, however 
was unable to block the sustained phase (Figure 4.11 Q. The mean data show a 
significant 73.5% inhibition of the SPH-response at 1 min after application, while at 10 
min the average block was 20.4%, and not significant (Figure 4.11 D). 
Preincubation with non-dialysed antibody at 1: 4000 dilution inhibited the SPH response 
(Figure 4.12 A). The mean data from 9 different patients shows TM3E3 gives a 
significant block of both phases, 20.7% after 1 min after SPH application and a slightly 
stronger block of 29.9% after 10 min (Figure 4.12 B). 
In summary, non-specific TRP channel blockers and TM3E3 can significantly inhibit 
TRPM3 under physiological conditions. 
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Figure 4.11. Inhibition of the SPH-induced Ca 2+ response at physiological 
temperature Ca'. signals were measured as the 340/380 ratio of emission. Traces are 
representative mean data (±SEM) from 6 wells within a single plate. Ethanol (vehicle) 
was present throughout recordings, which were performed at 37°C. A. SPH (20 UM) 
application (arrow) caused a hiphasic Ca+ response in HSV SMC compared to EtOH 
control. B. The SPH response was inhibited by preincubation with 2-APB (75 1. tM, 
closed circles) compared to vehicle control (open circles). C. The SPH response was 
also inhibited by preincubation with Gd3+ (100 µM, closed circles). D. Mean data 
(±SEM) showing significant inhibition of both phases of the Ca'+ response at I and 10 
min after SPH application. Data are normalised to control response in absence of 
inhibitor (2-APB n/N=4/25, Gd3+ n/N=3/14). 
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Figure 4.12. T\13F3 inhibits SPH-induced Ca 2+ response at physiological 
temperature Cap , ignal, were measured as the 340/380 ratio of emission. EtOH 
(vehicle) was present throughout recordings, which were performed at 37°C. A. 
Representative mean data (±SEM) from 6 wells within a single plate. The SPH response 
was inhibited by preincubation with dialysed TM3E3 antiserum (open circles) 
compared to preimmune serum (closed circles). B. Mean data (±SEM) normalised to 
preimmune control showing significant inhibition of both phases of the Cal' response 
by TM3E3 at I or 10 min after SPH application (pre n/N=9/45, TM3E3 n/N=9/46). 
152 
Specificity of TM3E3 
Sphingosine-1-phosphate (SIP) activates TRPC5 in HSV SMC and regulates cell 
motility, effects that can be inhibited by the anti-TRPC5 antibody T5E3 (Xu et al., 
2006b). To demonstrate the specificity of E3-targeted antibodies, the effect of TM3E3 
on the SIP response in HSV SMC was examined. 
In this study, SIP (10 µM) caused Ca2+ response in HSV SMC compared to the MeOH 
(vehicle) control (Figure 4.13 A). At 30 seconds after application the response to SIP 
was significantly larger than the MeOH control (Figure 4.13 B). Preincubation with 
dialysed TM3E3 at 1: 500 dilution had no effect on this response (Figures 4.13 C& D). 
In addition, TM3E3 does not block the endogenous ATP response in HSV SMC 
(Figures 4.13 E& F). 
The data demonstrate TM3E3 specifically inhibits TRPM3 in HSV SMC. 
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Figure 4.13. T\13E3 does not inhibit SIP- or ATP-induced Ca'' responses 
Recordings were performed at RT. Traces are representative mean data (±SEM) from 4- 
6 wells within a single plate. A. SIP (10 uM) application 
(arrow) causes an increase in 
Cat' in HSV SMC compared to methanol (MeOH) control. B. Mean data (±SEM) 
showing significant Ca increase 30 sec after SIP application (S 1P n/N=5/21, MeOH 
n/N=5/ 18). C. The SIP response was not inhibited by preincubation with dialysed 
TM3E3 antiserum. D. Mean data (±SEM) normalised to preimmune control show no 
inhibition of the Ca" response by TM3E3 30 sec after SIP application (n/N=2/9 for 
each). E. ATP (100 «M) caused Ca'* responses that were not inhibited by preincubation 
with dialysed TM3E3 antiserum. F. Mean data (±SEM) normalised to preimmune 
control show no inhibition of the Ca" response by TM3E3,30 sec after ATP application 
(n/N=1 /6 for each). 
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siRNA knockdown of TRPM3 expression 
Small interfering RNA (siRNA) consist of short, double stranded RNA molecules that 
act as mediators of the messenger RNA degradation pathway (Elbashir et al., 2001). 
Transfecting siRNAs into mammalian cells disrupts the RNA interference pathway to 
prevent expression of a given gene in order to study gene function. Depending on the 
turnover rate of the protein, gene knockdown can be transient, thus experiments must be 
performed within 48 hours of siRNA transfection. In order to further confirm TRPM3 is 
present and functional in HSV SMC, and that it is responsible for Ca2+ entry in response 
to known TRPM3 modulators, siRNA knockdown was performed on HSV SMC. These 
cells were then assayed using Ca2+ fluorimetry and the Ca2' indicator dye Fura-2. 
TRPM3 expression following siRNA transfection was examined by 
immunocytochemistry. The nuclear staining agent DAPI was used to locate cells and 
TM3E3 staining was indicated by the secondary FITC conjugated antibody. Dialysed 
TM3E3 at a dilution of 1: 4000 was able to detect TRPM3 in both mock-transfected and 
TRPM3 siRNA-transfected HSV SMC, however TRPM3 siRNA transfected cells 
showed reduced TRPM3 protein expression (Figure 4.14 A). Average data comparing 
the percentage of FITC stained cells revealed a significant 38.2% decrease in staining 
for siRNA transfected cells (Figure 4.14 B). 
HSV SMC transfected with TRPM3 siRNA showed reduced Ca2+ influx in response to 
SPH application (Figure 4.15 A). The mean data show that siRNA knockdown 
produced a 67.9% inhibition of the SPH response (Figure 4.15 B). TRPM3 siRNA also 
inhibited PregS-stimulation (Figure 4.15 C), producing an average 21.1% inhibition of 
the Ca2+-response (Figure 4.15 D). 
In summary, HSV SMC cells transfected with TRPM3 siRNA show a reduction in 
TM3E3 staining, indicating a reduction in TRPM3 protein expression as a result of 
successful knockdown of the TRPM3 gene in these cells. Furthermore siRNA 
knockdown strengthens the idea that TRPM3 is responsible for Cat -entry in vascular 
smooth muscle. 
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Figure 4.14. siRNA knockdown of TRPM3 A. Immunocytology performed on non- 
permeabilised HSV SMC fixed with 2% PFA. Cells were co-stained with DAPI and 
TM3E3 antibody plus a FITC conjugated secondary antibody. For negative controls, 
TM3E3 was preadsorbed to its antigenic peptide (TM3E3 + pep) or primary antibody 
was omitted. Images are representative of cells from 3 different patients. Scale bars 
represent 20µm. B. Mean data (±SEM) showing significant reduction in the number of 
TM3E3 stained cells for siRNA transfected cells (-siRNA n/N=4/81, +siRNA 
n/N=4/ 100). TRPM3. siRNA trans f eetions perforrnecl by Dr. J. Li. 
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Figure 4.15. TRPM3 siRNA inhibits TRPM3-like Ca'+ responses Ca'_ signals were 
measured as the 340/380 ratio of emission. Traces are mean data (±SEM) representative 
of 6 wells within a single plate. Ethanol or DMSO (vehicle) were present throughout 
recordings, which were performed at RT. A. SPH (20 uM) application caused an 
increase in Ca in HSV SMC that was reduced in cells transfected with siRNA (open 
circles) compared to mock transfected control (closed circles). B. Normalised mean 
SPH data (±SEM) for cells transfected with control (black bar) or TRPM3 siRNA (grey 
har). n/N=3/18 for each. C. PregS (25 uM) application caused an increase in Ca 2+ in 
HSV SMC that was reduced in cells transfected with siRNA (open circles) compared to 
mock transfected control (closed circles). D. Normalised mean PregS data (±SEM) for 
cells transfected with control (black bar) or TRPM3 siRNA (grey bar). n/N=3/18 for 
each.. Exec rintents pert urnºec! by Dr. J. Li. 
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Function of TRPM3 
The data presented in this chapter suggest that TRPM3 forms functional channels in 
vascular smooth muscle. However, the purpose of such a channel is unknown. An early 
stage in neointimal formation following bypass surgery is the proliferation and 
migration of smooth muscle cells (SMC). This is dependent on the degradation of the 
basement membrane by the gelatinases, or matrix metalloproteinases (MMP) -9 and -2, 
which are secreted by SMC themselves. Specifically, production of MMP-9 occurs 
during neointima formation (Porter et al., 1998), and the inhibition of MMP-9 causes a 
reduction in neointima formation in cultured human saphenous vein segments (Porter et 
al., 2002). As other TRP channels are known to be involved in neointimal formation 
(Kumar et al., 2006), a role for TRPM3 in MMP secretion was thus examined. 
Gelatin zymography allows for the detection of MMP-2 and MMP-9 in cell media to 
give an indication of the levels secreted by SMC. The proteins are resolved by SDS- 
PAGE electrophoresis, and then incubated to allow digestion of a gelatin infused SDS- 
PAGE gel. Conditioned medium from HT-1080 (HT) cells is used as a control to 
identify MMP-9 and MMP-2 bands. 
MMP-2 secretion from HSV SMC is constitutive, whereas MMP-9 secretion can be 
induced by the phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA, lOOnM) 
(Turner et al., 2005). In this study, zymography analysis confirmed TPA treatment 
significantly increased MMP-9 secretion after a 48 hour period (Figure 4.16 A&B). As 
the secretion of MMP-2 was much greater than that of MMP-9, the MMP2 band 
saturated. For this reason, MMP-2 could not quantified by densitometry. 
The effect of TRPM3 modulators on TPA-induced MMP-9 secretion was subsequently 
examined. SPH appeared to slightly reduce MMP-9 secretion compared to the vehicle 
control, but this was not significant, and inclusion of TM3E3 also had no effect (Figure 
4.16 Q. However, PregS treatment caused a significant reduction in MMP-9 secretion, 
while inclusion of TM3E3 had no significant effect, suggesting a reversal of the PregS 
effect (Figure 4.16 D). 
In summary, the TRPM3 activator PregS causes a reduction in TPA-induced MMP-9 
secretion by HSV SMC, an effect that does not occur in the presence of TM3E3. 
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Figure 4.16. TPA increases MMP-9 secretion, which is inhibited by PregS 
Densitometric values for bands of lysis at 92 kDa (MMP-9) were determined using 
Image J software. Mean data (±SEM) are from 3 different patients, normalised to 
control (without TPA treatment) or vehicle response. A. Representative gelatin 
zymogram of HSV SMC culture medium. Bands of lysis were apparent at 92 kDa 
(MMP-9), 72 kDa (pro-MMP-2) and 66 kDa (MMP-2). Conditioned medium from HT- 
1080 cells was included as a positive control. B. Mean data (±SEM) show TPA causes a 
significant increase in MMP-9 secretion. C. Mean data (±SEM) shoe SPH alone and in 
the presence of TM3E3 (SPH+AB) has no significant effect on MMP-9 secretion. D. 
Mean data (±SEM) show PregS alone causes a significant reduction in MMP-9 
secretion, which does not occur in the presence of TM3E3 (PregS+AB). 
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IL-6 and MMP-9 ELISA 
The zymography analysis of MMP-9 secretion was confirmed using ELISA, a sensitive 
and accurate method for the detection and quantification of proteins present in cell 
culture media. 
ELISA analysis performed to detect MMP-9 in the culture media shows a significant 
increase in secretion by TPA-treated cells (Figure 4.17 A). MMP-9 secretion was very 
variable between different patients, therefore for the mean data, values were normalised 
for each patient to the vehicle control response. The normalised mean data for SPH 
treated cells shows a significant 21.5% reduction in MMP-secretion, with no significant 
effect in the presence of TM3E3, and a further significant reduction in cells exposed to 
TM3E3 preadsorbed to its antigenic peptide (Figure 4.17 B). This suggests TM3E3 can 
reverse the inhibition observed with SPH, which is prevented when the antibody cannot 
bind the TRPM3 channel. 
ELISA analysis also confirmed the zymography result for PregS inhibition of MMP-9 
secretion by SMC (Figure 4.17 Q. PregS treatment caused a significant 25.9% 
inhibition of TPA-induced MMP-9 secretion. However, in the presence of TM3E3 there 
was a significant increase in secretion that was not completely reversed by peptide- 
preadsorption. This suggests that TM3E3 may have a non-specific effect to cause 
secretion independently of PregS effect. 
In addition to MMP-9, IL-6 is also an important regulatory factor secreted by VSMC. 
SMC secrete IL-6 in response to biomechanical stress, a mechanism that may contribute 
to the onset of atherosclerosis (Zampetaki et al., 2005). For this reason, the effect of 
TRPM3 modulators on IL-6 secretion was also examined by ELISA. ELISA analysis 
shows a significant increase in IL-6 secretion by TPA-treated cells (Figure 4.18 A). The 
mean data for SPH treated cells shows no significant effect on IL-6 secretion with 
TM3E3 or peptide-bound antibody treatment (Figure 4.18 B). For PregS treatment, the 
ELISA indicated a 52.9% reduction in secretion, however there was no significant effect 
on secretion when TM3E3 was present, suggesting the antibody had prevented the 
PregS inhibitory effect (Figure 4.18 C). As for MMP-9, this data indicates TM3E3 can 
reverse the effect of PregS, although for IL-6 secretion the peptide bound-antibody 
control was not able to significantly reverse the antibody effect. 
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As the antibody appeared to have an effect of its own on IL-6 secretion, this was 
examined in the absence of a TRPM3 stimulus. The DMSO vehicle control was 
however still present throughout these experiments. TM3E3 caused a significant 
increase in IL-6 secretion, while when preadsorbed to its antigenic peptide had no 
significant effect. (Figure 4.18 D). 
In summary, the data suggest that PregS and to some extent SPH have an effect on 
TPA-induced MMP-9 and IL-6 secretion in HSV SMC. The role of TRPM3 cannot be 
exclusively proved as the antibody also has an effect on secretion, potentially 
representing inhibition of constitutive TRPM3 activity, although non-specific effects 
can't be ruled out at this stage. 
161 
A 
u. v yr 
cý 0.4 
.., ý 
CL 0.2- 
0.0. 
C0 ýA 
ýý'iºo 9 
f 
B 
ö 1.51 
;.. 
At 
W1 
L J^ý 
1n '1 N I. V 
V 
d 
ý 0.5 
E 
0 Z O. 0 
* 
sss ý"c ýoy . oyx "o, ý, x ý9 9ý o 
C 
c 2.5 
I= 
* 
* 
2.0ý 
ýý 
1.5 
.! 2 
1.0 
E 0.5 
0 
z 0.0 
Figure 4.17. ELISA analysis of MMP-9 secretion Conditioned media were collected 
and MMP-9 concentration determined by ELISA. Mean data (±SEM) are from 6 
different patients, normalised to vehicle response. A. TPA induces secretion of MMP-9. 
B. SPH causes a significant reduction in MMP-9 secretion, which does not occur in the 
presence of TM3E3 (AB). C. PregS alone causes a significant reduction in MMP-9 
secretion, however in the presence of TM3E3 (AB) or peptide-bound TM3E3 
(AB+pep), secretion is significantly increased. 
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Figure 4.18. ELISA analysis of IL-6 secretion Conditioned media were collected and 
IL-6 concentration determined by ELISA. Mean data (±SEM) are from 6 different 
patients. A. TPA induces secretion of IL-6. B. SPH has no significant effect on IL-6 
secretion. C. PregS causes a significant reduction in IL-6 secretion, which does not 
occur in the presence of TM3E3 (AB). D. TM3E3 affects IL-6 secretion independently 
of TRPM3-activation. 
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Discussion 
The data presented in this chapter demonstrate that TM3E3 is valuable for the 
characterisation of expression and function of native TRPM3, and importantly that 
TRPM3 is a novel calcium channel of vascular smooth muscle. 
TRPM3 activation in HSVSMC 
The mechanism of TRPM3 activation in HSV SMC is not yet understood. Gd3+ and 2- 
APB both caused significant inhibition of SPH- and PregS-activation of TRPM3, 
suggesting that Cat+-responses in HSV SMC were at least partly due to influx through 
cation channels (Figures 4.6 & 4.8). TM3E3 inhibition suggests this cation channel is 
TRPM3 (Figures 4.9 & 4.10). However, the inhibition of TRPM3 responses by Tg- 
induced store depletion suggests that not all of the SPH- or PregS-induced Ca2+ 
response is due to influx across membrane, and there may be some contribution of store 
depletion to the activation of TRPM3. This could be investigated further by performing 
experiments in the absence of extracellular Ca2+. Alternatively, Tg, 2-APB and Gd3+ 
may alter local Ca2+ concentrations within the cell, a mechanism which can modulate 
several Ca2+ sensitive TRP channels. 
Interestingly, following pre-treatment with Tg the starting baseline in HSV SMC was 
not altered, unlike the baseline in the stable TRPM3 cell line which was significantly 
increased (Figure 3.16). Although the evidence appears to suggest there are no 
endogenous SOC in HSV SMC, this is not the case, as previous reports have confirmed 
the presence of SOC in VSM (Xu et al., 2001). A more plausible explanation is that 
there are SOC present, but they have had time to desensitise, or that they are Cat+- 
inactivated channels, thus the baseline Ca2+ levels have returned to resting levels before 
recording. A further discrepancy between the native and over-expressed systems is that 
stores did not contribute to the PregS repsonse in the stable cell line, whereas there is 
clear inhibition of the PregS response in HSV SMC (Figure 4.8 Q. Although further 
experiments in the absence of extracellular Ca2+ are needed to explore this effect, a 
possible explanation is that in native cells, PregS can activate a channel other than 
TRPM3, in particular one that is sensitive to Tg. This would also explain why TM3E3 
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and siRNA inhibit the PregS response to a lesser extent than they do the SPH response 
(Figure 4.16), suggesting another channel contributes to the response. 
Established as an endogenous inhibitor of PKC (Hakomori et al., 1998), SPH is also 
reported to be an endogenous vasoactive agent, having a vasoconstrictive role in the 
vasculature. Micromolar concentrations cause concentration dependent contraction of 
rat mesenteric vessels (Bischoff et al., 2000), and cause contraction of porcine coronary 
arteries (Murohara et al., 1996). Upregulation of lipids in disease states is common, and 
in particular the phosphorylated metabolite of SPH, SIP, is known to play a role in the 
inflammatory response to vascular injury (Siess, 2002). As sphingolipid metabolism is 
closely regulated, a role for SPH in vascular disease either directly, or related to SIP, 
cannot be ruled out. 
The role of a neurosteroid such as PregS in the vasculature is not well understood, and 
the case may be that PregS is not a physiologically relevant activator for TRPM3 in 
HSV SMC, and instead may be relevant in other cell types and tissue that express 
TRPM3. However, steroids are known to affect vasoconstriction, thus the hormonal 
regulation of blood pressure by PregS can not be excluded, and further experiments 
such as contraction studies are required. 
Antibodies as tools to determine native ion channel function 
E3-targeted antibodies are useful for studies involving live cells as they target an 
extracellular epitope. Therefore, permeabilisation of cells or a complex intracellular 
delivery method is not required for inhibitory activity. This proved useful for Ca2+ 
imaging and especially for secretion assays, where native activity of TRPM3 could be 
examined over a period of several days with no apparent adverse affect on the cells 
involved. 
Members of the TRP family are believed to exist as tetramers. TRPM6 and TRPM7 are 
known to form heteromers (Chubanov et al., 2004), and the coiled coil domain of 
TRPM2 is required for the assembly of functional channels, suggesting a common 
structural motif for TRPM channel assembly (Mei et al., 2006). The sequence similarity 
with other TRPM family members and the conserved C-terminal coiled coil domain 
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suggests that TRPM3 could form multiple different channels with different 
combinations of splice variants or other TRPs, creating more than one type of functional 
channel. Although the heteromeric structure of TRPM3 may affect its native 
pharmacology, this chapter demonstrates that TM3E3 can block native TRPM3 
channels, regardless of how it exists in native tissues. The same is also true for the E3- 
targeted anti-TRPC5 antibody, which can inhibit TRPC1-TRPC5 heteromers (Xu et al., 
2006b). 
Function of TRPM3 
Neointimal hyperplasia is initiated in blood vessels as a result of tissue damage caused 
during bypass grafting, and is dependent on SMC proliferation and migration (Angelini 
et al., 1989). The movement of SMC is dependent on degradation of basement 
membranes by matrix metalloproteinase MMP-9 and MMP-2, which are secreted by the 
SMC themselves in response to vascular damage. The MMP-9 knockout mouse shows 
decreased SMC migration to the intima, suggesting MMP-9 is necessary for formation 
of neointima (Cho et al., 2002), and MMP-9 activity is increased during neointima 
formation in cultured HSV (Porter et al., 1998). Recently statins have been suggested to 
delay the progression of vein graft failure by decreasing MMP-9 mRNA levels, thus 
inhibiting MMP-9 secretion (Turner et al., 2005). My own study has suggested a 
possible role for TRPM3 in MMP-9 secretion, demonstrating that channel activation 
can reduce MMP-9 secretion (Figures 4.16 & 4.17). 
TRPM3 also appears to play a role in IL-6 secretion (Figures 4.19). IL-6 is a 
proinflammatory cytokine implicated in the development of vascular diseases and 
present in the arterial atherosclerotic wall (Rus et al., 1996). IL-6 is also upregulated in 
the neointima following vascular injury (Takaoka et al., 2006). Atherosclerosis is 
chronic inflammatory process, known to be mediated by the production of inflammatory 
cytokines such as IL-6, and parallels can be drawn between the SMC pathogenesis of 
neointimal hyperplasia, suggesting that an agent that delays graft failure may also help 
in the treatment of atherosclerosis. Neointimal hyperplasia results from both 
proliferation and migration of the smooth muscle cells, and if TRPM3 regulation of 
SMC secretion could be directly linked to both of these processes, therapeutic 
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treatments could be developed. TM3E3 appears to increase secretion independently of 
TRPM3 activation, perhaps as a result of inhibiting constitutive TRPM3 activity. 
However, TM3E3 does not increase IL-6 secretion in the presence of SPH (Figure 
4.17). This would suggest SPH has a dual effect on TRPM3-regulated secretion. SPH 
can activate TRPM3 and therefore decrease IL-6 secretion, however it can also prevent 
the effect of TM3E3, suggesting that a longer exposure to SPH downregulates 
constitutively active channels. Alternatively, the antibody may have a non-specific 
effect on secretion. Perhaps the antiserum or the TM3E3 antibody itself can increase IL- 
6 secretion independently of the TRPM3 channel. 
Summary 
E3-targeted antibodies will prove useful for further characterisation of endogenous 
TRPM3 in other cell types and tissues. For the time being, TM3E3 has successfully 
shown that TRPM3 is a functional Ca2+ channel of vascular smooth muscle with a role 
in regulating secretion. The exact mechanism by which TRPM3 regulates MMP-9 and 
IL-6 remains to be seen, and may be a result of TRPM3 modulation of signalling 
pathways by changes in intracellular Cat+. While the stimulatory effect TM3E3 has on 
secretion rules out the antibody itself as a therapeutic tool for the treatment of vascular 
damage, the antibody will serve as a useful tool for further study. Understanding 
mechanisms of SMC proliferation and migration will enable a therapeutic approach to 
prevent HSV graft stenosis and perhaps even the development of atherosclerosis. 
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Chapter 5 
Pharmacology of TRPM3 
To further realize the importance of the TRPM3 channel and its physiological function, 
it is necessary to understand fully its pharmacology. As discussed throughout this thesis, 
existing TRP channel modulators are non-specific and, although they have been used to 
investigate TRP-mediated function, rarely selective. 
The application of high-throughput screening (HTS) has been used by the 
pharmaceutical industry for drug discovery for 20 years (Pereira et al., 2007). HTS 
allows for the in vitro investigation of large numbers of compounds to identify novel 
modulators of a biological target or pathway. This may involve screening chemical 
libraries for activators or inhibitors of a particular receptor or ion channel. Usually fully 
automated, HTS can generate a large amount of experimental data very quickly. A HTS 
assay should be considered as a screen of potentially active compounds, and it is vital 
any positive compounds are followed up with further experimentation and appropriate 
controls. This will usually involve generation of concentration response data to 
determine EC50 or IC50 values, testing compounds under physiological conditions, and 
demonstrating selectivity for a particular target by cross-testing `hits' against related 
targets. 
In drug discovery, active compounds identified by a HTS that share structural or 
chemical features can be studied by chemists and used to generate drugs with increased 
activity at the designated target, and to enhance the pharmacological activity of said 
compound as a drug. At this stage pharmokinetics are important, and the adsorption, 
distribution, metabolism and excretion (ADME) of the drug must be considered. 
For the purpose of the study of TRPM3 function, the identification of a complete set of 
pharmacological tools such as agonists, allosteric modulators, inhibitors and so on 
would be useful for the further characterisation of the channel. The aim of this chapter 
was to perform HTS for the TRPM3 ion channel to identify interesting targets for 
further study. Due to the expression of TRPM3 in HSV SMC, we were particularly 
interested to find TRPM3 modulators with potential vascular relevance. 
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Known TRP channel modulators as regulators of TRPM3 
Mechanisms of TRP channel activation are diverse. Often, structurally related 
compounds will have similar effects on a particular ion channel, and may even also 
modulate related channels. For this reason, known TRP modulators were examined for 
an effect on TRPM3. 
Sphingosine (SPH) is known to activate TRPM3 (Grimm et al., 2005). SPH-related 
compounds including ceramide, glucosylsphingosine (psychosine), sphingosine-l- 
phosphate (SIP) and the upstream metabolite palmitoyl Coenzyme A, plus a naturally 
occurring mixture of varying chain length SPH (bovine SPH), were screened for 
TRPM3 modulation using FlexStation fluorimetry. In addition, the known TRP 
modulators 4aPDD, L-a-lysophosphatidylcholine (LPC), L-a-lysophosphatidylinositol 
(LPI), gadolinium (Gd3+), carbachol (CCh) and hydrogen peroxide (H2O2) were also 
tested. A2 addition protocol was adopted, which comprised a ls` addition of the test 
compound, followed by a 2nd addition of PregS (10 µM) as a positive control and to 
search for channel inhibitors. 
There was no significant difference between Ca2+ responses in tet- and tet+ TRPM3 
cells, suggesting none of the compounds can activate TRPM3 (Figure 5.1 A). However, 
several of the compounds inhibited or potentiated the Ca2+ response to PregS (Figure 5.1 
B). 
In summary, TRPM3 is not activated by SPH-related compounds, despite structural 
similarities, although SIP can inhibit the PregS-response. In addition, TRPM3 is 
inhibited by 4aPDD and H202, compounds which are known to activate TRP family 
members TRPV4 and TRPM2 respectively (Hara et al., 2002; Watanabe et al., 2002). 
PregS responses were potentiated by the known TRPC5 activators LPC and LPI 
(Flemming et al., 2006). TRPM3 was also inhibited by the recognised TRP blocker 
Gd3+, consistent with previous reports (Grimm et al., 2003; Lee et al., 2003a). The data 
demonstrate that TRPM3 can be affected by existing physiological TRP modulators. 
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Figure 5.1. Effect of TRP channel modulators on TRPM3 FlexStation screen 
performed at RT. Cells were induced by incubation with tetracycline (tet+), non- 
induced cells (tet-) were included as a control. A. Mean data (±SEM) from 3 
independent experiments shows activation in tet+ (black) compared to tet- (grey) cells 
(n/N=3/9). B. Inhibition of PregS response l min after PregS application (n/N=3/9). 
Control refers to l" application of vehicle (DMSO), followed by PregS addition. Data 
are normalised to control PregS response. Significance from control determined using 
Student's t test, *p<0.05. 
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PregS analogues inhibit TRPM3 
In addition to pregnenolone and its sulphate, there are a variety of related neurosteroids 
formed from cholesterol that are very similar in structure. Following the production of 
pregnenolone from cholesterol, catalysed by cytochrome P450 side-chain cleavage (scc) 
enzyme, progesterone is formed by 30-hydroxysteroid dehydrogenase/05-04- 
isomerase. The reduction of progesterone by 5a- or 50-reductases results in the 
formation of several pregnane steroids with a or p stereochemistry at C3 and C5 (Figure 
5.2) (Rupprecht et al., 1999). Analogues including progesterone, 5p-pregnan-3a-OL-20- 
one (pregnanolone), 5a-pregnan-3a-OL-20-one, 3p-hydroxy-5a-pregnan-20-one 
(allopregnanolone), and 5-pregnan-3p-OL-20-one were also investigated using Ca2+ 
fluorimetry. 
None of the pregnenolone-related compounds (25 µM) activated TRPM3. However, 
progesterone and 5ß-pregnan-3a-OL-20-one caused significant inhibition of the PregS 
response in TRPM3 expressing cells (Figure 5.3 A&B). The mean data indicate that 
progesterone can significantly inhibit TRPM3 by approx. 25.6%, and 5ß-pregnan-3a- 
OL-20-one by 54.1% (Figure 5.3 Q. 
Dose response data give the IC50 for progesterone inhibition of the PregS response as 
35.5 ± 9.18 µM with a Hill coefficient of 0.9 ± 0.29 (Figure 5.3 D). The IC50 for 50- 
pregnan-3a-OL-20-one inhibition of the PregS response was 11.9 ± 3.28 p. M with a Hill 
coefficient of 0.9 ± 0.18 (Figure 5.3 E). 
The data indicate that converse to the effect of PregS, some pregnenolone-related 
neurosteroids have an inhibitory effect on the TRPM3 channel. 
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cholesterol and common neurosteroids, plus the enzymes that catalyse their formation. 
Pregnane steroids produced by 5a- or 50-reductases are diverse due to a or ß 
stereochemistry at positions C3 and C5. 
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Figure 5.3. Effect of PregS-analogues on TRPM3-expressing cells Ca 2+ signals were 
measured as the 340/380 ratio of emission in fura-2 loaded cells. DMSO (vehicle) was 
present throughout recordings, which were performed at RT. 1'' addition of test 
compound or control at 1 min (arrow), followed by 2'' addition of PregS at 8 min. 
Traces are mean data (±SEM) from 3 wells within a single plate, and show inhibition of 
the PregS response by A. progesterone (prog) and B. 5 3-pregnan-3a-OL-20-one 
(5 3preg3u). C. Mean data (±SEM) showing inhibition 1 min after PregS application 
(control n/N=3/ 18, test n/N=3/9). Data are normalised to control (is' application of 
vehicle (DMSO), followed by PregS addition). D. Mean dose response data (±SEM) 
normalised to control PregS response, show inhibition of the PregS response by prog 
(n/N=3/9), and E. 5(3preg3a (n/N=3/9). 
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A high throughput compound screen to identify TRPM3 modulators 
A FLIPR fluorimeter and the Ca2+ indicator dye Fluo-4 allowed for the screening of 
large numbers of compounds, from a chemical library supplied by AstraZeneca, as 
modulators of TRPM3. Following extensive optimisation of the method, a2 addition 
protocol was employed to screen for both activators of TRPM3, and for inhibitors of the 
control PregS response. 
The HTS screen was divided into sections determined by the compounds tested. Lipid- 
mediated modulation of TRP channels is common, and lipids are upregulated in 
vascular disease states. For this reason various physiological lipids were screened. In 
addition, vascular-relevant peptides plus a large database of known ion channel 
modulators was tested. 
Each test compound was applied at 10 µM in triplicate within a single plate of cells, and 
experiments were performed at RT. The number of cells per well was kept constant at 
50,000 cells per well. `Hits' of particular interest were subjected to further analysis as 
will be discussed. The data from the compound screen are presented as a comparison of 
the maximum Ca2+ response in induced (tet+) and non-induced cells (tet-) following the 
first addition of test compound (10 µM), or as inhibition of the control PregS Ca2+ 
response for 2 different concentrations, the EC20 and the EC80 for PregS activation of 
TRPM3. PregS dose response data were determined prior to experiments, and gave an 
EC2o of 3 µM plus an EC80 of 10 µM. 
The peptide screen failed to identify any compounds with a convincing effect on 
TRPM3, although there was a significant but small inhibitory effect of Arg-vasopressin, 
bombesin and neurotensin on the PregS-response (Figure 5.4). Several of the screened 
lipids gave small but significant activation of TRPM3, including SPH-related 
compounds DHS and safingol, plus the alky lysophospholid ET-18-OCH3, 
methanandamide (mAEA), a-lipoic acid, palmitic acid, thromboxane B2 (TX B2), the 
thromboxane A2 antagonist U-46619, the prostaglandin E2 antagonist AH6809 and 
several dihydroxyeicosatetraenoic acids (DiHETEs) (Figure 5.6,5.8 & 5.10). 
Convincing lipid activators of TRPM3 causing an increase in the fluorescence signal 
that was greater than 500 ORFU included hepoxillin A3 and ß-cyclodextrin (Figure 9). 
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Lipids appeared much more effective at inhibiting the PregS response. The 
phospholipid phosphatidylinositol-4,5-bisphosphate (PIP2), known to modulate several 
TRP channels and reported to activate the TRPM family member TRPM8 (Liu et al., 
2005), caused significant inhibition of the PregS response at both the EC20 and EC80 
(Figure 5.5). Other lipids that also inhibited both the EC20 and EC80 PregS responses 
included SPH, ET-18-OCH3 and carbocyclic thromboxane A2 (CTX A2) (Figure 5.6 & 
5.8). Prostaglandins as a whole appeared to have little inhibitory effect, although 
significant inhibition of the PregS response was apparent with 15-Deoxy-i-12.14- 
prostaglandin J2 (15d-PG J2) and prostaglandin K1 (PG K1) (Figure 5.8). Platelet 
activating factor (PAF)-16 plus related the compounds lyso PAF-16 and PAF-16 
antagonist all inhibited TRPM3, while PAF-18 and lyso PAF-18 significantly 
potentiated the PregS response (Figure 5.10). 
In the screen for ion channel modulators, the known TRP channel inhibitor 2-APB 
served as a useful positive control to demonstrate inhibition of the TRPM3 PregS- 
response (Figure 5.11). A further TRP channel inhibitor SKF 96365, reported to be 
ineffective at inhibiting TRPM3 (Grimm et al., 2003), caused a significant inhibition of 
the PregS-response (Figure 5.17). Ruthenium red (RR), an established blocker of TRPV 
and TRPM channels, showed potent inhibition of the PregS response (Figure 5.14), 
while clotrimazole, a potent TRPM2 inhibitor, potentiated the PregS response (Figure 
5.12). The TRPV 1 activators anandamide (AEA) and capsaicin significantly inhibited 
TRPM3 (Figure 5.11 & 5.14), however arachadonic acid (AA) had no effect (Figure 
5.10). Menthol, an activator of TRPM8, had no effect on TRPM3 (Figure 5.14). 
Of all the known ion channel modulators screened, only nifedipine significantly 
activated TRPM3 (Figure 5.15 A). Related dihydropyridine L-type voltage-gated 
calcium channel blockers including nitrendipine, nicardipine, nimodipine, and the T- 
type blocker mibefradil did not activate, and instead inhibited TRPM3 (Figure 5.15). 
Conversely nifedipine appeared to potentiate the PregS response, as did felodipine 
(Figure 5.13). Established calcium channel blockers including the benzothiazepine 
diltiazem, and the phenylalkylamines verapamil and gallopamil had no effect on 
TRPM3 (Figure 5.13,5.14 & 5.17). 
The typical antipsychotics chlorpromazine (CPZ) and thioridazine, both of which are 
phenothiazines, plus haloperidol (a butyrophenone) and fluspirilene (a 
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diphenylbutylpiperidine), all inhibited the PregS response. The atypical benzamide 
antipsychotic sulpiride had no effect (Figure 5.20). Diphenhydramine hydrochloride 
(DPHA), commonly recognized by its trade name Benadryl, which can be used to treat 
side effects experienced with typical antipsychotics, also inhibited TRPM3 (Figure 
5.16). 
Antidepressants also inhibited the PregS response, regardless of their type. The selective 
serotonin reuptake inhibitors (SSRI) citalopram and fluoxetine, plus the tricyclic 
antidepressants (TCA) imipramine, nortriptyline, doxepin and amitriptyline, all 
inhibited TRPM3 (Figure 5.11-5.15). However, the SSRI fluoxamine, and venalfaxine, 
a serotonin-norepinephrine reuptake inhibitor (SNRI), did not inhibit TRPM3 activity 
(Figure 5.13 & 5.17). 
Amino-amide type local anaesthetics mepivacaine, lidocaine and bupivacaine and 
benzocaine potentiate the PregS response, but quaternary derivatives of lidocaine, the 
membrane impermeant QX314 and QX222, had no effect. (Figure 5.11,5.14 & 5.16). 
Disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) is a cross-linking 
reagent with isothiocyanate groups known to block TRPC40 (Walker et al., 2002), 
inhibited the PregS response (Figure 5.12). Loperamide, a derivative of piperadine and 
an opoid receptor agonist, inhibited the PregS response (Figure 5.14), and the anti- 
anginal agents bepridil hydrochloride and perhexiline maleate significantly inhibited 
both EC20 and EC80 PregS response (Figure 5.11 & 5.16), as did the alkoid papaverine 
hydrochloride (Figure 5.16). The anti-arrhythmic agents mexiletene and amidarone, plus 
the PKC inhibitor Bisindolylmaleimide I (BIM I) and the K+ channel blocker CP 
339818, were also effective inhibitors (Figure 5.11,5.12 & 5.15). N-acetylprocainamide 
(NAPA), also an anti-arrhythmic drug, had a dual effect on the channel and potentiated 
the EC20 but inhibited the EC80 PregS response; however its parent compound 
procainamide had no effect (Figure 5.15 & 5.16). The CaM antagonists calmidazolium 
chloride (CMZ) and N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) 
inhibited the TRPM3 PregS response (Figure 5.12 & 5.15). 
In summary, HTS is a useful method for identifying ion channel modulators of potential 
interest for further study. 
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Figure 5.4. Peptide screen Figure 5.6. Lipid screen FLIPR compound screen 
performed at RT. Changes in Ca 2+ were measured as relative fluorescence units (RFU) 
in tluo-4 loaded tet+ cells. DMSO (vehicle) was present throughout recordings. Mean 
data (±SEM) from 3 wells within a single plate, normalised to control PregS response, 
show: A. Activation in tet+ (black) compared to tet- (grey) cells, B. Inhibition of PregS 
response at ECG(), and C. Inhibition of PregS response at ECxO. 
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Figure 5.5. Lipid screen Figure 5.6. Lipid screen FLIPR compound screen performed 
at RT. Changes in Ca" were measured as relative fluorescence units (RFU) in fluo-4 
loaded tet+ cells. DMSO (vehicle) was present throughout recordings. Mean data 
(±SEM) from 3 wells within a single plate, normalised to control PregS response, show: 
A. Activation in tet+ (black) compared to tet- (grey) cells, B. Inhibition of PregS 
response at EC2,,, and C. Inhibition of PregS response at ECxi,. 
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Figure 5.6. Lipid screen FLIPR compound screen performed at RT. Changes in Ca 2+ 
were measured as relative fluorescence units (RFU) in fluo-4 loaded tet+ cells. Ethanol 
(vehicle) was present throughout recordings. Mean data (±SEM) from 3 wells within a 
single plate, normalised to control PregS response, show: A. Activation in tet+ (black) 
compared to tet- (grey) cells, B. Inhibition of PregS response at EC)(), and C. Inhibition 
of PregS response at EC «). 
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Figure 5.7. Lipid screen FLIPR compound screen performed at RT. Changes in Ca 2+ 
were measured as relative fluorescence units (RFU) in tluo-4 loaded tet+ cells. Ethanol 
(vehicle) was present throughout recordings. Mean data (±SEM) from 3 wells within a 
single plate, normalised to control PregS response, show: A. Activation in tet+ (black) 
compared to tet- (grey) cells, B. Inhibition of PregS response at EC-),,, and C. Inhibition 
of PregS response at ECsO. 
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Figure 5.8. Lipid screen FLIPR compound screen performed at RT. Changes in Ca2+ 
were measured as relative fluorescence units (RFU) in fluo-4 loaded tet+ cells. Ethanol 
(vehicle) was present throughout recordings. Mean data (±SEM) from 3 wells within a 
single plate, normalised to control PregS response, show: A. Activation in tet+ (black) 
compared to tet- (grey) cells, B. Inhibition of PregS response at EC',,, and C. Inhibition 
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Figure 5.9. Lipid screen FLIPR compound screen performed at RT. Changes in Ca 2+ 
were measured as relative fluorescence units (RFU) in fluo-4 loaded tet+ cells. Ethanol 
(vehicle) was present throughout recordings. Mean data (±SEM) from 3 wells within a 
single plate, normalised to control PregS response, show: A. Activation in tet+ (black) 
compared to tet- (grey) cells, B. Inhibition of PregS response at EC2(), and C. Inhibition 
of PregS response at EC« ). 
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Figure 5.10. Lipid screen FLIPR compound screen performed at RT. Changes in Ca 2+ 
were measured as relative fluorescence units (RFU) in fluo-4 loaded tet+ cells. Ethanol 
(vehicle) was present throughout recordings. Mean data (±SEM) from 3 wells within a 
single plate, normalised to control PregS response, show: A. Activation in tet+ (black) 
compared to tet- (grey) cells, B. Inhibition of PregS response at EC-),,, and C. Inhibition 
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Figure 5.11. Ion channel modulators FLIPR compound screen performed at RT. 
Changes in Ca 2+ were measured as relative fluorescence units (RFU) in fluo-4 loaded 
tet+ cells. DMSO (vehicle) was present throughout recordings. Mean data (±SEM) from 
3 wells within a single plate, normalised to control PregS response, show: A. Activation 
in tet+ (black) compared to tet- (grey) cells, B. Inhibition of PregS response at EC,,,, 
and C. Inhibition of PregS response at EC8o. 
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Figure 5.12. Ion channel modulators FLIPR compound screen performed at RT. 
Changes in Ca" were measured as relative fluorescence units (RFU) in fluo-4 loaded 
tet+ cells. DMSO (vehicle) was present throughout recordings. Mean data (±SEM) from 
3 wells within a single plate, normalised to control PregS response, show: A. Activation 
in tet+ (black) compared to tet- (grey) cells, B. Inhibition of PregS response at ECG,,, 
and C. Inhibition of PregS response at ECG,. 
185 
A 6000, 
B 
C 
2.5 
5 2.0 0 
° 1.5 
-v 
1.0 
E 0.5 
0 0.0 
2.0 
C 
ý 1.5 
0 11.0 
0.5 E 
0 0.0 
* 
f, 
eý Aýe O%if '%, o9F Fr ýo% h ýci 9S 'aý +°. o 
ý'G'ý4,, °y ca% °+ s"o ýo 0, 
. , o%'j o. °f% .% +a 01 0 dN 'jio , 
ij O'ý ý 
* 
** * 
c O. " O, o eFF Fý A% T Tj Tj ýA oe ýf, 6?, 1, ýieo00 'ý 
oý 
oos`+op; ýý, d, 'ýä+ofýo+ý 
* 
*** 
*, o =. L * 
* 
0+0 G' 
A` ý`, eGýA Ah 
^°V ý'7 
'ý', 
^° ok+c+aýý: +Ot, aA'; '. ia° 
e 
Figure 5.13. Ion channel modulators FLIPR compound screen performed at RT. 
Changes in Cat` were measured as relative fluorescence units (RFU) in fluo-4 loaded 
tet+ cells. DMSO (vehicle) was present throughout recordings. Mean data (±SEM) from 
3 wells within a single plate, normalised to control PregS response, show: A. Activation 
in tet+ (black) compared to tet- (grey) cells, B. Inhibition of PregS response at EC'(), 
and C. Inhibition of PregS response at EC «). 
186 
ýº 8000, 
B 
C 
2.0- 
01.5- 
C. ) 
0 
-0 1. Oa aý ý 
cu 0.5- E 
1- Z 0.0- 
c 2.0- 
a- 
1.5 0 
0 
1.0- 
0.5- 
E 
0 0.0 
* 
* 
C'o ca G'a Cap tiaý ýý. " o, a 
a 
Fef la loo, 
120, 
to ýe 'lie 
f^o; cos b o. oa o . 
oa o coý , oty. 
oca,; ýýa fhoV , `a ao. ý aqo ',; 'ý7 
O, e 
a'O' io 
Figure 5.14. Ion channel modulators FLIPR compound screen performed at RT. 
Changes in Ca 2+ were measured as relative fluorescence units (RFU) in fluo-4 loaded 
tet+ cells. DMSO (vehicle) was present throughout recordings. Mean data (±SEM) from 
3 wells within a single plate, normalised to control PregS response, show: A. Activation 
in tet+ (black) compared to tet- (grey) cells, B. Inhibition of PregS response at EC ), 
and C. Inhibition of PregS response at ECH,,. 
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Figure 5.15. Ion channel modulators FLIPR compound screen performed at RT. 
Changes in Ca 2+ were measured as relative fluorescence units (RFU) in fluo-4 loaded 
tet+ cells. DMSO (vehicle) was present throughout recordings. Mean data (±SEM) from 
3 wells within a single plate, normalised to control PregS response, show: A. Activation 
in tet+ (black) compared to tet- (grey) cells, B. Inhibition of PregS response at EC-),,, 
and C. Inhibition of PregS response at EC «). 
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Figure 5.16. Ion channel modulators FLIPR compound screen performed at RT. 
Changes in Ca" were measured as relative fluorescence units (RFU) in fluo-4 loaded 
tet+ cells. DMSO (vehicle) was present throughout recordings. Mean data (±SEM) from 
3 wells within a single plate, normalised to control PregS response, show: A. Activation 
in tet+ (black) compared to tet- (grey) cells, B. Inhibition of PregS response at EC-),,, 
and C. Inhibition of PregS response at EC80. 
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Figure 5.17. Ion channel modulators FLIPR compound screen performed at RT. 
Changes in Ca 2+ were measured as relative fluorescence units (RFU) in fluo-4 loaded 
tet+ cells. DMSO (vehicle) was present throughout recordings. Mean data (±SEM) from 
3 wells within a single plate, normalised to control PregS response, show: A. Activation 
in tet+ (black) compared to tet- (grey) cells, B. Inhibition of PregS response at ECIU, 
and C. Inhibition of PregS response at EC80. 
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TRPM3 inhibitor IC50 curves 
Compounds indicated in the screen that were of particular significance or interest were 
further investigated. Dose response data were obtained for novel inhibitors to determine 
IC50 values. As the exact mechanism of inhibition was not known for new modulators, a 
direct inhibition of the channel was assumed, thus data were analysed using the Hill 
equation (Figure 5.16-5.21). IC50 and Hill coefficient values are presented in Table 5.1. 
IC50 values where the Hill equation fit appeared not to be the best fit and are therefore 
unreliable are designated by #. 
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Figure 5.18. Lipid modulators ICso Mean dose response data (±SEM) show inhibition 
of the PregS response by A. PIP2, B. PAF-16, C. lyso PAF-16 and D. PAF-16 
antagonist. Data are normalised to control PregS response, n/N=3/9 for each. 
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Figure 5.19. Ion channel modulators IC5o Mean dose response data (±SEM) show 
inhibition of the PregS response by A. 2-APB, B. SKF 96365, C. ruthenium red and D. 
calmidazolium chloride. Data are normalised to control PregS response, n/N=3/9 for 
each. 
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Figure 5.20. Ion channel modulators ICso Mean dose response data (±SEM) show 
inhibition of the PregS response by A. nifedipine, B. nicardipine, C. nimodipine, D. 
perhexiline maleate, E. loperamide and F. mibefradil. Data are normalised to control 
PregS response, n/N=3/9 for each. 
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Figure 5.21. Ion channel modulators ICso Mean dose response data (±SEM) show 
inhibition of the PregS response by A. citalopram, B. fluoxetine, C. imipramine, D. 
nortriptyline, E. chlorpromazine, and F. haloperidol. Data are normalised to control 
PregS response, n/N=3/9 for each. 
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Compound name IC: O Hill coefficient 
PIP2 49.0 ± 6.29 µM 0.3 ± 0.04 
P. aF-16 14.3 ±44.78 uM 0.2 ±0.09 
; LýSOP. aF-16 75.3±31.02uM 0.6 ± 0.17 
PaF-16 antagonist 25.9 ± 52.71 uM 0.2 ± 0.22 
F 2-APB 34.8 ± 5.46 uM 1.1 ± 0.19 F 
ý it SKF 9636; 0.1 ± 1.92 «M 0.2 ± 0.21 
Ruthenium red 0.4 ± 0.04 uM 2.6 ± 0.66 
('almidau, lium chloride , 14.1 ± 4.90 uM 1.1 ± 0.37 
Nifedipine 
\icardipinv 
\imudipine 
Perhexiline maleate 
Luperamide 
. 
NIihefradil 
(italopram 
Fluoxetine 
194.6±42.33 uM 
? 6.6±3.81 uk1 
0.8 ± 0.15 
0.8±0.10 
1->". 8±3.65 uM 0.9±0.? ' 
13.2 ±7.06uM 0.7±0.23 
23.1±3.55uM 0.7±0.08 
20.8 ± 3.39 uM F ?.? ± 0.63 
22.7 ± -t. IB UM 1.2 ±0.? 3 
42.3±3.20uM 
Imipraminr 92.0 ± 17.10 uM 
rtript% line 1.4 ± 7.17 «M 
I: ialuperidul 75.5 ± 41.93 uM 
Chlorpromazine 
1 
28. I ± I. 42 iOv1 
F- 
1.3 ±0.13 
0.8 ±0.15 
0.1 ±0.16 
1.1 ± 0.5? 
2.2 ± 0.28 
Table -. I. I(':,, and Hill coefficients for novel TRP\13 inhibitors Compounds where 
. the Hill equation did not produce a good fit are 
designated by 0 
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Cross screening of TRPM3 modulators against native ATP responses and TRPM2 
Novel TRPM3 inhibitors identified by the HT screen were further investigated as 
modulators of endogenous ATP responses in TRPM3-expresing cells, and by cross 
screening against TRPM2 cells, to determine their selectivity for TRPM3. Furthermore 
IC50 values were calculated for TRPM2 inhibition and are presented in Table 5.2. IC50 
values obtained when application of the Hill equation did not appear to give the best fit, 
suggesting they are unreliable, are designated by *. 
In addition to inhibiting the TRPNI3 PregS-response, 2-APB, lyso PAF-16, PAF-16, 
mibefradil and calmidazolium chloride also inhibited the endogenous ATP response, 
whereas fluoxetine significantly potentiated this response (Figure 5.22). 
For TRPM2-expressing cells, clotrimazole served as a useful positive control for the 
dose-dependant inhibition of TRPM2 (Figure 5.23 A&5.25 Q. 2-APB is reported to be 
ineffective at blocking ADP-ribose activated TRPM2 current at concentrations up to 75 
µM (Xu et al., 2005a), yet this study demonstrates 54% inhibition of the H202 response 
by 2-APB (Figure 5.23 A). However, the inhibition observed with 2-APB was not 
reproduced in the dose response data at concentrations lower than 100 µM (Figure 5.25 
A). Although the TRP inhibitor SKF 96365 also appeared to cause inhibition of TRPM2 
(Figure 5.23 A), again there was a discrepancy with the dose response data and the 
block seems unreliable (Figure 5.25 B). 
PIP2, significantly inhibited the TRPM2 H202 response, while PAF-16 and lyso PAF-16 
only displayed an inhibitory effect at high concentrations (Figure 5.23 & 5.24), as did 
the ion channel modulators calmidazolium chloride, perhexiline maleate, mibefradil, 
nortriptyline, chlorpromazine and loperamide (Figure 5.23,5.25 & 5.26), suggesting 
that these compounds are not selective inhibitors of the TRPM3 channel. Converse to 
TRPM3, nifedipine did not activate TRPM2, and instead significantly inhibited the 
H202 response (Figure 5.23 & 5.26 A). 
The data indicate that many recognised ion channel inhibitors are non-selective, and 
block both endogenous cellular responses and those of other TRP channels. In addition, 
discrepancies between the HTS and dose response data demonstrate the importance that 
leads identified by a compound screen are followed up with further investigation 
including repeat experiments and different experimental techniques. 
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Figure 5.22. Ion channel modulators ATP FLIPR compound screen performed at RT. 
Changes in Cal+ were measured as relative fluorescence units (RFU) in fluo-4 loaded 
tet+ cells. Mean data (±SEM) normalised to control ATP response, show: A. Inhibition 
of ATP response by TRP modulators. B. Inhibition of ATP response by Ca 2+ channel 
blockers. C. Inhibition of ATP response by antidepressants and antipsychotics. n/N=3/9 
for each. 
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Figure 5.23. Ion channel modulators TRPM2 FLIPR compound screen performed at 
RT. Changes in Cat' were measured as relative fluorescence units (RFU) in fluo-4 
loaded tet+ cells. Mean data (±SEM) normalised to control H202 response, show: A. 
Inhibition of H, O, response by TRP modulators. B. Inhibition of H, O, response by Ca 2+ 
channel blockers. C. Inhibition of H, O, response by antidepressants and antipsychotics. 
n/N=3/9 for each. 
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Figure 5.24. Ion channel modulators ICso TRP1`12 Mean dose response data (±SEM) 
show inhibition of the H202 response by A. PAF-16, B. lyso PAF-16 and C. PIP2. Data 
are normalised to control H202 response, n/N=3/9 for each. 
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Figure 5.25. Ion channel modulators ICso TRPM2 Mean dose response data (±SEM) 
show inhibition of the H202 response by A. 2-APB, B. SKF 96365, C. clotrimazole and 
D. calmidazolium chloride. Data are normalised to control H202 response, n/N=3/9 for 
each. 
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Figure 5.26. Ion channel modulators IC5o TRPM2 Mean dose response data (±SEM) 
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each. 
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Compound name I C; () Hill coefficient 
0.5± 0.11 
0.2 f 0.28 
2.9 ± 1.23 
1.8 ± 0.38 
0.1 f 0.11 
0.8 ± 0.22 
1.2 ± 0.12 
0.4 ± 0.03 
0.8 ± 0.19 
0.6 ± 0.18 
2.0 ± 0.61 
PIP, 
# PAF-16 
k Lyso PAF-16 
2-APB 
4 SKF 9636-5 
Clotrimazole 
Calmidazolium chloride 
Nifedipine 
Mibefridil 
Loperamide 
Chlorpromazine 
5.7 f 2.22 µM 
162.0f61.42µM 
27.3 ý 2.92 µM 
55.6 ý 7.95 µM 
0.1 f 2.40 µM 
29.8 f 9.65 µM 
43.7 ± 3.54 µM 
225.0 ± 26.85 µM 
16.1 ± 4.88 µM 
97.7 f 35.00 µM 
41.3t7.65µM 
Table 5.2. IC5 and Hill coefficients for TRPM2 inhibitors Compounds where the 
Hill equation did not produce a good fit are designated by '. 
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Nifedipine activates TRPN13 
The high throughput screen demonstrated significant activation of TRPM3 with the 
calcium channel inhibitor nifedipine, plus potentiation of the PregS response at low 
concentrations. In addition, nifedipine has been suggested as an activator of mouse 
variant TRPM3a2 (J. Oberwinkler, personal communication). FLIPR fluorimetry of 
fluo-4 loaded cells was used to further investigate the effect of nifedipine on TRPM3. 
Nifedipine (10 µM) activated a rapid and sustained Ca 2+ response in cells expressing 
TRPM3 (tet+) but not in non-induced cells (tet-) (Figure 5.27 A). The mean data show 
that after 3 min, nifedipine-induced responses in tet+ cells were significantly larger than 
tet- cells (Figure 5.27 B). 
Increasing concentrations of nifedipine were applied to wells of test and control cells 
within the same plate, allowing for direct comparison. Responses increased in 
magnitude with higher concentrations, demonstrating concentration-dependant 
activation. Fitting of the Hill equation indicated the concentration for half maximal 
activation, the EC50, was 26.0 ± 4.27 µM, with a Hill coefficient of 1.3 ± 0.16 (Figure 
5.27 C), however this EC50 value is unreliable and may be an underestimate of the true 
value as a maximum response was not achieved. 
The data confirm that nifedipine can activate human TRPM3 in a concentration 
dependant manner. 
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Figure 5.27. Nifedipine increases Ca 2+ signals in tet+ TRPM3 cells Changes in Ca2+ 
were measured as relative fluorescence units (RFU) in fluo-4 loaded cells. Cells were 
induced by incubation with tetracycline (tet+). Cells not treated with tetracycline were 
included as a control (tet-). DMSO (vehicle) was present throughout recordings. A. 
Representative mean data (±SEM) from 3 wells within a single plate show nifedipine 
(10 µM) causes an increase in Ca2+ in tet+ TRPM3 compared to tet- (open circles). B. 
Mean data (±SEM) showing significant increase in Ca2+ 3 min after nifedipine 
application (n/N=3/9). C. Mean dose response data (±SEM) analysed using the Hill 
equation (n/N=3/9). 
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Cholesterol inhibits TRPM3 
Cholesterol has important physiological functions. Most importantly, it maintains the 
structure of the cell membrane by regulating fluidity of the lipid bilayer (Spector et al., 
1985). Cholesterol also regulates the activity of membrane-bound proteins such as TRP 
channels (Bergdahl et al., 2003). Cholesterol is a highly hydrophobic molecule, but can 
be made soluble in aqueous solutions through the formation of complexes with 
cyclodextrins. These cyclic oligosaccharides possess a hydrophilic exterior that makes 
them soluble, and a less hydrophilic interior that provides a favorable environment for 
hydrophobic molecules. Preincubation with an excess of the 7-sugar unit ß-cyclodextrin 
(ßCD) extracts cholesterol from the plasma membrane in live cells. 
The high throughput lipid screen demonstrated small but significant activation of 
TRPM3 following direct application of ßCD (Figure 5.9). FLIPR fluorimetry of fluo4 
loaded cells was used to further investigate this effect, and demonstrated that ICD (10 
µM) activated a slowly developing small Ca2'-response in both tet- and tet+ cells 
(Figure 5.28 A). The mean data show that after 4 min, ßCD-induced responses in tet+ 
cells were significantly larger than tet- cells (Figure 5.28 B). Note that direct application 
of cholesterol (10 µM) had no significant effect on TRPM3 (Figure 5.5). This is most 
likely because the cholesterol was insoluble in the bath solution. Alternatively, TRPM3 
may be tonically inhibited by cholesterol that is already present in the plasma 
membrane. 
The effect of membrane cholesterol on the TRPM3 channel was further investigated by 
providing cholesterol complexed to methyl ß-cyclodextrin (mßCD). This methylated 
derivative of ICD is more efficient than its parent compound at forming complexes with 
hydrophobic molecules such as cholesterol, thus enhances their solubility in aqueous 
solutions, and delivers them to cell membranes (nodal et al., 1999). Preincubation of 
cells with the soluble cholesterol complex at physiological temperature for 2 hours was 
sufficient to allow cholesterol molecules to insert into the favourable conditions of the 
plasma membrane (Hinzpeter et al., 2007). Cholesterol enrichment of the cell 
membrane inhibited PregS-induced activation of TRPM3 (Figure 5.29 A). The mean 
data indicate that preincubation with the soluble cholesterol complex (1 MM) caused a 
70.2% inhibition of the Ca2+ response, with no effect on non-induced (tet-) cells (Figure 
206 
5.29 B). Dose response data give the IC50 for this cholesterol inhibition as 0.5 ± 0.06 
mM; with a Hill coefficient of 2.5 ± 0.58 (Figure 5.29 Q. 
To determine the specificity of cholesterol inhibition of TRPM3, the effect of 
cholesterol enrichment on other TRP family members was examined. Cholesterol 
decreased the starting baseline in tet+ and tet- TRPM2 cells, and potentiated the H2O2 
response (Figure 5.30 A). In TRPC5-expressing cells, cholesterol completely inhibited 
the Gd3+-response (Figure 5.30 B), but had no effect on the 4aPDD response in TRPV4- 
expressing cells (Figure 5.30 Q. 
The data demonstrate that TRPM3 activity is regulated by cholesterol, and that 
cholesterol enrichment of the cell membrane has varied effects on different TRP family 
members. 
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Figure 5.28. ß-cyclodextrin increases Ca 2+ signals in tet+ TRPM3 cells Changes in 
Ca2+ were measured as relative fluorescence units (RFU) in fluo-4 loaded cells. Cells 
were induced by incubation with tetracycline (tet+). Cells not treated with tetracycline 
were included as a control (tet-). A. Representatiive mean data (±SEM) from 3 wells 
within a single plate show ß-cyclodextrin (10 µM) causes a greater Ca2+ increase in tet+ 
cells compared to tet- (open circles). B. Mean data (±SEM) showing significant increase 
in Ca2+ 3 min after ß-cyclodextrin application (n/N=3/9). 
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Figure 5.29. Cholesterol enrichment inhibits PregS induced Ca 2+ response in tet+ 
TRPM3 cells Ca 2+ signals were measured as the 340/380 nm ratio of emission in fura-2 
loaded cells. Cells were induced by incubation with tetracycline (tet+). Cells not treated 
with tetracycline were included as a control (tet-). A. Repesentative mean data (±SEM) 
from 6 wells within a single plate show inhibition of the tet+ PregS response by 
cholesterol (chol, 1 mM). B. Mean data (±SEM) showing significant chol inhibition of 
Cat responses 1 min after PregS application (n/N=3/18). C. Mean dose response data 
(±SEM) analysed using the Hill equation (n/N=3/9). 
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Figure 5.30. Cholesterol enrichment effect on other TRP channels Ca2+ signals were 
measured as the 340/380 nm ratio of emission in fura-2 loaded cells. TRPM2 and 
TRPC5 cells were induced by incubation with tetracycline (tet+). Cells not treated with 
tetracycline were included as a control (tet-). For TRPV4 cells, CHO parent cells were 
included as a control. Representative mean data (±SEM) shown are from 6 wells within 
a single plate for each cell type. A. Chol (1 mM) enrichment potentiates H202 activation 
of TRPM2. B. Chol inhibits Gd3+ (100 µM) activation of TRPC5. C. Chol does not 
affect TRPV4 activation by 4aPDD (10 µM). 
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Removal of membrane cholesterol activates TRPM3 
Previous experiments demonstrating ICD activation of TRPM3 involved a direct, short 
application of ßCD. A longer preincubation using m3CD, reported to be both more 
soluble and more effective at cholesterol removal (Rodal et al., 1999), was used to 
investigate the effect of cholesterol depletion on TRPM3. 
Preincubation with mßCD (10 mM) significantly increased the starting baseline for 
recording in both tet+ and tet- cells (Figure 5.31 A& B). This would suggest mßCD 
preincubation had already activated calcium entry into cells prior to PregS addition. The 
mean data show that there was a reduction in the magnitude of the PregS response in 
mßCD treated cells (Figure 5.31 Q. This could be because the PregS response 
saturated, and could not increase by a similar magniturde in cells with a high starting 
baseline. Following mßCD preincubation, PregS was also able to elicit a significant 
Ca2+ response in tet- cells (Figure 5.31 Q. 
Further experiments were performed using stable cells expressing additional TRP 
channels. Preincubation with mICD (10 mM) also increased the starting baseline in tet+ 
and tet- TRPM2 cells, and completely inhibited the H2O2 response (Figure 5.32 A). In 
TRPC5-expressing cells, again the baseline was increased following m(3CD 
preincubation, and Gd3+-induced Ca2+ entry reached a much higher maximum 
fluorescence, suggesting potentiation of the Gd3+ response (Figure 5.32 B). 
Interestingly, mßCD had no effect on the baseline or Ca2+ responses in TRPV4 
expressing CHO cells (Figure 5.32 Q. 
The data show that in addition to cholesterol enrichment of cell membranes, the removal 
of cholesterol can also modulate TRPM3 and other TRP family members. Cholesterol 
depletion removes tonic inhibition of TRPM3, increasing the starting baseline for 
recordings. The same is true for TRPC5, and in addition the Gd3+ response is 
potentiated in the absence of cholesterol. However, cholesterol depletion inhibits the 
TRPM2 H202 response, and has no effect on TRPV4-expressing cells. The data 
provides evidence that cholesterol can differentially regulate TRP channels in the 
plasma membrane. 
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Figure 5.31. Methyl ß-cyclodextrin preincubation modulates TRPM3 Ca2+ signals 
were measured as the 340/380 nm ratio of emission in fura-2 loaded cells. Cells were 
induced by incubation with tetracycline (tet+). Cells not treated with tetracycline were 
included as a control (tet-). A. Mean data (±SEM) from 6 wells within a single plate 
show that methyl ß-cyclodextrin (m3CD) preincubation (10 mM) causes an increase in 
starting baseline for recordings. B. Mean data (±SEM) showing significant increase in 
baseline (n/N=3/18). C. Baseline subtracted mean data (±SEM) taken 1 min after PregS 
application. The tet+ PregS Ca 2+ response is reduced in mfCD treated cells, whereas 
Ca2+ responses in tet- cells are increased in mfCD treated cells (n/N=3/18). 
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Figure 5.31. Methyl ß-cyclodextrin preincubation modulates TRPM3 Ca 2+ signals 
were measured as the 340/380 nm ratio of emission in fura-2 loaded cells. Cells were 
induced by incubation with tetracycline (tet+). Cells not treated with tetracycline were 
included as a control (tet-). A. Mean data (±SEM) from 6 wells within a single plate 
show that methyl f3-cyclodextrin (mßCD) preincubation (10 mM) causes an increase in 
starting baseline for recordings. B. Mean data (±SEM) showing significant increase in 
baseline (n/N=3/18). C. Baseline subtracted mean data (±SEM) taken I min after PregS 
application. The tet+ PregS Ca 2+ response is reduced in mßCD treated cells, whereas 
Cat+responses in tet- cells are increased in mßCD treated cells (n/N=3/18). 
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Figure 5.32. Cholesterol enrichment effect on other TRP channels Ca 2+ signals were 
measured as the 340/380 nm ratio of emission in fura-2 loaded cells. TRPM2 and 
TRPC5 cells were induced by incubation with tetracycline (tet±). Cells not treated with 
tetracycline were included as a control (tet-). For TRPV4 cells, CHO parent cells were 
included as a control. Representative mean data (±SEM) shown are from 6 wells within 
a single plate for each cell type. A. mICD (10 mM) preincubation inhibits H202 
activation of TRPM2. B. mßCD potentiates Gd3+ (100 µM) activation of TRPC5. C. 
m3CD does not affect TRPV4 activation by 4aPDD (10 µM). 
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Cholesterol analogues important in the vasculature inhibit TRPM3 
The metabolism of dietary cholesterol involves oxidation of the double bond to produce 
oxysterols including 7-ß-hydroxycholesterol (ß-OH) and 7-ketocholesterol (7-keto) 
(Figure 5.33). These oxysterols are believed to play a role in the development of the 
atherosclerotic plaque (Brown et al., 1999). The importance of oxysterols in vascular 
disease makes them of particular interest as potential TRPM3 modulators. 
The oxysterols investigated were both soluble in ethanol (vehicle); therefore delivery by 
mJCD was not required. As the concentration of oxysterols in the plasma of 
hypercholesterolemic patients is between 20-30 µM (Biasi et al., 2004), ß-OH and 7- 
keto were applied at 2 different concentrations at the low and high end of this range. 
The application of 10 or 50 µM of either compound failed to activate TRPM3 (Figure 
5.34 A&B). However, ß-OH (50 µM) caused significant inhibition of the PregS 
response (Figure 5.34 Q. 
The data indicate that in addition to cholesterol, certain oxysterols can also inhibit the 
TRPM3 PregS response. 
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Figure 5.33. Biosynthesis of cholesterol analogues Chemical structures of cholesterol 
and the common oxysterols 7-ketocholesterol and 7-ß-hydroxycholesterol. 
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Figure 5.34 Effect of cholesterol analogues on the PregS response Changes in Ca 2+ 
were measured as relative fluorescence units (RFU) in fluo-4 loaded tet+ cells. Ethanol 
(vehicle) was present throughout recordings. I" addition of test compound or control at 
1 min indicated by arrow, followed by 2°`' addition of PregS control at 10 min. Traces 
are mean data (±SEM) from 3 wells within a single plate and show effect on the PregS 
response by A. 7-Ketocholesterol (7-keto, 50 uM) and B. 7-3-hydroxycholesterol ((3- 
OH, 50 uM). C. Mean data (±SEM) show effect on Ca 2+ responses 1 min after PregS 
application (n/N=3/9). Control refers to I" application of vehicle (DMSO), followed by 
PregS addition, to which data are normalised. 
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Investigation of nitric oxide 
In addition to cholesterol and oxysterols, further compounds implicated in vascular 
disease were investigated. In blood vessels, NO is synthesised from L-arginine and 
oxygen by nitric oxide synthase (NOS), and is an important inter-cellular signalling 
molecule that regulates vascular tone and blood pressure. NO is gaseous and therefore 
difficult to utilise directly in physiological studies. NG-Nitro-L-arginine methyl ester (L- 
NAME) is an analogue of L-arginine characterised as an inhibitor of NOS, and is 
therefore useful for decreasing NO levels in cells and tissues. Alternatively, (±)-S- 
nitroso-N-acetylpenicillamine (SNAP), a derivative of nitrosothiol, can be used to 
release NO. 
Preincubation of TRPM3-expressing cells with L-NAME (100 µM) slightly inhibited 
PregS (10 µM)-induced Cat+-responses in TRPM3-expressing cells (Figure 5.35 A). 
The mean data indicate that L-NAME can significantly inhibit TRPM3 by -23% 
(Figure 5.35 Q. It therefore seemed that an NO donor might potentiate the PregS 
response. However preincubation with SNAP (100 µM) did not affect the PregS 
response (Figure 5.35 B). In addition, direct application of SNAP (300 µM) did not 
activate TRPM3 when compared to the control PregS application (Figure 5.35 D). 
In summary, the inhibition of PregS responses following L-NAME preincubation 
suggests that endogenous product of NOS may slightly potentiate TRPM3 activity, 
however the direct application of NO via SNAP failed to activate the channel. 
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Figure 5.35. Nitric oxide effect on PregS induced Ca 2+ response in tet+ TRPM3 
cells Changes in Cap` were measured as relative fluorescence units (RFU) in fluo-4 
loaded cells. DMSO (vehicle) was present throughout recordings, which were 
performed at RT. A. Representative mean data (±SEM) from 6 wells within a single 
plate show inhibition of PregS-response following preincubation with L-NAME 
(100uM). B. SNAP (100uM) preincubation did not affect the PregS-response. C. Mean 
data (±SEM) for PregS response inhibition taken 1 min after PregS application (10 [IM), 
normalised to control response (control n/N=7/27, L-NAME n/N=6/21, SNAP=7/25). 
D. Mean data (±SEM) showing activation in tet+ (black) compared to tet- (grey) cells. 
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Temperature Regulation of TRPM3 
The temperature sensitivity of several TRP channels, known as thermo-TRPs, is well 
characterised (Bandell et al., 2007). ThermoTRPs believed to play a role in 
thermosensation include the TRPV subfamily members TRPV 1-4, which are heat 
activated channels, and TRPM8 and TRPA1, activated by cold temperatures. The effect 
of temperature on the PregS response in HEK-TRPM3 was therefore investigated using 
FlexStation fluorimetry of fluo-4 loaded cells. 
To demonstrate temperature dependence in TRP channels, experiments were first 
performed with TRPM2- and TRPV4-expressing cells. TRPM2 is activated by warm 
temperatures, and ß-NAD+- or ADP-ribose activation is potentiated (Togashi et al., 
2006). In agreement with this study, physiological temperature (37°C) potentiated the 
H202 response in TRPM2-expressing cells compared to RT resulting in a more rapid 
response, and also increased the starting baseline, indicating TRPM2 was already 
activated prior to H202 addition (Figure 5.36 A). Physiological temperatures are also 
reported to activate TRPV4 (Nilius et al., 2004b). As for TRPM2, at 37°C the starting 
baseline was increased, consistent with temperature activation of TRPV4. However 
there was no effect on the maximum 4aPDD response, suggesting temperature and 
4aPDD are independent activators of TRPV4 (Figure 5.36 B). 
In TRPM3-expressing cells, PregS activated a rapid and sustained Ca2+ response at RT, 
whereas at 37°C the response was transient and had a much higher baseline (Figure 5.36 
Q. At 37°C the starting baseline was significantly higher for both TRPM3-expressing 
(tet+) and non-induced (tet-) cells. However as the baseline at 37°C for tet+ cells was 
significantly higher than for tet- cells, this indicates temperature activation of TRPM3 
(Figure 5.36 D). 
Background-subtracted data show that the magnitude and concentration dependence of 
PregS responses was not affected by temperature (Figure 5.37 A&B). Fitting of the Hill 
equation to mean data taken from the peak of the PregS response gave the EC50 at RT as 
1.3 ± 0.16 µM, with a hill coefficient of 1.3 ± 0.18, while at 37°C this was slightly 
shifted right to 1.8 ± 0.24 µM, with a hill coefficient of 1.2 ± 0.15 (Figure 5.37 Q. 
It is evident that temperature is an important regulatory mechanism of TRP channel 
activity, and physiological temperature can significantly affect TRPM3 Ca2+ responses. 
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Figure 5.36. Temperature regulation of TRP channels Changes in Ca 2+ were 
measured as relative fluorescence units (RFU) in fluo-4 loaded cells. TRPM2 and 
TRPM3 cells were induced by incubation with tetracycline (tet+). Traces are mean data 
(±SEM) from 6 wells within a single plate. Appropriate vehicle was present throughout 
recordings. A. Physiological temperature potentiates the TRPM2 H202 (1 mm) 
response. B. Physiological temperature does not affect the maximum TRPV4 4aPDD 
(10 µM) response. C. Physiological temperature increases the starting baseline for 
recording, and results in a more transient PregS response. D. Mean data (±SEM) 
showing effect of temperature on the starting baseline for TRPM3 recordings 
(n/N=3/18). 
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Figure 5.37. Temperature effect on PregS induced Ca 2+ response in tet+ TRPM3 
cells Cells were induced by incubation with tetracycline (tet+). DMSO (vehicle) was 
present throughout recordings. Representative nean data (±SEM) from 3 wells within a 
single plate show dose-dependent activation of TRPM3 expressing cells in response to 
PregS (0.03-100 µM) at A. RT and B. 37°C. C. Mean dose response data (±SEM) taken 
1 min after PregS application and analysed using the Hill equation (n/N=3/9). 
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Discussion 
The data presented in this chapter demonstrate that TRPM3 can be regulated by several 
different compounds and mechanisms, and that HTS is a useful method for identifying 
leads to search for ion channel modulators. Novel and seemingly selective small 
molecule inhibitors of TRPM3 include antipsychotics and antidepressants, CaM 
antagonists and ruthenium red, while nifedipine and local anaesthetics activate or 
potentiate the activation of the channel respectively. Apparent physiologically relevant 
modulators include PIP2, cholesterol and temperature. TRP channels are commonly 
activated by several different signals within a single cell. TRPC5 exhibits both store- 
operated and receptor activation, and can also be activated by lanthanides and 
intracellular Ca2+ (Zeng et al., 2004). Similarly, TRPV4 is gated by several factors, 
including hypotonicity, heat, 4aPDD, arachadonic acid (AA), endocannabinoids and 
epoxyeicosatrienoic acids (Nilius et al., 2004b). 
Pregnenolone analogues have opposite effects on TRPM3 activity 
Data presented in previous chapters of this study revealed PregS is a novel activator of 
TRPM3. Interestingly, pregnenolone analogues do not activate TRPM3, and instead 
progesterone and 5p-pregnan-3a-OL-20-one cause dose-dependent inhibition (Figure 
5.3). The differential activities of pregnenolone analogues and isomers are well 
characterised for ligand-gated ion channels including GABAA and NMDA receptors. 
Non-sulphated neurosteroids such as pregnanolone and allopregnanolone potentiate 
GABAA receptor function, while sulphated steroids like PregS are inhibitory, 
presumably as a result of the negatively charged sulphate group in the C-3 position 
(Park-Chung et al., 1999). However this sulphate group is not essential for inhibition, as 
DHEA also inhibits GABAA receptors, albeit less potently than DHEAS. Sulphated and 
non-sulphated steroid do not share the same binding site, and as a further level of 
complexity the non-sulphated steroids require 3a stereochemistry for activity. The 
PregS inhibition of the receptor is independent of GABA binding, channel activation 
state, or membrane potential. In other words PregS is a non-competitive antagonist that 
acts allosterically, rather than occluding the ion pore (Gibbs et al., 2006). 
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PregS also potentiates NMDA receptors. However analogues that differ only in the 
absence of the C-5 C-6 double bond such as pregnanolone sulphate and 
epipregnanolone sulphate, bind to distinct modulatory sites and inhibit NMDA activity 
(Park-Chung et al., 1997). Pregnenolone and pregnanolone are inactive at NMDA 
receptors, suggesting the C-3 sulphate is again important for activity. Further study is 
needed to determine the mechanism of TRPM3 activation by PregS, but stereochemistry 
may prove to be major factor in TRPM3 modulation. 
Established TRP regulatory mechanisms also modulate TRPM3 
A common mechanism of TRP channel regulation is by PIP2. PIP2 activates the TRPM 
family members TRPM5, TRPM7 and TRPM8, plus the TRPV members TRPV5 and 
TRPV6, and has both an inhibitory and activating effect on TRPV 1 (Lukacs et al., 
2007; Rohacs et al., 2005). In contrast to other TRPM family members, this study 
demonstrates extracellular PIP2 inhibition of TRPM3 and TRPM2 (Figure 5.5 & 5.23). 
The mechanism of TRPM inhibition by PIP2 is not clear. Diacylglycerol (DAG) is 
produced as a result of PLC-mediated PIP2 hydrolysis, and has an inhibitory action on 
TRPCI, 4 and 5 that is mediated by PKC (Venkatachalam et al., 2003). The effect of 
PKC activation as an inhibitory mechanism of TRPM3 activity has not been examined, 
however the PKC inhibitor bisindolylmaleimide I (BIM I) strongly inhibited TRPM3 
activity, suggesting PKC inhibition can also regulate the channel (Figure 5.11). This 
would suggest that perhaps PIP2 has a direct effect on the TRPM3 channel. The C 
terminus of TRPV 1 binds PIP2 directly (Prescott et al., 2003). Three positively charged 
residues within the conserved TRP domain motif are fully conserved in all TRPM 
family members, including TRPM3, and are responsible for PIP2 sensitivity in TRPM8 
required for PIP2 binding in TRPM8 and TRPV5 (Rohacs et al., 2005). This motif is 
also conserved in TRPM3, so it is perhaps not surprising that the channel appears to be 
regulated by PIP2. 
The majority of members of the TRP superfamily contain N- and C-terminal binding 
motifs that can interact the Ca2-sensing protein, calmodulin (CaM) and the binding of 
CaM is a common regulatory mechanism (Zhu, 2005). Although specific CaM binding 
sites have yet to be identified for TRPM3, this chapter demonstrates that the CaM 
inhibitors W-7, calmidazolium chloride (CMZ), chlorpromazine (CPZ) all inhibit 
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PregS-activation of TRPM3 (Figure 5.12 & 5.15). The same CaM inhibitors can also 
inhibit the activation of TRPC5 by disrupting signalling protein complexes (Kim et al., 
2006; Shimizu et al., 2006). Conversely, CMZ activates TRPC4ß, suggesting 
Cat /calmodulin binding to TRPC4 channels causes inhibition of the channel (Walker et 
al., 2002). The inhibition of the PregS response by CaM antagonists suggests CaM- 
binding may be an important regulatory feature of TRPM3, and further study to 
demonstrate the exact mechanism and the possible association with signalling protein 
complexes is required. 
TRPM3 is activated by hypotonic shock (Grimm et a!., 2003), which is a common 
mechanism of activation for several TRP channels, including TRPC1, TRPC6, TRPV2, 
TRPM2, TRPM4 and TRPP2 (Kraft et a!., 2005). It has been suggested that the 
activation of TRPV4 by hypotonic shock is due to the cell swelling that results from 
PLA2-mediated release of arachadonic acid (AA) and its metabolites (Stutzin et a!., 
2006). Downstream products of PLA2 do not activate TRPM3; for example, AA and 
LPC have no effect (Grimm et a!., 2005), nor do the majority of intermediates in AA 
metabolism, such as prostaglandins, leukotrienes and hydroxyeicosatetraenoic acids 
(HETEs) (Figure 5.7-5.10). However the endogenous lipid mediator hepoxillin A3, 
which activates the release of AA and DAG, did cause a small but significant activation 
of TRPM3 (Figure 5.9). Therefore AA metabolism cannot be completely ruled out as a 
mechanism for TRPM3 activation. Stretch-activated channels can be inhibited by 
chlorpromazine (CPZ), which interacts with membrane phospholipids to produce a 
concave curvature of the plasma membrane, an effect which is opposite to causing 
membrane stretch (Maingret et a!., 1999). CPZ inhibited PregS-activation of TRPM3 
(Figure 5.12 & 5.21). This would suggest that PregS may need to insert into the plasma 
membrane to exert its effect in order access its TRPM3 binding site, thus causing a 
change in the curvature or fluidity of the surrounding membrane which regulates the 
channel. 
TRPM3 baseline activity and PregS-induced Ca2{'-responses were potentiated by 
increased temperature (Figure 5.36). Temperature is a common modulator for several 
TRP channels involved in peripheral thermosensation (Huang et al., 2006). The ability 
of TRPM8 and TRPV 1 to sense temperature change has been linked to the intrinsic 
voltage dependent gating of the channels, and channel activation results from a shift in 
the voltage dependence of activation (Voets et al., 2004a). Domain swapping studies 
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using TRPV 1 and TRPM8 have demonstrated that residues necessary for 
thermosensation exist in the C terminus (Brauchi et al., 2006). 
Novel modulators with vascular importance 
Cholesterol enrichment of the plasma membrane regulates TRPM3 (Figure 5.29). 
Cholesterol is an essential component of cell membranes and an important constituent 
of lipid rafts. These specialised regulatory membrane domains are enriched in 
cholesterol and protein components required for cell signalling. Cholesterol is also 
known to regulate ion channels, including TRP channels. Vascular store-operated 
calcium (SOC) activity is reduced following cholesterol depletion by cyclodextrin, 
presumably as a result of disruption of lipid rafts and the redistribution of TRPC1 
channels (Bergdahl et al., 2003). Furthermore, direct application of cholesterol- 
saturated mICD activates TRPC3 and the induced cholesterol enrichment promotes 
TRPC3 expression at the plasma membrane (Graziani et al., 2006). As previously 
discussed, ankyrin repeats have not been identified in TRPM3 channels. Therefore there 
is as yet no data to suggest TRPM3 can anchor itself to the cytoskeleton and associate 
with lipid rafts. Further study will demonstrate whether TRPM3 activity is dependent 
on changes in raft structure as a mechanism for regulating the channel in different cell 
types or in disease states where cholesterol levels are increased. 
The direct application of m(3CD caused significantly greater basal Ca2+ entry in 
TRPM3-expressing cells (Figure 5.31 A& B). This would suggest that membrane 
bound cholesterol is tonically inhibiting the constitutive activity of TRPM3, and its 
depletion by mJCD allows Ca2+ entry through the channel. It is interesting that 
cholesterol and the potent TRPM3 activator PregS are very similar in structure, and it is 
possible that they share a binding site on the channel. If this were true, PregS may exert 
its activatory effect by displacing cholesterol and releasing the tonic inhibition of the 
channel. Following preincubation with m3CD, tet- cells also displayed an increased 
basal Ca2' entry, and responded to PregS (Figure 5.31 Q. The data in Chapter 3 of this 
thesis demonstrated that SPH caused a small Ca2+-response in tet- cells that was 
sensitive to block by TM3E3, suggesting it was the result of native TRPM3. RT-PCR 
confirmed TRPM3 expression; however PregS did not cause activation in the tet- cells. 
The data in this chapter (Figure 5.31) would suggest that mfCD has removed the tonic 
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inhibition of native TRPM3 in tet- cells, allowing for the activation of channels by 
PregS in tet-. SPH activation of the channel must occur via a distinct, cholesterol- 
independent mechanism. 
Platelet-activating factor (PAF) is a pro-inflammatory lipid mediator that, unlike other 
phospholipid-derived mediators, functions as an intact phospholipid and binds a specific 
G-protein-coupled receptor to mediate intracellular effects. The carbon-16 compounds 
PAF-16 and lyso PAF-16 inhibited TRPM3, but the carbon-18 compounds PAF-18 and 
lyso PAF-18 did not (Figure 5.10). PAF-16 could also inhibit endogenous ATP 
responses in TRPM3-expressing cells (Figure 5.22), but did not inhibit H202-responses 
in TRPM2-expressing cells (Figure 5.23). This suggests that while PAF-16 may 
selectively inhibit TRPM3, it perhaps does not directly affect the TRPM3 channel. In 
relation to the underlying theme of this study, the progression of atherosclerosis, the 
PAF receptor (PAF-R) is expressed in human carotid arterial SMC of contractile 
phenotype, suggesting it is relevant to their proliferation and migration to invade the 
initima to form atherosclerotic plaques (Brocheriou et al., 2000). As the previous 
chapter demonstrated TRPM3 is also expressed in the vasculature, the activity of PAF- 
R and TRPM3 channel may be directly related. TRPM3 inhibition was not related to 
products downstream of PAF-R activation, such as PLC induced DAG production, or 
PLA2 induced AA, prostaglandin or leukotrienes (Grimm et al., 2005). Furthermore the 
inactive lyso PAF-16 and PAF-16 antagonist both also inhibited PregS- and ATP- 
responses, further evidence that PAF-16 modulation of TRPM3 is independent of PAF- 
R activation. 
L-NAME preincubation slightly inhibited subsequent activation of TRPM3 by PregS 
(Figure 5.35). However, it is unclear whether L-NAME exerts its effect on the TRPM3 
channel indirectly by inhibiting the NO pathway (through competitive antagonism of 
NOS), or directly by interacting with the channel to prevent subsequent activation. L- 
NAME can bind to and inhibit the nicotinic acetylcholine receptor (nAChR) (Scheller et 
al., 1998), so a direct effect on the TRPM3 channel that does not involve NO 
production cannot be ruled out. This may also explain why direct application of NO 
using SNAP did not activate the channel. The ineffectiveness of SNAP could also be 
explained if it is not NO, but some other intermediate, which inhibits TRPM3. The NO 
produced by L-NAME can rapidly react with superoxide to form the potent oxidant 
perxoynitrite (Murphy et al., 1998). Peroxynitrite is a highly reactive species that can 
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induce lipid peroxidation, and is implicated in the development of atherosclerosis (Uppu 
et al., 2007). Further investigation will elucidate whether the damaging effects of free 
radicals and their byproducts result from interactions with the TRPM3 channel. 
Antipsychotics and antidepressants inhibit the PregS response 
Antidepressants and antipsychotics display dose-dependant inhibition of TRPM3, 
regardless of their type (Figure 5.21). These drugs exert their effects by inhibiting the 
re-uptake of neurotransmitters, thereby increasing levels in the synapse in order to 
enhance mood. Other than direct effects in the central nervous system, the effect of 
these drugs elsewhere is poorly understood. Tricyclic antidepressants (TCA) in 
particular have been shown to inhibit ligand gated ion channels (LGIC) including 
nACh, GABA, NMDA and serotonin receptors (Ueta et al., 2004). In addition, the two- 
pore domain K+ channels TREK-1 and TREK-2, responsible for background or `leak' 
K+ current, are inhibited by both typical and atypical antipsychotic drugs with IC5o 
values in the micromolar range, similar to those obtained in this study for TRPM3 
inhibition (Thummler et al., 2007). Also, haloperidol binds to HERG K+ channels and 
increases rate of their inactivation (Suessbrich et al., 1997). The evidence suggests in 
addition to their major therapeutic effects, antipsychotics and antidepressants may also 
target ion channels expressed in the brain, including TRPM3, to mediate their effect or 
elucidate their side effects. 
Summary 
HTS has allowed for the development of a pharmacological profile for TRPM3, which 
will undoubtedly assist the understanding of biological function. The different 
modulatory properties of TRPM3 may be physiologically regulated by varying 
expression levels in different cell types, the differential expression of splice variants, or 
association with different signalling protein complexes. The expression of the TRPM3 
channel in both in brain tissue and throughout the vasculature, plus regulation by known 
antipsychotic and anti-atherogenic modulators suggests a functional role in psychosis or 
the development of atherosclerosis. Ultimately the increased understanding of TRPM3 
pharmacology and function may provide a basis to chemically improve existing 
modulators to produce more selective, improved agonists, or even drugs. 
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Chapter 6 
Conclusions and further experiments 
General summary 
The aim of my thesis was to investigate the expression, modulation and biological 
function of the transient receptor potential channel TRPM3. These investigations were 
assisted by the development of a set of pharmacological tools specific for TRPM3. E3 
targeting (Xu et al., 2005b) was used to design and develop TM3E3, an antibody that 
served as a selective inhibitor of the TRPM3 ion channel. The antibody could 
specifically bind the channel in live cells, producing an inhibitory effect against known 
activators of TRPM3. Furthermore the development of a stable TRPM3 cell line 
allowed for the use of medium throughput technologies to search for TRPM3 
modulators, and led to the identification of a novel TRPM3 inhibitor, cholesterol. 
In combination these tools were used to explore the expression of TRPM3 in vascular 
smooth muscle. TM3E3 blocked endogenous TRPM3 channels, and proved a useful 
tool in the elucidation of native channel function. My findings suggest that TRPM3 is a 
functional Ca2+ channel of vascular smooth muscle cells, with a protective role as an 
inhibitor of MMP-9 and IL-6 secretion. Although the mechanism by which TRPM3 
regulates secretion has yet to be determined, both MMP-9 and IL-6 play important roles 
in vascular remodelling, which contributes to vascular diseases such as atherosclerosis. 
Screening a chemical library allowed me to find further TRPM3 modulators with 
potential vascular relevance. In particular cholesterol and an oxysterol inhibited 
TRPM3, and these effects may contribute to the damaging effects of these agents in 
coronary artery disease. It was originally hoped that TM3E3 may have therapeutic 
potential, although my data suggest that for neointimal hyperplasia and atherosclerosis 
it is a TRPM3 activator that would have therapeutic value. However, it remains to be 
seen whether the antibody could benefit situations where VSM profliferation and 
migration are necessary, such as providing new blood supply to skin grafts. 
Ultimately, a better understanding of TRPM3 is required, aided by the selective TM3E3 
tool, which may identify novel TRPM3 modulators that are suitable as therapeutic 
agents. While the findings of this study help the understanding of TRPM3 
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pharmacology and function, and provide a basis to develop novel therapeutic 
approaches to the treatment of cardiovascular disease, further investigation is still 
required. 
Further experiments to investigate TRPM3 activation 
The first chapter of the study identified PregS as a novel activator of TRPM3. PregS 
activated TRPM3 independently of store depletion, but its exact mechanism of action is 
not clear. Further experiments are required to determine whether PregS can directly 
bind to the TRPM3 channel, or whether it acts indirectly via signalling pathways, 
perhaps involving intracellular sigma (a) or steroid receptors. Although expressed in a 
number of tissues including liver, spleen, testis, ovary, placenta and adrenal gland, a 
receptor expression has not been demonstrated in vascular smooth muscle (Ola et al., 
2001). A combination of RT-PCR and immunostaining might demonstrate a receptor 
expression, and perhaps show colocalisation with TRPM3. The dependence of TRPM3 
activation on a receptors could be investigated further using siRNA knockdown of the a 
receptor gene, which might inhibit the PregS response. Furthermore, inhibitors specific 
for downstream intermediates in a receptor signalling cascades could be used to 
investigate their involvement in the activation of the TRPM3 channel. If these 
experiments suggest direct PregS binding to TRPM3 this could be confirmed by excised 
patch data and lipid bilayer experiments to explore if PregS activates single channels in 
isolation. Mutagenesis could be employed to identify the PregS binding site, and may 
help determine the importance of stereochemistry, to develop new and more potent 
related activators. 
Preincubation with thapsigargin (Tg) reduced the amplitude of the PregS-response. 
However, the Ca 2+ response was completely inhibited in the absence of extracellular 
Ca2+, suggesting that the PregS-induced Ca2+ response in TRPM3-expressing cells 
results entirely from Ca2+ influx across the plasma membrane. The inhibition observed 
with Tg is perhaps due to an initial increase in the baseline of resting cells, as a result of 
endogenous SOC activation, and then a saturation of the PregS response. This could be 
confirmed by repeating experiments with a less saturating concentration of PregS. In 
HSV SMC, Tg significantly inhibited TRPM3 responses, but did not affect the baseline. 
Further investigation is required to confirm this effect was a result of the involvement of 
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stores, such as repeating experiments in the absence of extracellular Ca2+ to demonstrate 
the responses result from Ca2+ influx. Alternatively the inhibitory action of Tg may 
prove to be as a result of changes in the local intracellular Cal' concentration, a known 
modulator of many TRP channels. 
TRPM3 is a constitutively active channel (Grimm et al., 2003). Chapter 5 of this study 
demonstrated that the constitutive TRPM3 activity was significantly increased at 
elevated temperatures. It would be interesting to repeat the chemical screening at 
physiological temperature in an effort to reveal previously ineffective activators, 
inhibitors and potentiators of the TRPM3 response. Constitutive activity could be 
further explored using whole cell patch clamping to investigate the direct application of 
TRP channel inhibitor Gd3' and 2-APB, and even the TM3E3 antibody, on basal 
TRPM3 activity. 
TRPM3 can also be activated by hypotonic shock, suggesting it may function as a 
stretch activated channel (Grimm et al., 2003). My own data show that chlorpromazine, 
a compound that causes a concave curvature of the plasma membrane, inhibits TRPM3. 
Further experiments could involve the use of cell-attached voltage clamping to 
determine pressure sensitivity of TRPM3, or the application of the mechanosensitive 
channel activator 2,4,6-trinitrophenol to mimic membrane stretch and induce 
activation. Preincubation with TM3E3, or including the antibody in the patch pipette, 
should inhibit stretch activation, proving the effect is TRPM3-related. 
Several agents known to modulate TRP channels were identified by the chemical screen 
as significant activators or inhibitors of the TRPM3 channel. Further experiments using 
PKC activators, or inhibitors of phosphoinositide 3-kinases such as wortmanin, could be 
used to investigate the mechanism of PIP2 inhibition, which is suggested to directly bind 
other TRP channels (Rohacs et al., 2005). The covalent modification of cysteine 
residues by agents including iodoacetamide and (2-aminoethyl)methanethiosulphonate 
activates TRPA 1 (Macpherson et al., 2007). In addition, free cysteine residues in 
TRPA 1 are predicted to react with dihydropyridines, resulting in channel activation (C. 
Jones, personal communication). The dihydropyridine nifedipine caused significant 
TRPM3 activation. Cysteine modifying agents could be employed to discover a putative 
activation mechanism for TRPM3, providing further evidence for the polymodal nature 
of TRPM3. 
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Further experiments to characterise the TM3E3 antibody 
The means by which E3-targeted antibodies cause channel inhibition has yet to be 
elucidated. All E3-targeted antibodies block by -30-40% within 10 min of application, 
suggesting a shared mechanism of inhibition. Protein trafficking studies using 
fluorescent labels and immunostaining techniques may be useful to investigate the 
possibility that antibody-bound TRPM3 channels are internalised. If the data indicate a 
direct occlusion of the channel pore, it may be possible to target antibodies to different 
regions and even other extracellular loops in an effort to produce more effective 
inhibitors. The production of a monoclonal TRPM3 antibody is also possible. Although 
monoclonal E3-targeted antibodies have proven less effective channel blockers 
(Klionsky et al., 2006), they are useful in that large amounts of identical antibodies can 
be produced, unlike polyclonal antibodies for which there is a finite supply. 
Improvement of the antibody by affinity purification will further improve the use of the 
TM3E3 as a pharmacological tool. The removal of non-specific effects of the antiserum 
would allow for further experiments to search for TRPM3 expression in native tissue, 
particularly in techniques such as western blotting where non-specific bands are a 
problem. A useful, further, control for antibody selectivity would be to compare 
staining or blotting in tissues known to express TRPM3 with those that do not, such as 
by using siRNA to transiently knockdown the TRPM3 mRNA, or by using tissues from 
a knockout animal. As yet, there is not a TRPM3 knockout available. 
Further experiments to determine TRPM3 function 
Cholesterol enrichment of the plasma membrane inhibited TRPM3 activity. It would be 
interesting to examine if cholesterol can affect TRPM3 Cat+-responses in HSV SMC, 
and in particular whether cholesterol can regulate MMP-9 and IL-6 secretion. As 
TRPM3 activation decreases secretion, it would be expected that inhibition by 
cholesterol would have the opposite effect, and increase secretion. 
The secretion data presented in Chapter 4 of this study still requires further work. There 
was often a large amount of variation between patient samples, resulting in large SEM. 
This will be markedly improved by increasing the n number of these experiments. 
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Further experiments are required to determine the concentration dependence of the 
PregS and SPH effect on MMP-9 and IL-6 secretion, in order to identify and use 
physiologically relevant concentrations. It would also be useful to perform siRNA 
knockdown of the TRPM3 gene to confirm TRPM3 role in secretion experiments; this 
should parallel the antibody effect and prevent decrease in secretion following TRPM3 
activation. 
Interestingly TM3E3 did not increase secretion in the presence of SPH (Figure 4.17). 
This suggests that SPH has a dual effect on TRPM3-regulated secretion, causing both 
activation of TRPM3 (thus inhibition of TRPM3-related secretion) but also inhibition of 
the TM3E3 effect. This effect must be further investigated, and may be aided by the use 
of an affinity purified antibody to rule out non-specific effects of the anti sera. It would 
also be useful to determine whether pre-treatment with SPH can inhibit the PregS 
inhibitory effect on secretion. 
Further to effects on secretion, an obvious experiment would be to investigate a role for 
TRPM3 in SMC proliferation and migration. The anti-TRPC5 antibody, T5E3, has been 
shown to inhibit SI P-induced SMC migration (Xu et al., 2006b), and furthermore the 
anti-TRPCI antibody, T1E3, implicated TRPCI in progression of neointimal 
hyperplasia (Kumar et al., 2006). Similar experiments could be used to demonstrate an 
involvement for TRPM3 activators in proliferation and migration, the effects of which 
should be blocked by TM3E3. TRP channels are also described as regulators of 
myogenic tone (Earley et al., 2004). A role for TRPM3 in the regulation of blood 
pressure could be assessed using contraction studies. Sphingosine causes contraction of 
both rat mesenteric vessels and porcine coronary arteries (Murohara et al., 1996, 
Bischoff et al., 2000), and it would be interesting to investigate whether this effect can 
be inhibited using TM3E3. Sphingosine is also well characterised as an apoptotic agent 
(Taha et al., 2006), and cell viability experiments would be useful to determine whether 
the effect of SPH on secretion is the result of cell death. Knock-out mice have also 
proven useful for demonstrating a role for TRP channels in the vasculature (Kim et al., 
2000), and may be useful for TRPM3. 
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Final conclusion 
This investigation has revealed several novel pharmacological tools that have proven 
useful for the characterisation of TRPM3. The expression of the TRPM3 channel both 
in brain tissue and throughout the vasculature, plus regulation by known antipsychotic 
and anti-atherogenic modulators suggests a functional role in psychosis or the 
development of atherosclerosis. TM3E3 has served as a valuable selective tool for the 
description of the TRPM3 channel in both over-expressed and native systems, and in 
particular has allowed for the identification of TRPM3 as a functional channel in VSM. 
TRPM3 is involved in both IL-6 and MMP-9 secretion, and may play a protective role 
in VSM, perhaps mediating the negative effects of well-characterised vascular 
damaging agents. Although the exact mechanisms of the role of TRPM3 in the 
vasculature remain to be investigated, this study has demonstrated the effectiveness of 
medium throughput screening in identifying both TRPM3 ion channel modulators and 
areas that show promise as potential therapeutic targets. 
Although custom-made antibodies can have important therapeutic applications due to 
their specificity and unlimited diversity, it would appear TM3E3 inhibition of TRPM3 
may have a negative physiological effect, upregulating the secretion of atherogenic 
factors. However, the antibody will prove useful for the further characterisation of 
endogenous TRPM3 in a multitude of cell types and tissues. 
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